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ABSTRACT 
 Tuberculosis (TB) continues to kill globally and this is compounded by increasing 
drug-resistance. Neutrophil influx and tissue destruction are hallmarks of TB and this is 
detrimental to the host. A matrix degrading phenotype causes tissue damage in TB 
whereby the activity of matrix metalloproteinases (MMPs) is unopposed by their specific 
tissue inhibitors (TIMPs). The hypothesis is that neutrophils have a key role in causing 
MMP-dependent tissue destruction in human TB.  The aims are to investigate MMP and 
TIMP secretion from M.tuberculosis (M.tb) infected neutrophils, neutrophil networks 
regulating MMP secretion and MMP and TIMP activity regulation in neutrophils in vivo.   
 Using an in-vitro model, healthy primary human neutrophils were infected in vitro 
with M.tb or stimulated with conditioned media from M.tb-infected monocytes (CoMTB).  
MMP-8/-9 and TIMP-1/-2 secretion were analysed by Luminex array and zymography. 
Intracellular signalling pathways were investigated by phosphoarray, western blot and 
inhibitors. Gene expression was studied by real-time PCR.  Neutrophil extracellular traps 
(NETS) were examined by immunofluorescence. DQ collagen degradation was examined 
by confocal microscopy and quantitative fluorescence assay. These studies were extended 
to investigate MMP-8 and -9 secretion from patients with AMPK mutation to evaluate if 
AMPK regulates neutrophil MMP secretion. Induced sputum samples from 108 patients 
and controls were analyzed. Immunohistochemistry of human TB lung specimens was 
performed.   
 Neutrophil MMP-8 and -9 secretion are up-regulated 3 and 5 fold by M.tb 
respectively while CoMTB stimulation caused a 2 and 3 fold increase in MMP-8 and -9 
(all p<0.001). The MAPK, PI3-kinase and AMPK pathway regulate neutrophil MMP 
secretion in CoMTB-stimulated neutrophils but not M.tb-infected cells. M.tb-infected 
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neutrophils degrade collagen, which is abolished by the MMP inhibitor doxycycline. M.tb-
driven NET formation is associated with MMP-8 and -9.  MMP-8 and -9 concentrations 
are elevated in induced sputum of TB patients compared to controls (both p<0.001) and 
correlate with neutrophil markers myeloperoxidase and neutrophil gelatinase associated 
lipocalin.  MMP-8 concentration correlated with clinical TB severity score (r=0.55, 
p<0.0001) and CXR score (r=0.52, p<0.0001). Induced sputum from TB patients has 
increased collagenase activity which is suppressed by MMP-8 neutralisation.  MMP-8 
secretion is decreased in AMPK patients with CoMTB stimulation. Immunohistochemistry 
of human TB lung specimens confirmed cellular findings.   
 M.tb drives neutrophil MMP-8/-9 gene expression and secretion following direct 
infection and in monocyte-dependent networks.  Pathways regulating neutrophil MMP 
secretion are stimulus specific.  In vivo findings underscore the crucial role that neutrophils 
have in tissue destruction in TB.  
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CHAPTER 1 - INTRODUCTION 
1. The tuberculosis epidemic 
 In the Mortality Bills, pneumonia is an easy second, to tuberculosis; indeed in 
many cities the death rate is now higher and it has become, to use the phrase of Bunyan 
'the captain of the men of death.'  
— Sir William Osler, 1904 [1]   
 Tuberculosis (TB) is one of the oldest diseases that afflicts mankind and has been 
discovered in human remains more than 9000 years old [2].  Active TB often manifests 
itself by symptoms of fever, weight loss, loss of appetite and should the lungs be affected, 
cough and haemoptysis.  Nevertheless, any organ can be affected by the pathogen 
including the brain, pericardium, bone, reproductive system, urogenital system and the 
abdomen.   Active TB can be highly contagious, in contrast with its latent stage where the 
tubercle bacilli lie dormant and individuals asymptomatic.  One would have expected that 
mankind would have found a cure to such an ancient disease that has beleaguered humans 
since the beginning of history, but the converse is true and TB continues to plague. 
  TB was declared a global health emergency by the World Health Organisation in 
1993 and continues to be one of the world‘s leading killers.   It is estimated that one third 
of the world‘s population is infected with the causative organism, Mycobacterium 
tuberculosis(M.tb) [3].  Twenty years after the global health emergency was declared the 
incidence of TB is still in epidemic proportions with 8.7 million new cases in 2011 and 1.4 
million deaths [4].  Although 95% of TB cases arise from middle and low-income 
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countries [4], affluent nations are similarly afflicted.  London has been disgracefully 
declared the ‗TB capital of Europe‘ [5] and this can be attributed to the high immigrant 
population [5].   Moreover, Multi-drug resistant (MDR) and Extensively drug- resistant 
(XDR) TB incidences are rising [6] with very limited therapies available to treat these 
diseases.  This is reminiscent of the early 1900s when standard TB chemotherapy was not 
yet available and patients were either prescribed long stays at TB sanatoriums with or 
without surgery.     A variety of reasons including limited access to healthcare resources, 
lack of culture and susceptibility testing and inappropriate use of first and second-line 
drugs have led to the emergence of XDR-TB which are refractory not only to isoniazid and 
rifampicin but also to at least one fluoroquinolone and at least one injectable second-line 
drug.  XDR-TB has now been found in 77 countries, including the UK and US [7].   More 
alarmingly, totally-drug resistant TB has been found in Iran in 2009 [8] and Mumbai in 
2011 [9] and South Africa in 2013 [10] which leaves patients the bleak prospect of either 
major surgery or death.   
1.1 The compounding effect of HIV on TB 
 Contributing to the challenging situation is the rise in the number of people living 
with HIV.  HIV is a well recognised risk factor for contracting TB with at least one-third of 
the 34 million people with HIV having latent TB and 1.1 million having active HIV-
associated TB [4].  HIV leads to an increased risk of developing rapidly progressive 
primary TB following exposure as well as an increased risk of reactivation of latent TB 
infection to active disease [11].  TB can be an early manifestation of HIV infection, but the 
risk of developing TB and contracting disseminated TB increases as the CD4 count 
decreases. It is known that people living with HIV are more likely to succumb to TB as 
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patients with HIV may not be diagnosed with TB or vice versa until the disease is far too 
advanced.  Diagnosing TB among people living with HIV is particularly challenging 
because this population that is infected with pulmonary TB frequently have negative 
sputum smears and up to a third may have completely normal chest radiographs [12].  
Additionally, TB in people living with HIV often occurs in extraplumonary sites, evading 
traditional diagnostic tests.  Between 8-26% of patients die in the first year of anti-
retroviral treatment [13] and both diagnosed and undiagnosed TB are recognised as  major 
causes of this mortality.  Autopsy studies conducted in sub-Saharan Africa before and 
during the anti-retroviral therapy (ART) era in adult HIV-infected hospitalised patients 
discovered that TB, specifically disseminated TB was responsible for 40-50% of deaths 
[14-17].   Correspondingly, TB patients diagnosed with HIV and not receiving ART have a 
high risk of mortality, with death occurring early during the course of anti-TB treatment 
[18] and the risk increasing as the CD4 count decreases [4, 19, 20].   Furthermore, people 
living with HIV are more susceptible in contracting drug-resistant TB [21-23] which 
confers a higher mortality.  TB and HIV thus act synergistically within a population to 
cause excess morbidity and mortality. 
1.2 Risk factors for TB 
 HIV can be said to be globally the singular most important risk factor for 
contracting TB.  Other risk factors can be broadly categorised to those who have 
epidemiologic risk factors to M.tb, and those who are immunosuppressed.   Since TB is 
spread through aerosols, those who are in close contact with patients with active TB or 
certain high-risk populations such as homeless people, injection drug users, and people 
working with people at high risk for TB in institutions such as hospitals, homeless shelters, 
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prisons and nursing homes can become infected.  Certain members of these groups require 
TB prophylaxis when the situation is warranted to prevent progression of latent to active 
TB.   
 Diabetes mellitus has been recognised to be a moderate risk factor for active 
pulmonary TB as well as a predictor of poor treatment outcomes  and reduced survival.  
Most of these observations arise from case-control studies [24, 25]. The mechanisms by 
which diabetes mellitus increases TB risk are not well understood.  Several early studies 
reported reduced pro-inflammatory cytokines in murine models of diabetes mellitus after 
infection with M.tb.  Others found that cytokine responses were consistent with a Th2-
phenotype [26, 27] although more recently Th1 cytokines have been implicated [28, 29].    
Patients with chronic renal disease especially those requiring dialysis are 6 to 25 times 
more likely to develop TB than the general population due to impaired cell-mediated 
immunity.  They often have atypical clinical presentations, often presenting with 
extrapulmonary TB and thus resulting in a delay in accurate diagnosis [30, 31].   Another 
group at risk are patients who receive immunosuppressive therapy which are increasingly 
being used in this age of medical therapy. These include those on long term steroids as 
well as anti-TNFα agents.  The risk of re-activating latent TB infection has been well-
recognised in those using anti-TNFα therapies [32].  These agents include eternercept, 
infliximab and adalimumab.  Multiple factors are thought to be involved in reactivation 
such as the down-regulation of IFN-γ responses, down-regulation of CD8 T cells and 
disorganised structure or functioning of tuberculous granulomas [33-35]. 
 Given the multiple risk factors, what are the prevention strategies against TB?  The 
Bacillus Calmette Guerin (BCG) vaccine offers 70-80% efficacy against severe forms of 
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tuberculosis in childhood, particularly TB meningitis in infancy and miliary TB [36, 37].  
However when given later in adult life, the efficacy against TB varies in different part of 
the world for reasons which are not fully understood [36].  Uncertainty remains about how 
long the protection afforded by BCG vaccination will last [38].  Moreover, BCG exists as a 
live attenuated vaccine which precludes those with an already impaired immune system 
from receiving it lest they face the risk of contracting disseminated BCG.  Thus, there is a 
requirement for a better vaccine to prevent contracting TB. 
1.3 Current diagnostic tools for active TB 
 The current routine diagnostic tests for patients suspected of having active TB have 
their limitations. Chest radiographs are most often used, and characteristic lesions such as 
cavitation, infiltrates especially in the upper lobes of the lungs (akin to the one pictured 
below) would lead one to highly suspect the disease.   
 
Adapted from sharinginhealth.ca. 
http://www.sharinginhealth.ca/pathogens/bacteria/mycobacterium_tuberculosis.html 
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 Sputum smear microscopy (pictured below) is used to detect acid-fast bacilli (AFB) 
in sputum specimens by Ziehl-Neelsen (Z-N) or fluorescence staining.  It is a cost-effective 
tool for diagnosing and monitoring the progress of TB treatment especially in developing 
countries.  However there are multiple drawbacks such as difficulty of obtaining sputum 
samples especially in very young children and the elderly who have impaired cough 
responses.  Furthermore there is low sensitivity in detection especially in HIV-infected 
patients and the consequent false negative results.  It has been estimated that the sensitivity 
is approximately 70% in a recent systematic review [39] and can be as low as 35% in some 
settings with high rates of HIV coinfection [40]. Occasionally, there may be false positive 
results with non-tuberculous mycobacteria.   
 
Adapted from http://pathmicro.med.sc.edu/infectious%20disease/mycobacterial%20diseases.htm 
Ziehl-Neelson positive stain for Mycobacterium tuberculosis in sputum 
  
 Sputum culture is the gold standard for TB diagnosis with excellent sensitivity and 
specificity.  This traditional method of inoculating specimens onto solid medium such as 
Lowenstein-Jensen (LJ) or 7H10/7H11 media is however slow, requiring 10-14 days for 
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liquid culture and 3-4 weeks for solid culture weeks to diagnose the infection and further 
more time to ascertain the drug susceptibility patterns.  Drug sensitivity testing nonetheless 
is not routinely available in all labs and is sorely lacking especially in resource poor 
settings where drug-resistant TB is prevalent and where it is needed most.  Altogether, this 
translates to a delay in the initiation of appropriate therapy. 
 Technological advances have brought about incremental improvements in TB 
diagnostics since the 1980s.   The introduction of the automated liquid culture systems 
such as the Bactec 960 MGIT allowed the detection of M.tb in a few days compared to 
conventional culture methods.  These rapid automated systems have increased sensitivity 
of isolation of M.tb from clinical samples, decreasing the time to obtain positive culture 
results considerably to 9-10 days [41].  Automated systems additionally permit a higher 
throughput of specimens for testing. There are also several alternative, non-commercial, 
culture-based methods such as the microscopic observation drug susceptibility (MODS) 
assay, the nitrate reductase assay (NRA), colorimetric redox indicator (CRI) method which 
all have been approved by WHO to be used in the interim measure before leading to the 
eventual use of automated liquid culture.   
 Nucleic acid amplification tests (NAAT) for the diagnosis of TB and/or detection 
of drug resistance have also been approved by WHO [41].  The Gen-Probe assay for M.tb 
complex is a rapid detection, nucleic acid amplification test and results can be rapidly 
obtained in two hours.  Furthermore, it has a high sensitivity and specificity of more than 
90% [42].  The disadvantage is that it requires a positive culture which can take several 
days, and labs in resource poor settings would not be able to afford this technology. Line-
probe assays such as HAIN Genotype MTBDR plus and the microfluidic PCR device 
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(GenExpert/Cepheid) allow for both the fast detection of M.tb as well as the simultaneous 
detection of drug resistance patterns.   The HAIN test can be used both on culture-based 
isolates and directly on smear positive sputum samples from patients with pulmonary TB.  
This assay has the advantage of identifying mutations in the rpoB gene (rifampicin 
resistance) and concurrently mutations in the katG gene (high-level isoniazid resistance) 
and the inhA gene (low-level isoniazid resistance) [41].    More recently, WHO has 
endorsed the GeneXpert MTB/RIF in 2010 which uses a semi-nested real-time PCR 
reaction to amplify M.tb specific sequence of the rpoB gene which is then probed with 
molecular beacons for mutations within the rifampin-resistance determining region [43, 
44].   The sensitivity of a single direct MTB/RIF assay in culture-confirmed M.tb was 
92.2% [41] and provided results from unprocessed sputum in less than 2 hours.  However, 
approximately 60% of patients with TB worldwide present in resource-poor settings [45] 
where diagnostic tests based on sophisticated instruments such as Xpert MTB/RIF will not 
be feasible. Such novel technologies are expensive and additionally neglect testing other 
anti-tuberculous drugs.  There is thus a need for cheap, sensitive and specific diagnostic 
tests that can simulataneously detect drug-resistance and can be readily delivered at the 
point of care. 
1.4 Anti-tuberculous chemotherapy  
 One of the key arms that contribute to the strategy in controlling the TB epidemic is 
the development of new drugs.  The advances in the treatment of TB began with the advent 
of streptomycin in 1944 followed by a whole range of highly effective anti-tuberculosis 
therapies with rifampicin being the last discovery of that era in 1957.  With the availability 
of these drugs, TB was largely removed from the public perception as a feared and deadly 
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contagious disease. Yet, in the latter part of the 20th century a prolonged period of neglect 
of quality control program implementation, research and failure to develop new diagnostic 
tools led to persistently high TB incidence rates.  The flagrant misuse of anti-tuberculous 
drugs coupled with patient non-adherence led to the emergence of drug-resistant TB.  
Highly publicised nosocomial outbreaks in the 1990s of multidrug-resistant tuberculosis 
(MDR-TB) in New York City and California prisons which led to mortality even among 
healthcare workers brought TB back onto the radar screen.  Despite this, most of the world 
still relies on drugs discovered 50 years ago.  The current standard treatment of drug-
susceptible TB comprises multiple drugs for a minimum duration of six months. These 
consist of rifampicin/isoniazid/ethambutol/pyrazinamide for 2 months and then 
rifampicin/isoniazid for the remaining months.  This prolonged course of polypharmacy 
has contributed to high rates of non-compliance with the development of drug-resistant 
TB.  Nonetheless with the emergence of drug resistance, there was a renewal of efforts and 
promises in the development of new drugs for chemotherapy of TB.  There is now a long 
list of new molecules of potential interest for TB treatment that is beyond pre-clinical 
development:  ATP synthase inhibitor TMC 207, nitroimidazopyrans PA-824 and OPC-
67683, oxazolidinones PNU-100480 and AZD-5847, trehalose monophosphate transferase 
inhibitor SQ109 and benzothiazinones BTZ043.  Despite the hurdles of developing a new 
drug, and more so in developing a new drug regimen, a degree of optimism is allowed in 
that the US Food and Drug Administration has recently approved bedaquiline (TMC 207) 
in December 2012 for the treatment of drug-resistant tuberculosis [46].  However further 
evaluation needs to be done to determine if bedaquiline can truly shorten treatment in drug-
susceptible TB cases.  
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 A well-recognised phenomenon that occurs with TB treatment is TB paradoxical 
reaction, a clinical, often accompanied by radiological worsening of pre-existing TB 
lesions or the development of new lesions during treatment.  It is unpredictable in its 
timing, occurring as soon as a few days of initiation of anti-tuberculous treatment to many 
months after.  It also varies in its duration and severity.  In addition it is a diagnosis of 
exclusion, as factors such as treatment failure, drug-resistance or infections need to be 
simultaneously considered.  Most of these occurrences frequently run a self-limiting course 
however occasionally patient deterioration and death will occur.  The majority of such 
paradoxical reactions have complicated the treatment of TB lymph nodes, CNS-TB and TB 
pericarditis.  A large case series reported approximately 30% enlargement of lymph nodes 
while on anti-tuberculous treatment [47].  Corticosteroids were often prescribed for those 
with severe systemic manifestation which can lead to an improvement by shortening the 
duration of symptoms [48, 49].   Certainly, steroid adjunctive therapy has been advocated 
in most national guidelines when treating CNS-TB and TB pericarditis [50, 51] as it is 
well-established that the administration of steroids improves patient morbidity and 
mortality outcome.   In rare circumstance, anti-TNFα therapy has been prescribed for 
patients refractory to steroids in CNS-TB [52, 53] in an attempt to dampen the over-robust 
host inflammatory reaction.  There has furthermore been an increase in TB paradoxical 
reaction in the context of HIV coinfection, more commonly known as TB-associated 
immune reconstitution inflammatory syndrome (IRIS).  This frequently occurs in the 
setting of initiating anti-retroviral therapy soon after anti-tuberculous therapy.  The 
underlying mechanism for this is unclear although there was a suggestion that a rapid 
reduction in HIV plasma viral load may be associated with TB-IRIS [54].   Like TB 
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paradoxical reactions in HIV negative individuals, TB-IRIS can be life-threatening and 
steroids prescribed with severe manifestations.   
 
 In summary, there have been advances in anti-tuberculous therapy with a 
considerable number of new drugs in the drug discovery pipeline.    Treatment duration for 
TB however still requires a minimum of 6 months with multiple drugs, and emergence of 
drug-resistant disease underscore the lack of highly effective anti-tuberculous therapy. 
There is still a lack of appreciation of the mechanisms behind host-inflammatory reactions 
that accompanies the initiation of anti-tuberculous therapy and at times such reactions are 
life-threatening, refractory even to steroids.  As such, there is still a pressing need for new 
and adjunctive therapy to prevent and treat the active disease with a truly shortened course 
so as to halt the transmission of M. tb, stem the rising rates of drug-resistance and modulate 
host-pathogen responses.  To achieve this, it is imperative to understand the underlying 
mechanisms that cause pathology in TB infection.   
 
2. The concept of tuberculosis pathogenesis 
 Tuberculosis is transmitted primarily through the aerosol route where aerosolised 
droplets from an infected host can remain airbourne for several hours.  The mycobacterium 
is inhaled and establishes infection in the lungs of a new host.  The nature and importance 
of the host immune responses, specifically the cell-mediated host immune responses, is 
recognised to be key in the pathogenesis of tuberculosis [55, 56].  The important role of 
macrophages as effector cells in host defence against M.tb was initially identified from 
animal studies [57-60].  It is commonly believed that the mycobacteria are first 
phagocytosed by alveolar macrophages.  It is widely assumed that M.tb persists in 
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immature phagosomes by avoiding their maturation into phagolysosomes and acidification 
[61, 62].  This partially depends on the interference by M.tb of small GTPases termed 
Rabs, which control almost every aspect of intracellular trafficking in mammalian cells.  
Mycobacterial manipulation of Rab recruitment and function has a cascade of downstream 
effects, involving Rab-interacting partners and effectors such as phosphatidylinositol-3-
kinase (PI3K) which modifies membrane-associated lipids, specifically 
phosphatidylinositol (PI) by phosphorylating PI into phosphatidylinositol 3-phosphate 
(PI3P).  PI3P serves as a tag for the recruitment of factors that execute conversion of 
phagosomal organelles into phagolysosome [62].   M.tb phagosomes do not acidify 
properly as it does not acquire the late endosome Rab7 [63] which brings about recruitment 
of the vacoular proton ATPase responsible for phagosomal acidification and proteolytic 
activity of a phagosome.  This results in the host mistaking that the M.tb phagosome is 
static and allows M.tb to survive in the phagosome.  It has also been reported that after a 
prolonged incubation time in vitro, M.tb escapes into the cytosol where it can apparently 
replicate robustly [64].    
 By expanding its population, M.tb then invades the adjacent epithelial layer.  This 
results in a localised inflammatory response that leads to the recruitment of mononuclear 
cells from nearby blood vessels which in turn provides new host cells for the growing 
mycobacterial population [65].  These cells set the stage for the formation of the caseating 
granuloma which is pathognomonic of TB.   Initially the granuloma is an amorphous mass 
of neutrophils, monocytes and macrophages.  Thereafter, the macrophages differentiate 
into specialised subtypes such as multinucleated giant cells, foamy macrophages and 
epitheliod histiocytes.  Animal experiments then established that lymphocytes were the 
CHAPTER 1 - INTRODUCTION 
29 
 
primary component of the cellular response [66, 67]. With the arrival of lymphocytes, the 
granuloma acquires a more organised structure.  The center becomes surrounded by 
lymphocytes that may be enclosed by fibroblasts which demarcates the peripheral structure 
of the granuloma and may aid in the containment of the infection.   The appearance of 
M.tb-specific lymphocytes heralds the end of the phase of rapid bacterial replication and 
the onset of a ‗containment‘ stage.  Histology of infected tissues from patients with active 
TB reveal granulomas in all states of development from containment to active disease 
implying that the fate of each granuloma is not determined systemically but locally [65].  It 
is thought that ultimately the granuloma ruptures, spilling out abundant amounts of viable 
infectious bacilli into the respiratory airways [68]   Our understanding of the pathogenesis 
of tuberculosis supports a framework which includes the initial response to inhaled 
organisms, granuloma formation with the establishment of a state of latent infection, and 
reactivation of the latent infection triggered by a relative immunosuppressed state in the 
host resulting in active disease. 
3. The significance of the neutrophil 
 Neutrophils have been traditionally viewed as short-lived effector cells of the 
innate immune system, having limited capacity for biosynthetic activity and playing a key 
role in resistance against extracellular pathogens and in acute inflammation.  They are 
professional phagocytic cells, release lytic enzymes from their granules and generate 
reactive oxygen intermediates with antimicrobial potential.   However, this limited view 
was challenged by a demonstration that neutrophils survive longer than initially suggested, 
up to 5.4 days [69].  Neutrophils can also be induced to express genes encoding key 
inflammatory mediators including complement components, Fc receptors, chemokines and 
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cytokines [70].  Furthermore, new evidence suggests that neutrophils can also produce 
anti-inflammatory molecules and factors that can promote the resolution of inflammation 
[71].  Recent evidence underscored the de novo induction of microRNAs that may be part 
of the crucial regulatory circuit which regulate neutrophil gene expression [72].  
Neutrophils have thus emerged as a crucial component of the effector and regulatory 
circuits of the innate and adaptive immune systems [73] which has thus led to a renewed 
interest in their biology. 
3.1  Neutrophil morphology 
 Microscopic examination of the mature neutrophil reveals two striking features: a 
single multilobed nucleus and a dense granular appearance of the cytoplasm.  The nucleus 
comprises two to four segments and within this organelle the chromatin is coarsely 
clumped.  
 
Blood film with Giemsa staining showing the multilobed nucleus of neutrophils with 
their dense granular cytoplasm 
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 It is now appreciated that the mature neutrophil does perform active transcription [74, 75] 
although rates of biosynthesis are lower than those in monocytes.  The most abundant 
organelles within the cytoplasm are the granules, which are membrane-bound organelles 
containing an array of antimicrobial proteins.  Three major types have been identified:  
azurophil (primary), specific (secondary) and gelatinase-containing (tertiary) granules.  
Azurophils largely contain proteins and peptides directed towards microbial killing and 
digestion.  Their contents include myeloperoxidase (MPO) and three main serine 
proteinases that are cathepsin G, elastase and proteinase 3.  Specific granules contain 
neutrophil collagenase (MMP-8), lactoferrin, and neutrophil gelatinase-associated lipocalin 
and about two thirds of cellular lysozyme [76]. Gelatinase granules as its name suggests, 
contain gelatinase B (also known as MMP-9) in the absence of lactoferrin.  Lastly, 
secretory vesicles contain serum albumin [77] and provide a valuable reservoir of 
membrane components, reassociating with the plasma membrane and in so doing 
replenishing membranes that have been consumed during phagocytosis.  Neutrophil 
granules are formed sequentially during granulocytic differentiation in the bone marrow 
and there is a distinction in their mobilisation, with the granules that were formed latest 
being the ones to be released earliest [78].  Apart from containing degradative enzymes 
that may be extracellularly secreted from the neutrophil or else discharged into phagocytic 
vesicles, the membranes of these granules and vesicles contain important molecules 
including receptors (eg. CR1, CR3, CD11b/CD18) and cytochrome b of the NADPH 
oxidase.  A summary of neutrophil granule proteins profiled at the protein level and their 
location is summarised in Table 1. 
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 Azurophil granules 
(Primary granules) 
Specific granules 
(Secondary granules) 
Gelatinase granule 
(Tertiary granule) 
Secretory vesicles 
Membrane proteins 
Adhesion 
molecules 
N.A CD11b/CD18, CD66, 
CD67 
  
Antibacterial 
proteins 
N.A Gp91phox/p22phox Gp91phox/p22phox Gp91phox/p22phox 
Proteases N.A N.A MMP25 MMP25 
Receptors N.A uPA N.A CD35, CD14, 
CD16; C1q-R, IFN-
αR1, fMLPR 
Others CD63, CD68, 
presenilin 
SNAP-23, VAMP-2, 
stomatin 
SNAP-23, VAMP-2, 
Nramp1 
SNAP-23, VAMP-
2, Nramp1, alkaline 
phosphatase, DAF, 
CD10, CD13  
Matrix proteins 
Proteases Elastase,  
cathepsin G, 
proteinase-3 
Collagenase (MMP-8), 
uPA 
Gelatinase (MMP-9),  
Arginase 1 
N.A 
Antibacterial 
proteins 
Defensins (including 
human neutrophil 
peptides 1-3), BPI, 
MPO, lysozyme 
hCAP18, NGAL, 
B12BP, lysozyme, 
lactoferrin, 
haptoglobin, pentraxin 
3, prodefensin 
lysozyme N.A 
Others Sialidase, azurocidin 
(heparin-binding 
protein), β-
glucuronidase 
SLPI, orosomucoid, 
heparanase, β2-
microglobulin, 
CRISP3 
β2- microglobulin, 
CRISP3 
N.A 
B12BP, vitamin 12 binding protein; BPI, bactericidal permeability-increasing protein; CRISP, 
cysteine-rich secretory protein; DAF, decay-accelerating factor; hCAP, human cathelicidin 
antimicrobial protein; MPO, myeloperoxidase; NGAL, neutrophil gelatinase associated lipocalin; 
Nramp1, Natural resistance-associated macrophage protein 1; SLPI, secretory leukocyte peptidase 
inhibitor; SNAP, Synaptosomal-associated protein; uPA, urokinase plasminogen activator; VAMP, 
vesicle-associated membrane protein 
Modified from Borregaard et al [79]  
Table 1:  Neutrophil granule proteins.  Proteins mentioned in this thesis have been 
italicised. 
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3.2 Neutrophils in innate immunity 
 Neutrophils are highly mobile phagocytic cells and need to cross the vascular 
endothelial wall to arrive at the portal of entry of pathogens.  Migration occurs 
predominantly at postcapillary venules where the wall vessel is rather thin.  The initial   
attachment of neutrophils to endothelial cells is determined by the expression of integrins 
on their luminal surface and this mediates neutrophil rolling and firm adhesion (see picture 
below) [80].  Neutrophils then undertake a transcellular or paracellular route for 
transmigration and thereafter cross the endothelial lining, migrating through the basal 
membrane. They are highly equipped with proteases capable of breaking down basement 
membrane collagens and laminin including neutrophil elastase, MMP-8, MMP-9 and 
membrane attached matrix metalloproteinase MT6-MMP.   
 
Adapted from Kolaczkowska and Kubes, Nat Rev Immunol 2013 
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 Once they have migrated into tissues, they are more active as phagocytic cells than 
those neutrophils circulating in the blood [81], activating gene expression that results in the 
secretion of chemokines including IL-8 and attracting more of their kind.  Upon encounter 
with a pathogen these cells activate NADPH oxidase, generating reactive oxygen 
intermediates in an attempt to kill the pathogen.  The initiation of NADPH oxidase 
coincides with degranulation with a lag phase of approximately 20 seconds [82].  
Degranulation occurs with gelatinase granules being mobilised first, before specific 
granules.  Azurophil granules can only be partially mobilised [83].   The process of 
phagocytosis is dependent on the Fcγ receptors which initiate the extension of pseudopods 
that surround and ultimately entrap the pathogen [84].  Once engulfed, the abundant 
cytoplasmic granules which are bactericidal are discharged into the phagosome containing 
the microbe.  Changes in cystosolic calcium are required for granular fusion  with 
phagosomes in neutrophils [85].  It is also believed that protein kinases such as the Src 
family of protein tyrosine kinases are implicated in phagosome maturation [86].   
 Further to the formation of the mature phagosome, microbes which also have been 
termed pathogen-associated molecular patterns (PAMPs) interact with pattern-recognition 
receptors (PRRs) including toll-like receptors (TLRs).  TLRs 1,2 and 4-10 are expressed in 
human neutrophils [87, 88].  Activation of neutrophil TLRs especially TLRs-2 and -4 
activate signal transduction pathways that eventually enhances cell vibility [89], facilitate 
adhesion[90], phagocytosis [87], enhance release of cytokines and chemokines [87] and 
promote degranulation[91]. 
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 Cross-talk occurs between components of the innate immune system and 
neutrophils.   CCR2, the receptor for CC chemokine ligand 2 (JE, MCP-1) are highly 
expressed in circulating monocytes [92] and are critical not only for monocyte influx but 
also early accumulation of neutrophils [93].  Furthermore, components of neutrophil 
secretion such as LL-37 and heparin-binding protein can recruit inflammatory monocytes 
[94].  It has been shown that macrophages acquire neutrophil anti-microbial granule 
proteins when they engulf apoptotic neutrophils, providing a co-ordinated defence strategy 
involving different innate immune cells against invading pathogens [95].  For example, 
neutrophil granule proteins heparin-binding protein and the defensin human neutrophil 
peptides 1-3 (HNP1-3) triggers secretion of macrophage TNF-α and IFN-γ, concurrently 
thereby enhancing phagocytosis of Staphylococcus aureus [96].  There are thus 
considerable intercellular networks and crosstalk involving neutrophils. 
3.3 Neutrophil extracellular traps (NETs) 
 Neutrophil extracellular traps are a distinct anti-microbial activity that has been 
recently described [97].  They are a meshwork of chromatin fibers that contain granule-
derived antimicrobial peptides and enzymes extruded by neutrophils and are triggered 
when encountering microbes, or upon stimulation with Phorbol-12-myristate-13-acetate 
(PMA). The NET scaffold consists of chromatin fibers and comprises DNA and histones 
[97].  Mass spectrometry has identified an array of neutrophil granule proteins some of 
which possess anti-microbial properties associated with NETs [98].  The mechanism of 
how NETs are formed, termed NETosis, has been a subject of intense interest and 2 
models have been proposed.  The first proposes a form of active cell death, characterised 
by the dissolving nuclear and granular membranes, with nuclear contents decondensing 
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into the cytoplasm followed by plasma membrane rupture, and subsequent release of 
decondensed chromatin with granular contents into the extracellular space [97, 99].   The 
second proposed model involves the release of mitochondrial DNA with serine protease 
extrusion from intact neutrophils and is not associated with cell death [100].   There have 
also been in vivo studies demonstrating that neutrophils are live, mobile and anuclear after 
NET formation has occurred [101].    A vast array of micro-organisms ranging from 
viruses, bacteria, fungi and protozoa can trigger NET formation which serves to entrap and 
prevent further dissemination of pathogens.  NETs are however double-edged swords.  
They have been described as a source of autoantigens and immunostimulatory proteins and 
have been discovered to have crucial roles in inflammatory diseases such as systemic lupus 
erythematosis, vasculitis, gout and even thrombotic microangiopathies [102, 103].  The 
biological significance of NETs is just beginning to be revealed.   
3.4 Neutrophils in adaptive immunity 
 Phagocytosis of bacteria simultaneously triggers the transcription of neutrophil 
genes encoding numerous chemokines and cytokines including IL-1α, IL-1β, IL-6, IL-8, 
IL-12β, IL-15, IL-18, CCL2 (MIP1α), CCL3 (MIP1β) , TNFα,  VEGF and oncostatin M 
[71, 104-106].  Further to recruiting more neutrophils and subsequently modulating 
neutrophil functions, these molecules coordinate early responses of monocytes, 
macrophages, dendritic cells, natural killer (NK) cells and lymphocytes [71], serving as a 
bridge between the innate and adaptive immune responses [71].  More recent studies have 
demonstrated that human neutrophils are a main source of cytokines such as B cell-
activating factor (BAFF) [107, 108] and a proliferation ligand APRIL [107, 109] that are 
critical for the survival, maturation and differentiation of B cells.  The initial evidence that 
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neutrophils can interact with dendritic cells (DCs) s from investigations demonstrating that 
supernatants of cultured murine neutrophils stimulated with Toxoplasma gondii and this 
resulted in the maturation of bone marrow-derived DCs and their production of IL-12 and 
TNFα [110] while DCs in neutrophil-depleted mice infected with T. gondii had suppressed 
IL-12 and TNFα secretion.  Human neutrophils can modulate NK cell activation status, 
survival, cytotoxic activity and IFNγ secretion by the generation of reactive oxygen 
intermediates or the release of granule components [111, 112].  Additionally, crosstalk 
between human neutrophils and NK cells is present.  Culture of neutrophils with NK cells 
or NK cell-derived soluble factors such as GM-CSF and IFNγ induces neutrophil survival, 
expression of activation markers, priming of reactive oxygen intermediates [113, 114].  On 
a similar note, human neutrophils can also crosstalk with T-cells.  Activated neutrophils 
can attract Th1 and Th17 cells to sites of inflammation with the release of CCL2, CXCL9 
and CXCL10 and CCL20 [115].  Likewise, activated CD4 and CD8 T cells including Th17 
secrete cytokines such as IFNγ, GM-CSF and TNFα that modulate neutrophil survival and 
expression of activation markers [115, 116].   
  
3.5 The significance of neutrophils in TB 
 While it is accepted that neutrophils play an important role in the first line of 
defence against intracellular pathogens, the role of neutrophils in the pathogenesis of 
tuberculosis remains controversial.  This is partly due to a substantial body of literature 
that is derived from animal models, presenting us with a contradictory picture of the 
importance of neutrophils in tuberculosis.  Clinical studies and experimental infections 
have shown that acute pulmonary tuberculosis is accompanied by an influx of neutrophils 
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[117-121] and neutrophils are present in the early stages of TB infection [122-124].  It is 
well recognised that good quality sputum from patients with mycobacterial infections are 
neutrophil rich with 92% of sputum that contains neutrophils being smear and culture 
positive [125]. Furthermore, human studies show that neutrophils play a role in the risks of 
contracting TB with lower peripheral blood neutrophil counts [126], can be used to 
diagnose active TB from other infectious diseases [127] and when present in large numbers 
reflect a worse disease prognosis [128].    They are the predominant phagocytic cells in 
patients with pulmonary tuberculosis [121] and are found in sites of alveolar inflammation 
[129].  Neutrophil depletion ex vivo impaired the ability of whole blood to restrict 
mycobacterial growth via depletion of secreted anti-microbial peptides [126].  Conversely, 
severity of disease seemingly correlates with the degree of neutrophilia in humans:  
neutrophils are abundant in cavitatory pulmonary TB [118], and a high proportion of 
peripheral blood neutrophils is associated with poor prognosis and delayed sputum culture 
conversion [128, 130].  In murine TB models, a predominant neutrophilic response is 
frequently seen in genetically susceptible strains [131], in mice with impaired immune 
functions [132] as well as in infections with virulent compared to their attenuated 
counterpart [123].  Necrosis has been induced in the granulomata of mice with established 
M.tb infection by stimulating neutrophil influx using nasal LPS [133].   
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3.6 Neutrophil response to M. tuberculosis 
 Neutrophils contribute to the early defence against mycobacteria, as mice depleted 
of neutrophils have an increased bacterial load [134].  They are rapidly recruited to the site 
of M.tb infection and engulf the microbe [135].  Following the encounter with M. 
tuberculosis, neutrophils are activated, undergo a respiratory burst with release of 
superoxide radicals [136]  and have an increased phagocytic activity [137], a process 
which is calcium dependent and mediated by annexins [138].  Opsonisation appears to 
enhance neutrophil phagocytosis of M.tb [138].  The pathogen is killed or inactivated upon 
fusion of the neutrophil phagosome with lysosomal compartments and specialised 
cytoplasmic granules that contain a vast arsenal of antimicrobial effector molecules.  α-
defensins (HNP 1-3) [126], myeloperoxidase [139], neutrophil peptides cathelicidin LL-37 
and lipocalin-2 [126] have been demonstrated to have microbicidal activity or restrict 
growth of M.tb.  In addition to their direct microbicidal role, neutrophils secrete 
chemokines and cytokines such as TNF-α , IL-8 [140],  GRO-α [141] and MIP-1α [142] on 
exposure to M.tb to attract and instruct other immune cells.  M.tb also induces subcellular 
changes on infected neutrophils, leading to neutrophil-extracellular traps (NETs) which 
ensnare mycobacteria [143]. In one of the final stages of the neutrophil-microbe encounter, 
M.tb activates caspase-3 thereby causing apoptosis in human neutrophils [33].  They may 
also undergo necrotic cell death which is deemed less desirable as this may prevent the 
cross-presentation of antigens to antigen-presenting cells via apoptotic vesicles [144].  
Furthermore, the loss of plasma membrane allows the release of proteolytic enzymes and 
the antimicrobial arsenal which are likely to be detrimental to innocent bystanding host 
cells. 
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3.7 Neutrophil networks in the immune response against M.tb 
 There is increasing evidence that neutrophils play a role in coordinating both the 
host innate and adaptive immune response against M.tb.  The phagocytosis of M.tb-
induced apoptotic neutrophils markedly increased the production of proinflammatory 
cytokine TNF-α by human macrophages [145, 146] and results in decreased viability of 
intracellular M. tuberculosis [95]. IL-10 secreted by mycobacteria-stimulated murine 
neutrophils controlled the inflammatory response of dendritic cells, monocytes and 
macrophages in the murine lungs [147].  Similarly, phagocytosis of M.tb-induced apoptotic 
neutrophils by dendritic cells leads to lymphoproliferation [144].  Neutrophils also assist 
dendritic cells to cross-present mycobacterial antigens to T cells [148].  In vitro, dendritic 
cells that acquire mycobacterial antigens from apoptotic neutrophils migrate more 
efficiently compared to directly infected dendritic cells [149].  Recent studies have shown 
that recruitment of neutrophils and inflammatory monocytes occurs early in TB infection 
and precede the rise of IL-12 with consequent accumulation of adaptive T cells [122].   
Conversely, defects in T-cell immunity, primarily in patients with HIV, affects neutrophil 
functions towards M.tb including that of decreased respiratory burst [150], decreased 
chemotaxis [151] and impaired degranulation [152].  
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4. Matrix metalloproteinases 
 The matrix metalloproteinases (MMPs) currently comprises 25 related but distinct 
family of zinc-containing proteases of which 24 are found in mammals.  They share 
structural domains but differ in substrate specificity, cellular sources and inducibility.  
They are sub-classified on the basis of substrate specificity, such as the collagenases, 
gelatinases, stromelysins, matrilysin and elastase [153]. Their characteristics and substrates 
are detailed in Table 2.  MMPs have a flexible proline-rich hinge region and a carboxy 
(C)-terminal hemopexin-like domain, which functions in substrate recognition.  They are 
often the enzymes responsible for the turnover, degradation, catabolism and destruction of 
the extracellular matrix (ECM).   They are secreted or anchored to the cell surface, thereby 
confining their catalytic activity to membrane proteins and proteins in the secretory 
pathway or extracellular space.  Similar to all secreted proteinases, the catalytic activity of 
MMPs is regulated at four points — gene expression, compartmentalization (i.e 
pericellular accumulation of enzymes), pro-enzyme (or zymogen) activation and enzyme 
inactivation — and is further controlled by substrate availability and affinity.  MMPs have 
specific inhibitors, the Tissue Inhibitors of MMPs (TIMPs) that bind non-covalently in a 
1:1 manner to inactivate them [154].   
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Enzyme Common 
name 
Substrates Activated by Activator of 
Collagenases 
MMP-1 Collagenase-1 
(Interstitial 
collagenase, 
fibroblast 
collagenase) 
Collagen I, II, III (III>I), VII, 
VIII, X, gelatin, aggrecan, 
versican, proteoglycan link 
protein, L-selectin, entactin, 
tenascin, serpins, α2-
macroglobulin, Latent TNF 
MMP-3, -10, 
plasmin, 
kallikrine, 
chymase 
MMP-2 
MMP-8 Collagenase-2 
(Neutrophil 
collagenase) 
Collagen I, II, III (I>III), VII, 
VIII, X, gelatin, aggrecan, 
fibronectin, laminin, serpins, 
α2-macroglobulin 
MMP-3, -10, 
plasmin 
ND 
MMP-13 Collagenase-3 
(Rat 
collagenase) 
Collagen I, II, III (II>I or III), 
IV, IX, X, XIV, gelatin, 
aggrecan, perlecan, 
fibronectin, laminin, tenascin, 
fibrillin, serpins 
MMP-2, -3, -10,  
-14, -15, plasmin 
MMP-2, -9 
Gelatinases 
MMP-2 Gelatinase A 
(72-kDa 
gelatinase) 
Gelatin, collagen I, IV, V, 
VII, X, XI, XIV, aggrecan, 
versican, proteoglycan link 
protein, fibronectin, laminin, 
laminin-5, fibrillin, elastin, 
vitronectin, α2-
macroglobulin, latent TNF  
MMP-1, -7, -13,  
-14, -15, -16, -24 
MMP-9, -13 
MMP-9 Gelatinase B 
(92-kDa 
gelatinase) 
Gelatin, Collagen IV, V, VII, 
X, XIV, aggrecan, versican, 
proteoglycan link protein, 
fibronectin, elastin, 
vitronectin, α1-antitrypsin, 
α2-macroglobulin, latent 
TNF, latent TGF-β1, latent 
VEGF, fibrin, NG2 
proteoglycan 
MMP-2, -3, -13, 
plasmin 
ND 
Stromelysins 
MMP-3 Stromelysin-1 
(Transin-1) 
Collagen III, IV, V, IX, X, 
gelatin, versican, aggrecan, 
perlecan, fibronectin, 
laminin, tenascin, fibrillin,  
latent TGF-β 
Plasmin, 
kallikrein, 
tryptase, elastase, 
cathepsin G 
MMP-1, -8, -
9, -13 
MMP-10 Stromelysin-2 Collagen III, IV, V, gelatin, 
nidogen, aggrecan, 
fibronectin, elastin 
Plasmin, 
kallikrein, 
elastase, 
cathepsin G 
MMP-1, -7, -
8, -9 
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MMP-11 Stromelysin-3 α1-proteinase inhibitor, 
fibronectin, laminin 
Furin ND 
Membrane-type MMPs 
MMP-14 MT1-MMP Collagen I, II, III, gelatin, 
aggrecan, fibronectin, 
laminin, tenascin, vitronectin, 
fibrillin 
Plasmin, furin MMP-2, -13 
MMP-15 MT2-MMP Aggrecan, fibronectin, 
laminin, fibrin 
ND MMP-2, -13 
MMP-16 MT3-MMP Gelatin, casein, fibrin, 
Syndecan-1 
ND MMP-2 
MMP-17 MT4-MMP Gelatin, latent TNF ND MMP-2 
MMP-24 MT5-MMP ND ND MMP-2 
MMP-25 MT6-MMP 
(Leukolysin) 
ND ND ND 
Other MMPs 
MMP-7 Matrilysin Collagen IV, gelatin, 
aggrecan, fibronectin, 
laminin, elastin, vitronectin, 
Pro-α defensins 
FAS ligand, Latent TNF, 
Syndecan-1, E-cadherin, 
Elastin 
MMP-3, plasmin MMP-2 
MMP-12 Metalloelastase Collagen IV, gelatin, 
aggrecan, fibronectin, 
laminin, fibrillin, elastin, 
vitronectin, latent TNF, α1-
antitrypsin 
ND ND 
MMP-19  Gelatin trypsin ND 
MMP-20 Enamelysin Amelogenin ND ND 
MMP-21  ND ND ND 
MMP-22  ND ND ND 
MMP-23 CA-MMP ND ND ND 
MMP-26 Endomelase ND   
MMP-27  ND   
MMP-28 Epilysin ND   
 ND, Not determined. 
Modified from Parks et al[153], Kahari et al [155], Chandler et al [156] and Ashworth et al 
[157]. 
Table 2:  Matrix metalloproteinases, substrates, endogenous activators and their 
activating capacity.  
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 Physiological processes such as cell migration, embryonic development, 
reproduction and tissue remodelling involve MMPs.  MMP-1 is required for the repair of 
skin wounds, altering the migratory substratum that consists of Type I collagen [158].  
Similary, MMP-7 is expressed by wound-edge epithelial cells in mucosal tissues and is 
required for re-epithelialisation.  This presumably happens with the shedding of E-
cadherin, loosening cell-to-cell contacts thereby facilitating cell migration [159].  MMP-7 
also activates intestinal pro-α-defensins in murine models, and due to the lack of mature 
active α-defensins, MMP-7 deficient mice have impaired ability to mount a response 
towards pathogenic enteric organisms [160].   
 Specific MMPs control chemokine activity and this is mediated by MMP cleavage 
of these molecules resulting in enhancement, inactivation or antagonism of chemokine 
activaties.  CCL7 (MCP-3) is a substrate of MMP-2, losing its chemokine activity when 
cleaved [161].  On the same note, MMP-1, -3, -13 and -14 cleave MCP-1, MCP-2 and 
MCP-4 resulting in antagonist factors [161].  In contrast, the processing of IL-8 by MMP-9 
markedly increases its chemotactic activity [162, 163].  Similarly, ADAM-17, a member of 
the disintegrin family of metalloproteinases (ADAMs) cleave pro-TNFα into active TNFα 
[164, 165].  Several other MMPs including MMP-1, -2, -3, -9 and -17 can also process pro-
TNF to its active form in vitro [165, 166].   
 On the other hand, MMPs are also implicated in many disease processes involving 
abnormal matrix turnover, such as arthritis, tumour invasion and atherosclerosis.  Studies 
have confirmed the critical role of MMPs, specifically the collagenases as mediators of 
arthritic diseases [167], demonstrating that rheumatoid synovial tissue invading and 
destroying collagen.  As a result, there is a focus of therapies that specifically target these 
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enzymes.  The association of matrix breakdown and cancer is well-established and 
destruction of the basement membrane is a hallmark of malignancy.  This activity was the 
attributed to specific MMPs when Type IV collagenases/gelatinases MMP-2 and MMP-9 
were cloned and when the correlation between MMP-3 expression and tumour progression 
in mouse skin was shown [168].  The original concept of MMPs breaking down basement 
membranes to allow tumour cells to metastasise was challenged when it was shown that 
TIMP-1 expressing tumour cells can breach blood vessel endothelium and leave the 
circulation efficiently but cannot grow once they reach a secondary site [169].  
Subsequently, it was realised that MMP inhibition may not necessarily prevent escape of 
the tumour cells but it can be useful to keep small metastatic lesions in a dormant state.  
The interest in MMPs as a therapeutic target for cancer increased when MMPs were further 
shown to contribute to tumour angiogenesis and consequently affected the growth potential 
of primary and metastatic lesions [170, 171]. 
 MMPs were a prime target in the 1990s for drug development [172].  Batimastat 
was the first MMP inhibitor to be tested in humans [173] with the drug administered 
through intraperitoneal and intrapleural administration to treat oncological disease.  
Batimastat was rapidly replaced by Marimastat, a related compound which can 
administered through the oral route.  Nevertheless, it was soon reported that sustained 
treatment with Marimastat caused severe arthralgia commencing with the hands and 
spreading through the extremeties.  In an attempt to create specific inhibitors, those 
interested in oncological applications designed MMP inhibitors selective for gelatinases 
but with limited activity against collagenases.  Conversely, collagenases were considered 
the optimum target for arthritis.  By the 2000s, the pendulum had swung the other way 
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when multiple clinical trials demonstrated that oncology patients administered MMP 
inhibitor faired worse in terms of survival benefit than their placebo-treated counterparts 
[174] .  Further investigations are required to be done before concluding that MMP 
inhibitors do not have any beneficial effect.   
 One disease of which the role of MMPs is well understood is periodontitis.  
Inflammatory cytokines elicited by bacteria result in considerable tissue destruction by 
MMPs and loss of teeth.  This can be prevented by treating with doxycycline which 
inhibits MMP activity and also seem to decrease MMP expression.  Doxycyline is the only 
MMP inhibitor licensed by the US Food and Drug Aministration [175].    
 Other avenues in which MMP inhibitors have been investigated as therapeutic 
targets include corneal ulcers [176] as well as Batimastat-coated stent in the setting of 
restenosis after coronary angioplasty [177].  In animal models, MMP inhibitors could be 
effective in diseases such as multiple sclerosis, glomerulonephritis, emphysema, aortic 
aneurysm, bacterial meningitis and graft-versus-host disease [177].  Further evaluations are 
required before it can be truly ascertained that MMP inhibitors are beneficial in these 
context in humans. 
4.1 Matrix metalloproteinases in tuberculosis 
 As M. tuberculosis establishes infection, the local cellular organization of the 
surrounding tissues is modified to facilitate leucocyte infiltration and initiation of 
granuloma formation.  MMPs are likely to play a role in the tissue remodelling and 
destruction during the process [178]. Infection by M.tb has been shown to induce the 
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secretion of MMP-1, -2, -7 and -9 [179-181] as well as a decrease in expression of TIMP-
1, -2 and -3 [154, 182] from peripheral blood mononuclear cells and human airway 
epithelial cells. MMP-9 has been demonstrated to be involved in macrophage recruitment 
and granuloma development in an in vivo mouse model of tuberculosis [183]. Studies of 
M.tb infection in MMP-9-deficient mice revealed that host MMP-9 is required for full 
mycobacterial proliferation, as these mice showed reduced bacterial burden and reduced 
lung macrophage recruitment compared with wild type. In addition, the MMP-9 knockout 
mice displayed reduced ability to produce well-formed granulomas.  Volkman et al 
similarly demonstrated using Mycobacterium marinum infection of zebrafishes that MMP-
9 morpholinos (MMP-9 knockdown) transgenic zebrafish have reduced granuloma 
formation [184].   
 Our group has previously shown in two separate studies that MMPs are elevated in 
the induced sputum samples of TB patients.  Elkington et al had compared patients with 
respiratory symptoms with TB patients and found that MMP-1 and -3 were increased 
[185].  TB patients with more extensive disease on the chest radiograph also had a higher 
MMP-1 in their sputum.  Using MMP-1 knock-in transgenic mice, since mice do no 
express an orthologue of human MMP-1, it was demonstrated that there was more matrix 
destruction in such mice compared to wild type mice [185].  Walker et al had shown when 
comparing a cohort of HIV positive and negative patients that MMP-1, -2, -3 and -8 were 
elevated in their induced sputum [186].  It was found MMP-1, -2, -8 and -9 were 
significantly lower in the induced sputum from patients with advanced HIV-TB co-
infection than HIV-negative patients with TB.  In the same paper, doxycycline was shown 
to reduce MMP-1, -3 and TNFα secretion.  At the same time, doxycyline inhibited M.tb 
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growth in vitro as well as in guinea pigs.  These two studies supported the theory that 
MMPs are critical in inducing tissue destruction in TB infection. 
 In previously published work from our group, strong immunohistochemical 
staining of MMP-9 staining was found in monocytic cells at the centre of granuloma in 
M.tb-infected patient lymph nodes with minimal TIMP-1 staining, indicating MMP-9 
activity is unopposed in vivo [187].  Similar findings were found in the cerebrospinal fluid 
(CSF) of patients with TB meningitis [188] where MMP-9 activity was unrestricted by 
TIMP-1. Compared with other forms of meningitis, the MMP-9 per leukocyte ratio was 
significantly increased and associated with signs of tissue damage, such as neurological 
deficit, confusion, unconsciousness and death.  Monocyte-dependent networks have also 
been found to upregulate MMP-9 secretion from astrocytes [189] and correlate in vivo with 
increased immunohistochemical staining of MMP-9 in astrocytes [190].  Furthermore, in 
response to infection with tuberculosis, MMP secretion has also been found to be 
upregulated in other cells including fibroblasts [191], microglial [192], and multinucleate 
giant cells [193]. 
4.2 Matrix metalloproteinases in neutrophils 
 Neutrophils secrete MMP-8 (neutrophil collagenase) and MMP-9 (gelatinase B), 
which are present in the secondary and tertiary granules respectively.  These two MMPs 
are released extracellularly following exposure to bacteria [194, 195], and mycobacterial 
antigens [196].    
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 MMP-8 is an interstitial collagenase that degrades Type I, II and III collagen and 
cleaves chemokines such as IP-10 and MCP-1 [197].  It had been shown that when it 
comes to degradation of Type I collagen, the main structural of protein in human lungs as 
well as other organs in the human body [198], it degrades Type I collagen more potently 
than MMP-1 or MMP-13 [199-201].  It plays a crucial role in the disassembly of cell 
junction components and cell adhesion in bacterial meningitis [202].   
 Neutrophil collagenases have been implicated in diseased states and severity.  
MMP-8 knockout mice when subjected to high-pressure injurious ventilation had 
decreased neutrophil infiltration, lower levels of IFN-γ and significant increases in anti-
inflammatory cytokines IL-4 and IL-10.  Similar results were demonstrated when wild-
type mice were treated with an MMP-8 inhibitor [203].  Neutrophil MMP-8 has been 
found to be elevated in the bronchoalveolar lavage fluid of patients with bronchiectasis 
[204].  Sepper et al utilised 100 μM of doxycycline and its differential inhibition of MMP-
1(IC50 = 280 μM) and MMP-8 (IC50 = 26 μM) at this dose and found that interstitial 
collagenases originated from neutrophils and correlated with disease severity [204]. 
Furthermore, non-healing wounds in humans were found to predominantly have active 
MMP-8 while healing wounds have MMP-8 which are in their inactive form [205].   
 MMP-9 is able to cleave gelatin (denatured collagen) and type IV collagen, one of 
the main components of the basement membrane which also constitute the blood-brain 
barrier (BBB).  In addition, MMP-9 is also able to clip myelin compounds such as myelin 
basic protein (MBP) in humans, which are epitopes for T cells [206, 207], and may play a 
role in antigen presentation and T-cell activation. The major neutrophil chemoattractant, 
IL-8, is processed by MMP-9 and results in a truncation variant with increased activity 
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[208].  This results in an efficient amplification of neutrophil influx to combat infections. 
MMP-9 is thus not only an effector but also a regulator of leukocyte function.  MMP-9 
also has a role for the anti-microbial activity of neutrophil elastase.  With the activation of 
neutrophils, MMP-9 secretion degrades and neutralise serine protease inhibitor α1-
antiproteinase, a potent inhibitor of neutrophil elastase [209].    
 Similar to MMP-8, MMP-9 has been implicated in various diseased states but the 
data has been conflicting.  MMP-9 knock-out mice interestingly developed more severe 
lung injury when subjected to high-pressure ventilation compared to wild-type mice, with 
the effects correlating with an increased cell count and myeloperoxidase activity in the 
bronchoalveolar lavage fluid in the knock-out mice.  This has been attributed to an increase 
in IL-1β and IL-4 in the MMP-9 knockout mice [210].  This differed from clinical studies.  
In patients with viral meningitis, MMP-9 concentrations were found to be elevated 
compared to controls and is associated with CSF neutrophil count [211, 212].  CSF MMP-
8, -9 and TIMP-1 are also raised in patients with bacterial meningitis and raised MMP-9 is 
associated with long-term complications such as hearing impairment and focal epilepsy 
[213].  It is thus unclear if MMP-9 might be protective or harmful and this maybe 
attributed to the divergences in animal models. 
4.3 Neutrophils and MMPs in TB  
 There is limited literature describing neutrophil MMPs in TB.  In TB meningitis, 
CSF MMP-9 is markedly elevated [188, 214, 215] where it is well-recognised that there is 
loss of integrity of the blood-brain-barrier.  CSF MMP-9 activity supersedes that of 
bacterial and viral meningitis and this persists even when corrected for the total CSF 
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leukocyte number [188].  TIMP-1, which binds to MMP-9 was not raised in the CSF of 
patients with TB meningitis compared with those in bacterial meningitis and normal 
controls.   Furthermore, patients with CNS tissue injury, as manifested by unconsciousness 
scored with a Glasgow coma score of less than 11, confusion or focal neutrological deficit 
had significant higher levels of MMP-9/CSF leukocyte compared with other patients.  
Moreover, MMP-9/leukocyte ratios were higher in patients who died compared to 
survivors [188].  In a separate study, it was found that CSF MMP-9 in patients with TB 
meningitis correlated with absolute neutrophil count [215].  The administration of 
dexamethasone, an adjuvant treatment for patients with TB meningitis which improves 
prognosis and neurological outcomes [216], decreased the concentrations of MMP-9 in the 
CSF at day 5 of treatment of TB meningitis.  There was also a similar but less marked 
effect of dexamethasone on MMP-8 concentrations.  MMP-8 and -9 as well as MMP-3 fell 
significantly over the course of 9 months of anti-tuberculous treatment.  This suggests that 
neutrophils may play a central role in the early pathogenesis of TB meningitis. 
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5. Hypothesis and experimental aims 
With the background that neutrophils correlate with CSF MMP-9 and that a high MMP-
9/leukocyte ratio worsens the prognosis in patients with TB meningitis, my hypothesis is 
that in human M.tb infection, neutrophils have a central role in the development of a matrix 
degrading phenotype.  The specific aims of my project are to investigate: 
 MMP and TIMP secretion from M.tb-infected neutrophils 
 Neutrophil networks regulating MMP gene expression 
 MMP and TIMP activity and regulation in neutrophils in vivo  
. 
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1.  M. tuberculosis culture 
 M. tuberculosis H37Rv Pasteur (a kind gift of Dr R. Wilkinson, Imperial 
College London) was cultured in Middlebrook 7H9 medium supplemented with 10% 
ADC enrichment medium, 0.2% glycerol and 0.02% Tween 80 with agitation at 10 
rpm.  Culture growth was monitored with a Biowave cell density meter (WPA, 
Cambridge) and M.tb sub-cultured when the optical density exceeded 1.00.  For 
infection experiments, culture at mid log growth at an optical density of 0.50 – 0.70 
were used, which corresponded to 1 x 108 – 2 x 108 colony forming units (CFU) per ml.  
Optical density was correlated with CFU by performing colony counts in triplicate on 
Middlebrook 7H11 agar supplemented with OADC enrichment medium and 0.5% 
glycerol.  The amebocyte lysate assay (Associates of Cape Cod, East Falmouth, MA) 
was used to assay the endotoxin level of the M.tb culture and this was found to be less 
than 0.3ng/ml lipopolysaccharide.  The growth of luminescent M.tb H37Rv LuxG13 
[217] (a kind gift of Dr Nuria Andreu, Imperial College London) was also used in some 
experiments and these were cultured with the addition of kanamycin at 25μg/ml.  
Luminescence was measured with Glomax 20/20 luminometer (Promega).  In 
experiments assessing M. tuberculosis growth with neutrophil derived MMP-8/-9 (Enzo 
Lifesciences, Exeter, UK), CoNCont or CoNTB, H37Rv was grown with the respective 
agent diluted with 7H9 at an initial optical density of 0.1, and growth monitored using 
the cell density meter.  At specified time points, colony counts were performed on 
Middlebrook 7H11 agar.  This was done by taking 20μl of H37Rv in 7H9 and doing 
serial 1:10 dilutions and plating 20 μL of each dilution onto 7H11.  The plates were 
incubated at 37oC for 2-6 weeks before being read. 
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2. TB supernatant production  
 To control for the presence of TB antigens such as lipoarabinomannan, mycolic 
acid and ESAT-6 in experiments, TB supernatant (TB supp) was used.  This was made 
when M.tb growth reached an optical density of 1 and adding 70 µL of M.tb to 3 mls of 
7H9, and gives the equivalent of TB antigens present in CoMTB at a 1:5 dilution 
(CoMTB is described in Section 6 of this chapter).  The suspension was centrifuged, 0.2 
μm sterile filtered (Nalgene, Hereford, U.K) and frozen at -20 oC for further use. 
 
3.  Neutrophil isolation 
 Blood from healthy volunteers (Outer West London REC reference: 
09/H0709/46) were drawn in preservative-free heparin and mixed with equal volumes 
of 3% dextran/0.9% sodium chloride.  The suspension was incubated in an upright 
position for 20 minutes until a clearly defined interface was discerned.  The leukocyte-
rich plasma was pipetted and centrifuged at 250 x g at 5oC for 10 minutes. The cell 
pellet was resuspended with 0.9% sodium chloride and layered onto Ficoll-Paque (GE 
Healthcare, Little Chalfont, UK) and centrifuged at 400 x g at 20oC for 40 minutes. 
Thereafter, the saline layer and Ficoll were aspirated, leaving the neutrophil/erythrocyte 
pellet. The pellet was subjected to 30 seconds of hypotonic lysis with 0.2% sodium 
chloride and restoration of isotonicity with 1.6% sodium chloride.  The suspension was 
centrifuged at 250 x g at 5oC for 6 minutes, and the cycle is repeated 3 times.   The final 
neutrophil pellet was resuspended in RPMI 1640 supplemented with 10% FCS.  
Neutrophil purity was assessed by means of flow cytometry and staining with mouse 
anti-human CD66c-PE (phyco-erythrin, PE; BD Biosciences, Oxford, UK) and 
analysed on a BD FACSCalibur flow cytometer using CellQuest (BD, Mountain View, 
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California).  Neutrophil purity was over 98%. (Figure 1). Viability was consistently 
>99% by trypan blue viability assay.   
 
Figure 1: FACS analysis of neutrophil preparations.  Cells isolated were labelled 
with CD66c-PE  or isotype control and 10 000 events were gated. 
 
 Initially, there was a concern that neutrophils isolated using this protocol would 
be activated as control neutrophils were secreting substantial amounts of MMP-8 and 9 
at time = 0 (data not shown).  A trip to the University of Sheffield to Professor Moira 
Whyte‘s neutrophil laboratory was made to learn neutrophil isolation using Optiprep 
followed by Magnetic Activated Cell Sorting (MACS), and neutrophil supernatant from 
this method at time = 0 was also collected.  Baseline MMP-8, -9 and IL-8 as a marker 
for neutrophil activation from the 2 techniques were analysed, and were found to be 
comparable (Figure 2) and so the Ficoll-Hypaque hypotonic lysis method was used to 
isolate neutrophils.    
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Figure 2: MMP-8, -9 and IL-8 secretion from neutrophils from two different 
isolation protocols.  7.5 x 105 neutrophils were extracted using each protocol and 
supernatants at time = 0 was collected and analysed.  Experiment was done once with a 
single sample.  
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4. Neutrophil infection protocol 
 Neutrophils were infected immediately after isolation using M.tb at an OD of 
0.5-0.7 to provide the correct multiplicity of infection (MOI).  Initially, infection of 
neutrophils was done using M.tb in 7H9. Preliminary experiments demonstrated that 
neutrophils inherently release more MMPs with 7H9 compared to the PBS control 
(Gibco, Invitrogen, UK) (Figure 3), and so after this, infection of neutrophils was done 
with M.tb resuspended in PBS. This may be due to the effect of L-glutamate since it has 
been shown that L-glutamate also upregulates MMPs from astrocytes [218].  
Neutrophils were also found to secrete more MMPs with normal polystyrene tissue 
culture plates (data not shown) and after discussing with the neutrophil lab at University 
of Sheffield, subsequent experiments were done in 96-well flat bottom PVC plates 
(VWR, Leicestershire, UK) or polypropylene eppendorfs which resolved this problem.   
 
Figure 3: Effect of growth media on MMP-8 and -9 secretion from neutrophils.  1 
x 106 neutrophils were incubated with the stated media or M.tb MOI of 1 for 4 hours.  
Bars represent mean +/- SD of an experiment done in triplicate and is representative of 
2 independent experiments.  
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 The effect of M.tb infection versus concentration of neutrophils demonstrated a 
dose response in MMP secretion (data not shown). It was decided that a final 
concentration of 5 x 106 cells / ml should be used to reflect normal human physiology, 
and is within the concentration range often used in literature for neutrophil infection 
and stimulation experiments. After infecting neutrophils with M.tb at an MOI of 1 for 4 
hours, cell culture medium was collected and filtered through 0.2-μm sterile-filters 
(Nalgene, Hereford, U.K). Conditioned medium from M. tuberculosis infected 
neutrophils was termed CoNTB, and conditioned medium from uninfected neutrophils 
was termed CoNCont. 
 In inhibition experiments, neutrophils were preincubated for 30 minutes with 
p38 inhibitor  SB 203580 (Calbiochem), ERK inhibitor PD 98049 (Calbiochem), PI3 
kinase inhibitor  LY294002 (Enzo Life Sciences, Exeter, UK), Wortmannin (Sigma-
Aldrich), NF-kB inhibitor Helenalin (Sigma-Aldrich), IKK2 inhibitor SC-514 (Enzo 
Life Sciences), AMPK activator AICAR (Sigma-Aldrich), AMPK inhibitor  Compound 
C (Merck Biochemicals), Rapamycin (Sigma-Alrich), Akt VII inhibitor (Calbiochem) 
and dexamathasone (Sigma-Aldrich). 
5.  Monocyte purification and maturation into macrophages 
 Monocytes were isolated from single donor Component Donation Cones from 
the National Blood Transfusion Service, Colindale.  The leukocytes were mixed 50:50 
with Hanks‘ Balanced Salt Solution (HBSS), layered onto Ficoll Paque (GE Healthcare, 
Little Chalfont, UK) and centrifuged at 480 x g   for 30 minutes. The mononuclear cell 
layer was removed and then washed a total of five times in HBSS, spinning down the 
cell pellet at 308 x g after each wash.  Total monocytes were calculated by counting the 
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number of adherent cells in a Neubauer counting chamber after incubation for 5 
minutes at 37o. Monocytes were plated in at 250,000 monocytes /cm2 diluted in RPMI 
1640.  After one hour, non-adherent cells were removed by washing three times with 
HBSS, then the media was replaced with RPMI 1640 supplemented with 2mM 
glutamine and 10μg/ml ampicillin.  Monocyte purity was assessed using 2 colour flow 
cytometry for anti-CD3 (fluorescein isothiocyanate, FITC) and anti-CD14 (phyco 
erythrin, PE) and analysed on a BD FACSCalibur flow cytometer.  Monocyte purity 
was over 95%, with less than 5% cells CD3 positive.  For maturation into monocyte 
derived macrophages (MDM‘s), monocytes were cultured in RPMI 1640 supplemented 
with 2mM glutamine, 10% fetal calf serum (FCS), 10μg/ml ampicillin and 20ng/ml 
macrophage colony stimulating factor (M-CSF, R&D, Abingdon, UK).   After 4 days in 
the growth factor containing media, the media was changed to RPMI with 10% FCS but 
no growth factors, and 24 hours later the experiment was commenced.  
6. Monocyte infection protocol 
 Monocytes were infected immediately after the completion of adhesion 
purification, using M.tb at OD of 0.6 at multiplicity of infection (MOI) of 1.  Trypan 
blue exclusion was used to compare cell viability in uninfected and infected monocytes 
at 24 hours.  No difference in trypan blue uptake was observed.  At 24 hours, cell 
culture medium was collected and filtered through 0.2-μm sterile-filters (Nalgene, 
Hereford, U.K.). Conditioned medium from M. tuberculosis infected monocytes was 
termed CoMTB, and conditioned medium from uninfected monocytes was termed 
CoMCont.  Each batch of CoMTB and CoMCont was tested on A549 adenocarcinoma 
cell lines (ECACC) and the MMP-1 concentration secreted from the cells was 
measured.  CoMTB which had previously been tested before was used as a positive 
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internal control for comparison.  CoMTB contains minimal MMPs in part due to the 
sterile filtration process [219] and also verified with MMP-8 and -9 ELISAs (see Figure 
8A). 
 
7. Sterilisation of cell culture supernatants 
 Following experiments involving M.tb, samples required removal of M.tb by 
filtration before analysis.  Supernatants are centrifuged at 12 000 x g for 5 minutes, and 
subsequently transferred to 0.2 µm PVDF centrifugal filter units (Millipore, Watford, 
UK ) whereupon a further centrifugation at 12 000 x g for 1 minute was undertaken.     
8. Astrocyte and microglial cell culture 
 Human astrocytoma cell lines U87-MG, U373-MG Uppsala and U251 MG 
(ECACC nos. 89081402, 08061901, and 09063001 respectively) were maintained in 
Eagle‘s MEM supplemented with 10% FCS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 1% nonessential amino acids, and 10 µg/ml ampicillin according to the 
supplier‘s instructions. All experiments were performed in serum-free medium before 
passage 15. 
 Human CHME3 microglial cells (used with permission of Marc Tardieu, Paris, 
France, and kindly provided by Nicola Woodroofe, Sheffield Hallam University, 
Sheffield, U.K.) were maintained in DMEM with 10% FCS, (Biosera, Ringmer, U.K.) 
and 3 mM glutamine. Cells were seeded at 35– 50,000 cells per cm2 for experiments, 
which were performed in Macrophage Serum-Free Medium (Invitrogen).  
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9. MMP-8 and -9 ELISA 
 MMP-8 and 9 concentrations in cell culture medium were measured by Duoset 
ELISA Development System (R&D Systems) according to the manufacturer‘s 
instructions. ELISA plates were coated with 100 µL of capture antibody at 2.0 µg/ml 
and 1.0 µg/ml respectively overnight at room temperature, then washed three times with 
PBS / 0.05% Tween.  Free binding sites were then blocked for 1 hour with PBS / 1% 
BSA at room temperature.  Standards (serial dilutions 4000 to 62.5 pg/ml for MMP-8 
and serial dilutions 2000 to 31.25 pg/ml for MMP-9) and samples (1 in 30 and 1 in 300 
for MMP-8 in PBS / 1% BSA; 1 in 300 and 1 in 3000 for MMP-9) were added to the 
appropriate wells and incubated for 2 hours at room temperature.  After 3 washes, the 
detection antibody (50 ng/ml MMP-8; 200ng/ml MMP-9) was added for 2 hours at 
room temperature, 3 further washes were performed, then 100μl streptavidin-HRP (1 in 
200 dilution) was incubated with each well for 20 minutes, before washing again.  
100μl substrate solution containing tetramethylbenzidine (Sigma-Aldrich) was then 
added per well and the plate incubated for 1-5 minutes.  The reaction was then stopped 
with 50 µL per well of 2M sulphuric acid and the plate read at 450nm using a 
microplate reader (µQuant, Biotek Instruments, UK).  
10. TIMP-1 and 2 ELISA 
 TIMP-1 and 2 concentrations were measured using the Duoset ELISA 
Development System (R&D Systems) according to the manufacturer‘s instructions 
using protocols similar to those for MMP ELISAs.  ELISA plates were coated with 
100μl of capture antibody at 2.0μg/ml overnight at room temperature, then washed 
three times with PBS/ 0.05 % Tween 20.  Free binding sites were blocked for 1 hour 
with 1% BSA in PBS at room temperature.  After 3 washes, samples (1 in 3 and 1 in 30 
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dilutions, made in the appropriate culture medium) and standards (serial dilutions of 
2000 pg/ml to 31.2 pg/ml ) were added and incubated at room temperature for 2 hours 
then washed three times.  100μl of biotinylated detection antibody (50 ng/ml for TIMP-
1 and 2) was added to each well, incubated for 2 hours at room temperature, then 
washed 3 times.  After 20 minutes with 100μl Streptavidin horseradish peroxidise and 3 
further washes, 100 µL of substrate reagent was added to each well.  When the highest 
two standards neared an equal colour change, the reaction was stopped with 2M 
sulphuric acid and optical density was read at 450nm.  
11. Human myeloperoxidase (MPO) ELISA 
 The human MPO Quantikine ELISA kit (R&D Systems) was performed 
according to manufacturer‘s instructions.  100 µL of assay diluent RD1-62 was added 
per well.  Standards were diluted and commencing with a highest concentration of 100 
ng/ml with the lowest at 1.56 ng/ml.  50µL of standards and samples were added per 
well and this was covered and incubated for 2 hours at room temperature on a 
horizontal orbital microplate shaker set at 500 rpm.  The plate was washed three times 
with Wash Buffer.  200µL of MPO conjugate was added to each well and the plate 
incubated for a further hour on the shaker at room temperature.  The plate was washed 
three times, prior to the addition of 200µL of substrate solution and incubated for 20 
minutes in the dark.  50 µL of stop solution was added to each well, and the optical 
density was read using a microplate reader set to 450nm.   The lower limit for detection 
for MPO is 0.1ng/ml. 
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12.   Human neutrophil gelatinase-associated lipocalin (NGAL) ELISA 
 The human NGAL ELISA kit (Bioporto Diagnostics, Denmark) was performed 
according to manufacturers‘ instructions.  Standards commenced at the highest 
concentration of 1000 pg/ml down to the lowest of 10 pg/ml.  100 µL of standard and 
samples were added and incubated for 1 hour at room temperature on a shaking 
platform set at 200 per minute.  The wells were washed three times before dispensing 
100 µL of biotynylated NGAL antibody and incubated for 1 hour at room temperature.  
The plate was washed and then 100 µL of HRP-streptavidin conjugate added and 
incubated for another hour.  After washing 100 µL of TMB substrate (Sigma Aldrich) 
was added into each well for 10 minutes in the dark, and 100 µL of stop solution was 
added.  The wells were read at 450 nm (reference wave-length 650 nm).  The lower 
limit for detection NGAL is 1.6 pg/ml respectively.  
13. Gelatin zymography 
 Substrate zymography analyses total potential enzymatic activity by separating 
proteins on a substrate-embedded gel under non-reducing conditions, then facilitating 
re-constitution of the tertiary structure of the enzyme, followed by incubation to allow 
enzymatic degradation of the substrate.  Breakdown products diffuse out of the gel. 
Staining with Coomassie blue then reveals areas devoid of protein as a light band on a 
dark background  [220].  Both pro-enzymes and active forms are demonstrated as the 
pro-enzymes become activated during the process.   
Cell culture supernatants with 5x loading buffer (0.25M Tris pH 6.8, 50% glycerol, 5% 
SDS, bromophenol blue) were run on an 11% acrylamide gel impregnated with 0.1% 
gelatin (Sigma, Poole, UK) at 180V for approximately 3 ½ hours (buffer 25mM Tris, 
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190mM glycine, 0.1% SDS).  Standards of 2 ng MMP-9 (Oncogene, Nottingham, UK) 
were loaded on each gel.  Once the marker had reached the end of the gel, the gel was 
washed in 2.5% Triton X for 1 hour, then rinsed twice in low salt collagenase buffer 
(55mM Tris base, 200mM sodium chloride, 5mM calcium chloride, 0.02% Brij, pH 7.6) 
prior to incubation at 37o for 16 hours in collagenase buffer.  Areas of gelatinolytic 
activity were revealed by a single step stain-destain method using 0.02% Coomassie 
Blue (Pharmacia, Sweden) in 1:3:6 acetic acid : methanol : water.  Densitometric image 
analysis was performed using Scion Image version Beta.4.0.2.  A central problem to 
zymography is gel to gel variation, so to perform statistical analysis comparing samples 
between gels each densitometric value was divided by the MMP-9 standard value on 
the gel.  Wherever possible, all samples for comparison were run on the same gel to 
minimise this source of variability, and all samples from the same experiment were run 
concurrently.   
14. Western blotting 
 Pelleted neutrophils infected with M.tb or stimulated with CoMTB  at a set time 
point were mixed 1:1 with loading buffer (10% glycerol, 5% 2-mercaptoethanol, 2% 
SDS, 0.06M Tris pH 6.8, Bromophenol blue) before they were stored at -80oC for 
further analysis.  Samples are then heat denatured at 90o for 5 minutes and incubated on 
ice for 1 minute.  8 µL of each sample were then run on at 200V to the end of the 
NuPAGE® 4-12% Bis-Tris gels (Invitrogen, Paisley, UK) with MES (for protein 
<60kDa) or MOPS (for protein >60kDa) SDS Running buffer (Invitrogen, UK).   A 
Rainbow Molecular weight marker (GE Healthcare) was run on each gel.  Protein was 
then transferred onto a nitrocellulose membrane (GE Healthcare) at 400mA for 1.5 
hours (buffer: 20% methanol, 20mM Tris base, 150mM Glycine, 0.1% SDS).  The 
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membrane was then immersed in blocking buffer (1 x TBS, 5% skim milk, 0.1% 
Tween-20) for 1 hour. Primary antibody was diluted in 5% BSA/0.1% Tween in TBS 
with the dilutions listed in Table 3 and incubated overnight at 4oC with agitation.  After 
three washes in PBS with 1% Tween (5 minutes each), secondary antibody was added 
for one hour diluted in blocking buffer.  Blots were then washed three times (5 minutes 
each). ECL Substrate Reagent (Amersham) was added according to manufacturer‘s 
instructions and luminescence was demonstrated by exposing the membrane to 
Hyperfilm ECL (Amersham).  
Antibody Manufacturer Dilution 
Primary antibody   
Mouse anti-human Beta-actin Sigma-Aldrich 1 in 5 000 
Mouse anti-human MMP-8 Abcam 1 in 10 000 
Mouse anti-human MMP-9 Abcam 1 in 10 000 
Rabbit anti-human GAPDH Abcam 1 in 2 500 
Rabbit anti-human histone 2B 
Rabbit anti-human citrulline H3 
Abcam 
Abcam 
1 in 20 000 
1 in 5000 
Rabbit anti-human phospho-Akt Cell Signaling Technology 1 in 1 000 
Rabbit anti-human phospho-
AMPKα1/2(T172) 
Cell Signaling Technology 1 in 1 000 
Rabbit anti-human phospho-ERK Cell Signaling Technology 1 in 1 000 
Rabbit anti-human phospho-JNK Cell Signaling Technology 1 in 1 000 
Rabbit anti-human phospho-p38 Cell Signaling Technology 1 in 1 000 
Rabbit anti-human phospho-p70S6k (T229) Abcam 1 in 500 
Rabbit anti-human phospho-Tuberin 
(S1387) 
Cell Signaling Technology 1 in 2000 
Rabbit anti-human total Akt Cell Signaling Technology 1 in 1 000 
Rabbit anti-human total AMPKα Cell Signaling Technology 1 in 1 000 
Rabbit anti-human total ERK Cell Signaling Technology 1 in 1 000 
Rabbit anti-human total JNK Cell Signaling Technology 1 in 1 000 
Rabbit anti-human total p38 Cell Signaling Technology 1 in 1 000 
Secondary antibody   
Goat anti-mouse IgG (H+L) Jackson Immunoresearch 
laboratories, Baltimore, USA 
1 in 5000 
Goat anti-rabbit HRP linked  Cell Signaling Technology 1 in 2000 
Table 3. Primary and secondary antibodies used for western blotting 
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15. Human Phospho-kinase Array 
 The Proteome Profiler Human Phospho-kinase array kit (R&D Systems, 
Abingdon) which detects 45 phosphorylated proteins was performed according to the 
manufacturer‘s protocol.  Thirty minutes after neutrophils were stimulated with 
CoMTB, the cells were pelleted and lysed in lysis buffer (R&D Systems) before storing 
at -80oC for further analysis.  Total protein concentration was measured by Bradford 
assay (Bio-Rad) and equal total protein was loaded onto each array. Capture and control 
antibodies have been spotted in duplicate on the supplied nitrocellulose membranes and 
these were blocked with array buffer.  Cellular extracts are diluted and incubated 
overnight with the Human Phospho-Kinase Array at 4oC on a rocking platform.  The 
array was washed three times (10 minutes per wash) followed by incubation with a 
cocktail of biotinylated detection antibodies. Three washes of 10 minutes each were 
further done followed by the addition of Streptavidin-HRP.  After a third wash cycle, 
chemilumiscence was demonstrated by addition of ECL Substrate Reagent (Amersham) 
and exposing the arrays to Hyperfilm ECL (Amersham).  Densitometric analysis of 
each array was performed using Scion Image version Beta.4.0.2.  The positive signals 
seen on the developed film were identified by placing the transparency overlay on the 
array image and aligning it with the three pairs of positive control spots in the corners 
of each membrane.  The location of controls and capture antibodies were correlated 
with those in the appendix of the handbook provided. 
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16.    Flow cytometry 
To assess neutrophil viability with CoMCont and CoMTB stimulation, cells were 
stained with Annexin V-FITC and propidium iodide (eBioscience, Affymetrix, 
California, USA) according to manufacturer‘s instructions.  5 x 105 cells were washed 
with PBS, resuspended in 195 μL of 1 x binding buffer with 5 μL of Annexin V-FITC 
added and incubated for 10 minutes in the dark at room temperature.  The cells were 
subsequently washed in 1 x binding buffer before resuspending in 190 μL of 1 x 
binding buffer and 10 μL of propidium iodide at 20 μg/m was added.  50, 000 events 
were collected in the gate of live cells (excluding debris in the FSC versus SSC dot 
plot) and analysed on BD FACSCalibur flow cytometer using CellQuest (BD, Mountain 
View, California).  Data was analysed using FlowJo 7.6.5. 
17. RNA extraction  
 Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Crawley, UK) as 
described by the manufacturer.  2 x 10 6 neutrophils were suspended at a final 
concentration of 5 x 106 cells/ml.  At the relevant time points, cells were pelleted, 
supernatants removed, and the cell pellet was lysed with 350 µL of Buffer RLT and 
homogenised using the Qiashredder (Qiagen) by spinning at full speed for 2 minutes.  A 
volume of 70% ethanol was added to the homogenized lysate, and 700 µL of the sample 
was transferred to an RNeasy spin column before centrifuging for 15 seconds at 12 000 
x g.  350 µL of Buffer RW1 was added to the RNeasy spin column, centrifuged and the 
flow-through discarded.  Genomic DNA was eliminated by the addition of 80 µL of 
RNase-free DNase I digestion (Qiagen) for 15 minutes, before the addition of 350 µL of 
Buffer RW1 to the RNeasy spin column and centrifuge.  Following that, 500 µL of 
Buffer RPE was added to the RNeasy spin column and centrifuged for 2 times.  The 
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RNA was then eluted by the addition of 30 µL of RNase-free water. Total RNA was 
quantified by spectrophotometry (Nanodrop ND 1000, Thermo Scientific).   
18. Real-time Polymerase Chain Reaction 
 As neutrophils have only a small amount of RNA of approximately 1 µg/ 107 
cells [221], quantitative real-time RT-PCR was performed using the OneStep RT- PCR 
master mix (Qiagen, Crawley, UK) according to the manufacturer‘s instruction using a 
Stratagene Mx3000P platform. This allows between 1 pg to 2 µg of RNA to be 
transcribed.  5 – 10 µg per sample was used for MMP-8 and -9 gene amplification. The 
RT-PCR cycling conditions included 50 °C for 30 min, 95 °C for 15 min, followed by 
40 cycles of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min.  VIC-labelled beta-actin 
control reagent (Applied Biosystems) and HEX-labelled GAPDH (Sigma-Aldrich, 
Dorset, UK) were analyzed in parallel. MMP-8 (catalogue no. Hs00233972), AMPKα1 
(catalogue no. Hs01562308_m1) and AMPKα2 (catalogue no. Hs00178903_m1) 
primer and probe mixes were obtained from Applied Biosystems.  MMP-9 and GAPDH  
primers and probes are described in Table 4. 
 
MMP-9 
 
   Forward primer 5‘-AGGCGCTCATGTACCCTATGTAC-3‘ 
   Reverse primer 5‘- GCCGTGGCTCAGGTTCA-3‘ 
   Probe 5‘-FAM-CATCCGGCACCTCTATGGTCCTCG-TAMRA-3‘; 
 
GAPDH 
 
   Forward primer 5‘- CGCTTCGCTCTCTGCTCCT-3‘ 
   Reverse primer 5‘- CGACCAAATCCGTTGACTCC-3 
  Probe 5‘-HEX-CGTCGCCAGCCGAGCCACAT-TAMRA-3‘ 
Table 4: MMP-9 and GAPDH primer and probe sequences. 
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 Initial samples were run in individually to determine the optimal efficiencies of 
both gene of interest before multiplexing was attempted.  MMP-8 and 9 reaction 
efficiencies were 83.1% and 81.5% which were comparable to multiplex reactions (up 
to 96.1% and 104.3% respectively).  Subsequently, RT-PCR reactions were run in 
multiplex. To accurately determine the quantitative change in RNA levels, standard 
curves were prepared from plasmids as described in the proceeding section; plasmids 
standards were diluted in TE buffer and made from 5 x 107 copies/ml in serial 1 in 10 
dilutions down to 5 x 102 copies/ml. These standards were subjected to real-time PCR 
as above. Standard curves for CT vs input RNA were generated, and relative levels of 
starting RNA in each sample were determined. To account for differences in the amount 
of total RNA, the results of each MMP member were normalized to GAPDH levels 
from the same sample. 
 
19. Construction of plasmid standards for real-time PCR 
Plasmid standards were constructed for MMP-1, -3, -7, -8, -9, -10, -14, 18s, beta-actin, 
GAPDH, AMPKα1 and AMPKα2.  PCR was first done for all the genes using 
historical samples with primer and probe sequences listed in Table 4 and Table 5, 
using 2x SYBR Green mix (Sigma-Aldrich) with a thermal profile of activation step of 
95oC for 10 minutes, followed by 40 cycles of denaturation at 95oC for 30 seconds, 
annealing at 60oC for 30 seconds and extension at 72oC for 30 seconds. 
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MMP-1 (Sigma-Aldrich) 
Forward primer  5‘- AAGATGAAAGGTGGACCAACAATT -3‘ 
Reverse primer   5‘ -CCAAGAGAATGGCCGAGTTC -3‘ 
Probe                   5‘- FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA -3‘ 
 
MMP-7 (Sigma-Aldrich) 
Forward primer   5‘-CTTTGCGCGAGGAGCTCA -3‘ 
Rerverse primer  5‘-CAGGCGCAAAGGCATGA -3‘ 
Probe                   5‘- FAM-CCATTTGATGGGCCAGGAAACACG-TAMRA -3‘ 
 
MMP-10 (Sigma-Aldrich) 
Forward primer  5‘- GGACCTGGGCTTTATGGAGATATT -3‘ 
Reverse primer   5‘- CCCAGGGAGTGGCCAAG -3‘ 
Probe                    5‘- FAM- GAAGATGCATCAGGCACCAATTTATTC-TAMRA -3 
 
18s             (Applied Biosystems, catalogue no. 4308329) 
Beta-actin  (Applied Biosystems, catalogue no. 4310881E) 
MMP-3      (Applied Biosystems, catalogue no. Hs00968305_m1) 
MMP-8      (Applied Biosystems, catalogue no. Hs00233972_m1) 
MMP-14    (Applied Biosystems, catalogue no. Hs00237119_m1) 
 
Table 5: Primer and probe sequences of gene of interests and housekeeping genes. 
 PCR products were confirmed by running samples with EZ Vision (Amresco, 
Ohio, USA) on a 2% agarose gel in 1 x TAE buffer at 120V for 30-60 minutes with a 
DNA ladder (Invitrogen, Paisley, UK) and visualising under a UV transilluminator.   
 
 2 plasmids were created for general use: one contained MMP-1, -3 and -7 and 
the other containing MMP-8, -9, -10, -14, GAPDH, beta-actin and 18s. PCR products 
from individual genes were blunt ended using pfu polymerase (Promega, Wisconsin, 
USA) by the addition of 1Ü of enzyme with 60 µL of PCR product and incubating for 
10 minutes at 72oC.  These were then precipitated with equal volumes of PEG and 
placed on ice for 10 minutes.  The pellet was then washed with ethanol and resuspended 
with 30 µL of nuclease free water.  The mix was kinased by adding 1 µL of T4 kinase 
(Promega, Wisconsin, USA), 2 µL of each PCR product to be ligated and the mix was 
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incubated at 37oC for 10 minutes.  Thereafter, 1 µL of T4 ligase (Promega) was added 
with ligation buffer and incubated at room temperature for 15 minutes.  RT-PCR was 
done to obtain the ligated product using SYBR Green and the relevant primers.  The 
size of the product was confirmed by running on 2% agarose gel. 
  
 Once the PCR products were ligated as required, they were cloned using the 
TOPO TA cloning kit(Invitrogen, Paiseley, UK) according to manufacturer‘s 
instructions.  4 µL of fresh PCR product was added to 1 µL of salt solution and 1µL of 
TOPO vector to make up the cloning reaction.  The reaction was incubated for 5 
minutes at room temperature and subsequently placed on ice.  TOP10 competent E.coli 
were thawed on ice, and 2 µL of cloning reaction was added to the cells and incubated 
on ice for 5 minutes.  The cells were heat-shocked for 30 seconds at 42oC and then 
immediately transferred to ice.  250 µL of S.O.C. medium was added and incubated at 
37oC on a horizontal shaker.  After 1 hour, the mixture was added to LB broth 
containing 50 µg/ml ampicillin and incubated overnight at 37oC.  An aliquot was plated 
onto LB agar with 50 µg/ml ampicillin the following day, colonies subsequently 
selected, and grown in LB broth with ampicillin.  To confirm that the colonies 
contained the required gene, 50 µL of cells in broth were pelleted, resuspended in 50 µL 
of nuclease free water and heated at 95oC for 5 minutes to lyse the cells.  The cells were 
then pelleted and the supernatant collected.  PCR was done with 2 µL of supernatant 
with the relevant primer and probe mix and when positive, the appropriate clone was 
grown overnight.  Plasmids were extracted using GenEluteTM HP plasmid Miniprep kit 
(Sigma-Aldrich), and diluted to the desired concentration. 
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20. siRNA mediated gene silencing/knockdown 
 Neutrophil siRNA gene silencing was performed using the Deliver X siRNA 
transfection kit (Panomics, France) according to manufacturer‘s instructions.  Briefly, 5 
µM siRNAs (AMPKα1, AMPKα2, GAPDH and non-targeting siRNA, Dharmacon, 
USA) were prepared in Buffer-1, with the transfection reagent prepared in Buffer-2 
before mixing in a 1:1 ratio.  This was incubated at 37oC for 20 minutes.  Neutrophils 
were pelleted and resuspended with 300 μL of working siRNA/siRNA transfection 
reagent complex and incubated for 5 minutes.  300 µl of serum-free media was added 
and incubated for 4 hours and thereafter, 1ml of complete growth media was further 
added.  Stimulation with CoMTB occurred immediately, or after a rest overnight. All 
experiments were done with non-targeting siRNA. At the end of the experiment, cell 
viability was assessed using a flow cytometer (FACSCalibur, BD Biosciences, USA) 
registering 10 000 events staining for cells positive for propidium iodide (Invitrogen, 
Paiseley, UK).  Cells were then processed as for RNA extraction. 
21. MMP bead array 
 MMP-8 and -9 concentrations were analyzed by Fluorokine multianalyte 
profiling kit according to the manufacturer‘s protocol (R&D Systems, Abingdon, U.K.) 
on the Luminex platform (Bio-Rad, Hemel Hempstead, U.K.).  Samples were diluted 1 
in 5 (non-neutrophil samples) or 1 in 50 (neutrophil samples) with calibrator diluent.  
Standard were reconstituted according to manufacturer‘s instructions and serial 1 in 3 
dilutions were made for a 7 point standard.  The filter bottom plate was pre-wetted with 
100 µL of wash buffer, 17 µL each of MMP-8 and -9 beads were diluted with 
Microparticle Diluent, and 50 µL were added into each well. 50 µL of standard and 
samples were loaded onto the plate, incubated at room temperature for 2 hours on a 
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horizontal microplate shaker set at 500 rpm.  The microplate was washed three times, 
50 µL of diluted Biotin Antibody cocktail was added and the plate was incubated for 1 
hour on the shaker.  After 3 washes, 50 µL of streptavidin-PE was added, incubated for 
30 minutes and further washed 3 times.  The microparticles were resuspended with 
85µL of wash buffer, incubated for 2 minutes and read using the Luminex analyzer.    
The minimum level of detection for MMP-8 was 110 pg/ml and MMP-9 was 65 pg/ml. 
When analyzing MMP secretion from monocytes, the Luminex analyzer was set at high 
sensitivity. 
22. Cytokine bead array 
 Analysis of cytokine concentrations were analyzed using the Cytokine Human 
30-plex panel (Invitrogen, Paisley, UK) according to manufacturer‘s instructions.   This 
panel  comprise IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 
(p40⁄p70), IL-13, IL-15, IL-17, TNF-α, IFN-α, IFN-γ, GM-CSF, MIP-1α, MIP-1β, IP-
10, MIG, Eotaxin, RANTES, MCP-1, VEGF, G-CSF, EGF, FGF-basic, and HGF. 
Samples were diluted 1 in 5 with RPMI.  Standard was reconstituted according to 
manufacturer‘s instructions and serial 1 in 3 dilutions were made for a 7 point standard.  
The assay wells were pre-wet by adding 200 μL of Wash Solution and incubated 15-30 
seconds at room temperature prior to aspirating the Wash Solution using the vacuum 
manifold. 25 µL of Bead Solution were added into each well, 200 μL of Wash Solution 
were added to each well and the washing step repeated.  50 µL Incubation Buffer were 
pipette into each well.  100 μL of standard were added to the wells designated for 
standard.  For wells designated for samples, 50 μL of Assay Diluent followed by 50 μL 
samples were loaded onto the plate, covered with foil and incubated at room 
temperature for 2 hours on a horizontal microplate shaker set at 500 rpm.  The 
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microplate was washed three times with 200 μL of Wash Solution each using the 
vacuum manifold, 100 µL of diluted Biotin Detector Antibody was added to each well 
and the plate was incubated for 1 hour on the shaker at room temperature.  After 3 
washes, 100 µL of streptavidin-PE was added, incubated for 30 minutes at room 
temperature and further washed 3 times.  100 μL of Wash Solution was added to each 
well and the plate was incubated for 2 minutes on the shaker at room temperature.  The 
plate was read using the Luminex instrument (Bio-Rad).  
23. DQ collagen assay 
 Type I and IV collagen degradation were assessed using the EnzChek ® 
Gelatinase/Collagenase Assay kit (Molecular Probes, Leiden, Netherlands) and 
performed according   to manufacturer‘s instructions.  In brief, samples diluted in 1 x 
reaction buffer (1 in 5 for neutrophil supernatants; 1 in 10 for induced sputum samples) 
were activated with 4-amino-phenyl mercuric acetate (APMA) for 1 hour at 37oC.  
80µL of 1x reaction buffer or inhibitor (doxycyline hyclate, Sigma-Aldrich; Neutrophil 
elastase inhibitor N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone, Sigma-
Aldrich; Mouse anti-human MMP-1, R&D Systems; Goat anti-human MMP-8, R&D 
Systems; Mouse anti-human MMP-9, Calbiochem, UK) were added into a 96 well 
black fluorescence plate with 20µL of DQ collagen at a final concentration of 25µg/ml.  
100µL of activated samples was subsequently added, and fluorescence was measured at 
specified times using a fluorometer (FLUOstar Galaxy, BMG Labtechnologies, 
Germany) using a 10% gain setting. 
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24. Isolation and quantification of neutrophil extracellular traps 
 (NETS) 
 For experiments involving NETS, human neutrophils were infected with M.tb at 
an MOI of 10 or stimulated with CoMTB at 1:5 dilution over 4 hours in 96 well plates.  
A final concentration of 20nM PMA was used as a positive control.  50µL of 
micrococcal nuclease (Fermentas), a non processive nuclease that cuts DNA at linker 
sites, at a final concentration of 5U/ml was added in each well for 10 minutes at 37oC, 
after which EDTA at a final concentration of 5mM was used to halt the reaction.  
Supernatants were collected, sterile filtered throught 0.2 μm Anopore membrane and 
kept at 4oC until further use. NETS were quantified using QuantiT PicoGreen 
(Invitrogen, Paisley, UK) according to manufacturer‘s instructions.  In brief, a standard 
was made using serial 1 in 10 dilutions of Lambda DNA commencing from 2 µg/ml to 
2 ng/ml diluted in 1 x TE buffer.  50µL of samples and standards were loaded onto 96 
well black plates, and 50 µL PicoGreen at a 1 in 200 dilution were added in each well.  
The plate was then incubated at room temperature for 5 minutes, and then read using 
the fluorometer (FLUOstar Galaxy, BMG lab technologies, Germany). 
25. Co-immunoprecipitation 
 To determine if NETS were associated with neutrophil MMPs, co-
immunoprecipitation using Dynabeads Protein G (Invitrogen, Paiseley, UK) and the 
Dynabeads Co-immunopreciptation kit (Invitrogen) were used according to 
manufacturer‘s instructions.  For the former, 50 μL of Dynabeads in suspension were 
transferred to an eppendorf microcentrifuge tube, placed onto a magnet and suspending 
liquid removed.  1 – 10 μg of desired antibody was added with antibody binding and 
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washing buffer to make up to a final volume of 200 μl.  This was incubated with 
rotation for 10 minutes at room temperature, and thereafter the buffer was removed.  
When crosslinking of the antibody to the bead was desired, the antibody-coupled beads 
were washed twice in conjugation buffer (20 mM sodium phosphate, 0.15M sodium 
chloride, pH 7-9) and resuspended in 5mM BS3 solution.  This was incubated for 30 
minutes with rotation, and crosslinking was terminated with 12.5μl of quenching buffer 
(1M Tris HCl, pH 7.5).  Between 100-1000 μL of sample were added to the antibody-
coupled beads, incubated at room temperature for 10 minutes prior to washing 3-6 times 
with washing buffer.  The supernatant was then removed and 20 μl of elution buffer 
with 10 μl premixed LDS sample buffer (Invitrogen) and sample reducing buffer were 
added.  The sample was frozen as an antigen-bead complex at -80oC until analysis 
whereupon the beads will be emoved using a magnet.  When the Dynabeads Co-
immunoprecipitation kit was used, the appropriate quantity of Dynabeads M-270 Epoxy 
was weighed out, washed with 1 ml of C1 buffer, placed onto a magnet and supernatant 
removed.  The appropriate volume of antibody (5-7 μg Ab/ mg Dynabeads) with C1 
were added to the beads.  The appropriate volume of C2 was added and the mixture was 
incubated on a roller at 37oC overnight.  The next day, the supernatant was removed 
using a magnet and the beads were washed with HB wash, LB wash, twice with SB 
wash, and resuspended in the same volume of SB as was the total coupling reaction 
volume.  1.5 mg of antibody coupled Dynabeads was used for each 
coimmunoprecipitation and was resuspended with the sample and incubated on a roller 
at 4oC for 10-30 minutes.  The Dynabeads were washed three times with extraction 
buffer (1 x IP solution, 100mM NaCl, protease inhibitor (Sigma) and a final wash with 
last wash buffer (1 x LWB, 0.02% Tween 20).  The bead suspension was transferred to 
a clean tube, supernatant removed, and finally resuspended in 60 μL of EB and 
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incubated on a roller for 5 minutes at room temperature.  The supernatant was then 
transferred into another clean tube and frozen at -80oC until analysis. 
26. Patient recruitment and data collection 
Please see Chapter 6 for specific methodology for the analysis of induced sputum 
samples from TB patients and healthy controls. 
AMPK patients and control.  This study received the Institutional Review Board 
approval from Central London Research Ethics Committee (REC 11/LO/0913).  The 
cardiology specialty consultation service of The Heart Hospital, University College 
London identified patients who were clinically diagnosed to have cardiomyopathy, and 
confirmed via genotyping to have AMPKγ2 mutation.  Neutrophil isolation was done 
concurrently from patient and from a healthy volunteer and stimulated at the same time.   
27.      Immunofluorescence 
 Permanox chamber slides (Nunc Labtech, Thermo Fisher Scientific) were 
coated with 0.1 mg/ml fibrinogen with or without 25 µg/ml of DQ collagen for 30 
minutes and then aspirated.  Thereafter neutrophils were added and stimulated with 
CoMTB or infected with M.tb for the specified period before media was removed.  
Samples were then fixed with 4% paraformaldehyde for 30 minutes.  Cells were washed 
twice with PBS, and permeabilised with 0.5% saponin for 10 minutes.  Following 
permeabilisation, cells were washed twice with PBS before blocking with 10% human 
AB serum with 2.5% BSA and 0.05% saponin for 1 hour.  Primary antibodies at the 
stated dilution as in Table 6 were added overnight.  Blocking buffer alone was used as 
a control.  These were then aspirated and the chamber slides were washed twice again 
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with PBS  prior to the addition of secondary antibodies as stated in Table 6 for 1 hour.  
After 2 more washes, the chambers were removed from the slide, and Fluoroshield 
Mounting medium with DAPI (Abcam) was added prior application of the coverslip.  
Images were captured using Leica confocal microscope (Leica TCS SP5) and processed 
using Leica LAS AF Lite 2.6.0 (Leica Microsystems, Germany) and Image J 1.43U 
(NIH, USA).   
Antibody Manufacturer Dilution 
Primary antibody   
Mouse anti-human MMP-8 Abcam 1 in 200 
Mouse anti-human MMP-9 Abcam 1 in 500 
Rabbit anti-Mycobacterium tuberculosis  Abcam 1 in 50 
Rabbit anti-human Rab 5 Abcam 1 in 250 
Sheep anti-human histone 2B Abcam 1 in 1000 
Secondary antibody   
Donkey anti-Sheep IgG DyLight 488  Abcam 1 in 1000 
Goat anti-mouse IgM DyLight 549 Abcam 1 in 1000 
Goat anti-rabbit IgG Cy5 Abcam 1 in 1000 
Table 6: Primary and secondary antibodies used for immunofluorescence. 
28. Immunohistochemistry 
 Immunohistochemistry of lung biopsy specimens were done in collaboration 
with Dr Joanna Porter and Jenny Paterson at University College London.  Ethical 
consent for the study of anonymized paraffin-embedded sections from histopathology 
was obtained from the Hammersmith Hospitals Research Ethics Committee in 
accordance with The Human Tissue Act 2004.  Five non immunosuppressed patients 
with biopsy proven pulmonary M.tb infection were analysed.   The positive controls 
were breast (MMP-9) and colon (AMPK) tumours from 10 patients and inflammed 
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appendix (MMP-8).   Negative controls were performed using the appropriate isotype 
control antibodies.  Three-µm thick sections were immunostained for MMP-8 (Novus 
Biologicals, NBP1-85576, rabbit polyclonal; 1/250) and phospho-AMPK alpha 1 and 2 
(T172) (Abcam, ab51110, rabbit polyclonal; 1/8000) with heat induced epitope retrieval 
using a citrate-based solution (pH6.0) for 30 minutes; MMP-9 (Millipore, MAB3309, 
mouse monoclonal, clone 56-2A4; 1/8000) with heat induced epitope retrieval using an 
EDTA-based solution (pH9.0) for 20 minutes; and Neutrophil Elastase (Dako, M0752, 
mouse monoclonal, clone NP57; 1/10) with epitope retrieval performed by enzyme 
digestion using Bond Enzyme Pretreatment Kit. All antibodies were incubated for 15 
minutes at room temperature. All immunohistochemistry was performed using the 
Leica Bond-III automated platform and associated ancillary reagents (all Leica 
Biosystems, Newcastle Upon Tyne, UK). The antibodies were detected using the Bond 
Polymer Refine Detection System and Bond DAB Enhancer according the 
manufacturer‘s instructions 
 Analysis of CNS-TB brain biopsy specimens were done in collaboration with Dr 
Federico Roncaroli and Mrs Poonam Singh at the Division of Brain Sciences.  Tissue 
samples were provided by the Imperial College Healthcare Tissue Bank. Ethical 
permission for this study was obtained from the Hammersmith Hospitals Research 
Ethics Committee.  Five immunocompetent patients with biopsy proven 
CNS M.tb infection were analysed. Haematoxylin-eosin (HE) stained sections and 
paraffin blocks were retrieved from the archives of the Histopathology at Charing Cross 
Hospital. Samples were anonymyzed for the purpose of this study.  The original HE-
stained sections were reviewed by an experienced neuropathologist (FR) and the most 
representative samples were chosen for this project.  The cases were investigated using 
immunoperoxidase method with antibodies directed against MMP-8 (Abcam; 1/400), 
MMP-9 (Abcam; 1/200), neutrophil elastase (Dako, clone NP57; 1/100) and CD15 (BD 
Science, clone Leu-M1; 1/100). Sections of acute appendicitis were used as positive 
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control.  Immunostains with omission of the primary antibody were performed as 
negative controls.  Five-micron sections were cut from each block, 
dewaxed in xylene and rehydrated in decreasing alcohols to distilled water. 
Endogenous peroxidase activity was blocked by incubating the sections in 0.3% 
hydrogen peroxide for 30 minutes.  For antigen retrieval, sections were steamed for 20 
minutes in 0.01 M citrate, pH 6.5 and then gently cooled in water. In order to block 
nonspecific binding of the primary antibody, sections were incubated with 10% normal 
goat serum for 10 minutes (Vector Laboratories, Burlingame, California).  The primary 
antibodies were applied overnight at 4oC.  After incubation, they were washed for three 
times in PBS for 10 minutes each. Staining was visualised using the Vecta stain Elite 
ABC kit (Vector Laboratories) following the manufacturer instructions.  The reaction 
product was visualised with 2 ng/ml 3,39-diaminobenzidine and 0.0075% hydrogen 
peroxide in PBS.  
29. Statistics 
 Multiple intervention experiments were compared with one-way ANOVA 
followed by Tukey‘s post-test correction, using GraphPad Prism Version 5.04 for 
Windows (GraphPad Software).  A p – value of less than 0.05 was taken as statistically 
significant. For secretion analysis, experiments were all performed in triplicate on at 
least two occasions, while RNA analysis was performed on triplicate samples on a 
minimum of 2 separate experiments unless otherwise stated. 
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CHAPTER 3 – NEUTROPHIL MMP AND  TIMP SECRETION AND 
GENE EXPRESSION IN TB 
1. Introduction 
 This chapter is dedicated to characterising neutrophil MMP and TIMP secretion 
in response to M. tuberculosis and CoMTB stimulation at the protein level and at gene 
expression at mRNA level.  One of the key aims of my research is to determine how 
neutrophil MMPs are secreted in response to M.tb as well as in monocyte-dependent 
networks, the latter because both monocytes and neutrophils are present in the 
granuloma [222].  This was achieved with the use of CoMTB.  Once neutrophil MMP 
secretion was characterised, I next assessed if the secretion could be modulated by a 
variety of therapeutic agents including dexamethasone which is used in the context of 
CNS-TB and TB pericarditis, anti-TNFα which is occasionally used in CNS-TB 
patients refractory to dexamethasone, as well as the Th2 cytokine IL-4.  
 To determine if neutrophil MMPs are also detrimental to the host, the decision 
was made to investigate the effect of neutrophil MMPs secreted with M.tb and CoMTB 
on matrix destruction, in particular Type I collagen as this is the most abundant lung 
collagen [223].  When matrix destruction becomes extensive organ function becomes 
compromised, and in the case of the lung, respiratory impairment. Hence it is also 
crucial to determine if therapies could potentially abrogate matrix destruction and I 
looked into modulating neutrophil MMPs in vitro using the MMP inhibitor doxycyline. 
 One highly topical phenomenon that has recently been discovered, occurs when 
neutrophils encounter pathogens and instigate the production of neutrophil extracellular 
traps [97].  NET production has been described with various pathogens such as 
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staphylococcal species and streptococcal species, toxoplasmosis, candidal infections 
and with M.tb [143]. NETS are associated with neutrophil granule proteins such as 
myeloperoxidase, neutrophil elastase as well as histones.  I also sought to determine if 
NETS are associated with neutrophil MMP-8 and -9. 
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2. Results 
2.1  Neutrophils secrete MMP-8 and -9 in response to infection with live 
M.tb infection 
 MMP and TIMP secretion from live M.tb-infected neutrophils was investigated. 
An initial experiment confirmed that MMP-8 and -9 were secreted in high 
concentrations from neutrophils (Figure 4) after 16 hours, with very low concentrations 
of MMP-2, -3 and -12 (< 170 pg/ml, 12 pg/ml and 34 pg/ml respectively and below the 
detection limits of the standard curve).  These low levels of MMP-2, -3 and -12 may be 
derived from contaminating mast cells and eosinophils.  It was observed that MMP-8 
concentrations in M.tb-infected neutrophils were lower than control. As this difference 
could possibly be due to greater neutrophil cell death with M.tb, I went on to assess 
neutrophil survival in the presence of M.tb using Trypan blue viability assay.  Using a 
M.tb MOI of 1, the Trypan blue assay revealed that the viability of neutrophils infected 
with M.tb declined rapidly after 4 hours (data not shown), and thereafter experiments 
were done using 4 hour incubation periods.  After M.tb infection, MMP-8 and -9 
concentrations in cell supernatants were increased significantly compared to controls at 
4 hours (p<0.001) (Figure 5A and B).  A M.tb MOI of 1 resulted in a 1.5 fold increase 
in MMP-8 (p =NS) and 2 fold increase in MMP-9 (p < 0.05), and this increased to 5 
fold for MMP-8 and 3.5 fold for MMP-9 with M.tb MOI of 10 (both p <0.01).  Having 
characterised the basic pattern of MMP-8 and -9 secretion from M.tb-infected 
neutrophils, I next examined TIMP secretion.  There was a MOI dose-dependent 
response in secretion of TIMP-2 with M.tb MOI with a significant difference at a M.tb 
MOI of 10 (p<0.01).  This effect was however absent with no increase for TIMP-1 
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(Figure 5C).   In addition, the concentration of neutrophil MMPs are much greater than 
the concentration of TIMPs, swinging the balance towards matrix degradation.   
  
 
Figure 4:  MMP secretion from M.tb-infected neutrophils.  1.25 x 106 neutrophils at 
1500/μL were infected with an M.tb multiplicity of infection (MOI) of 1 for 16 hours.   
Bars represent mean +/- SD of an experiment done in triplicate.  # values below 
standard curve, *p<0.05  
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Figure 5:  Effect of direct M. tb infection on MMP and TIMP secretion from neutrophils. 
(A) Secretion of MMP-8 and -9 from M.tb-infected neutrophils after 4 hours.  7.5 x 105 at 5000 
/ μL neutrophils were infected with M.tb at an MOI of 1.  Bars represent mean +/- SD of an 
experiment done in triplicate and is representative of three separate experiments.  (B) Dose-
response secretion of MMP-8 and -9 from M. tb infected neutrophils after 4 hours.  7.5 x 105 
neutrophils were infected with the stated dose of M.tb.  Bars represent mean +/- SD of three 
samples and is representative of 2 separate experiments done in triplicate. (C) TIMP-1 and -2 
secretion from M.tb infected neutrophils after 4 hours.  Bars represent mean +/- SD from three 
samples from an experiment and is representative of 2 independent experiments.  
****p<0.0001, *** p<0.001, **p<0.01, *p<0.05. 
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2.2  Live M.tb infected neutrophils secrete IL-6, IL-8 and MIP-1β  
 The effect of M.tb-infection and the consequential release of cytokines from 
neutrophils were examined using Luminex array.  Using a 30-plex cytokine luminex 
array as a screening process, uninfected neutrophils and M.tb-infected neutrophils 
cytokine secretion were examined.  M.tb-infected neutrophils contained significantly 
more IL-6, IL-8 and MIP-1β compared to controls (p<0.001, p<0.01 and P<0.001 
respectively).  All other cytokines ( IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-7, IL-
10, IL-12 (p40/p70), IL-13, IL-15, IL-17, TNF-α, IFN-α, IFN-γ, GM-CSF, HGF, MCP-
1, MIP-1α, IP-10, MIG, Eotaxin, RANTES, MCP-1, VEGF, G-CSF, EGF, FGF-basic, 
and HGF)   were either below the standard curve or not secreted in significantly 
different amounts compared to controls (Figure 6). 
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Figure 6:  Cytokine secretion from M.tb-infected stimulated neutrophils.  7.5 x 105 
neutrophils were stimulated with M.tb MOI of 1 for 4 hours.  Bars represent mean +/- 
SD of an experiment done in triplicate.  *p<0.05, **p<0.01, ***p<0.001.  
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2.3 CoMTB stimulated neutrophils secrete MMP-8 and -9 
 Having determined the pattern of MMP, TIMP and cytokine secretion from 
neutrophils infected with the whole live organism, I then set out to examine the role of 
monocyte-dependent networks on neutrophil function by stimulating them with 
conditioned media from M.tb-infected monocytes (CoMTB).  Initial experiments 
demonstrated a dose–response effect from CoMTB stimulation after 6 hours (Figure 7).  
CoMTB at a dilution factor of 1:5 resulted in the greatest concentration of MMP-8 and -
9 secretion from neutrophils and subsequently, a 1:5 dilution was used to stimulate 
neutrophils in all subsequent experiments.  
 
 
Figure 7:  Effect of various dilution factors of CoMTB on neutrophils.  7.5 x 105 
neutrophils were stimulated with the stated dilutions of CoMTB over 4 hours.  Bars 
represent mean +/- SD of an experiment done in triplicate.  **p <0.01 by one-way 
Anova. 
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 CoMTB stimulation of neutrophils resulted in a 2-fold rise in MMP-8 secretion 
(p<0.001) and a 3-fold rise in MMP-9 secretion (p<0.001) compared to CoMCont 
(conditioned media from uninfected monocytes) (Figure 8A).  This effect is not due to 
the sole presence of TB antigens, as stimulation with TB supernatant (TB supp) only 
caused a 1.5 fold increase in MMP-8 and an approximate 2-fold rise in MMP-9 
concentration.  Similar data were seen using gelatin zymography which detects 
potentially active forms of MMP-9 (Figure 8B).  Next, the effect of CoMTB on 
neutrophil TIMP-1 and TIMP-2 secretion was examined.  There was a 2.5 fold increase 
in TIMP-2 secretion from CoMTB stimulated neutrophils compared to CoMCont 
(p<0.001), but no significant increase in TIMP-1 secretion (Figure 8C).  This concurs 
with the results seen when neutrophils were infected with live M.tb (section 2.1). As 
previously found, the concentration of MMPs secreted is sufficient to overwhelm TIMP 
activity bringing the milieu towards a matrix degrading phenotype. 
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Figure 8:  Effect of CoMTB and TB supernatant on neutrophil MMP and TIMP secretion.  
7.5 x 105 neutrophils were stimulated over 4 hours with CoMCont and CoMTB both at a 1:5 
dilution.  (A) ELISA readout.  Bars represent mean +/- SD of an experiment done in triplicate 
and is representative of 3 separate experiments.  *p<0.5, **p<0.01, ***p<0.001.  (B) Gelatin 
zymography with corresponding densitometric analysis.  Samples were diluted 1 in 20 before 
running the zymogram and is representative of 3 separate experiments.  Bars represent mean +/- 
SD of an experiment done in triplicate. *p<0.05.   (C) Secretion of TIMP-1 and 2.  Bars 
represent mean +/- SD of an experiment done in triplicate and is representative of 2 separate 
experiments.  **p<0.01, ***p<0.001 
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2.4 CoMTB stimulated neutrophils show increased MMP-8 and -9 gene 
expression  
 I next investigated the gene expression of MMP-8 and -9 from 3 different 
donors.  Real time-PCR analysis was performed using GAPDH as a medium copy 
number reference gene as it was more reliable than the high copy number ribosomal 18s 
RNA reference gene (data not shown).  The initial experiments from 3 different donors 
demonstrated that there was 2.3 fold up-regulation of MMP-8 (p<0.001) and 3.1 fold 
up-regulation of MMP-9 at 4 hours (p<0.01) (Figure 9A).  A literature search on MMP-
8 and 9 revealed that gene expression experiments in neutrophils were normally 
reported at the 24 hour time point [224, 225]  Hence, I repeated the experiment over a 
24 hour period and determined neutrophil viability.  This demonstrated that the gene 
expression of MMP-8 and 9 was increased to 2.0 fold and 1.9 fold respectively at 6 
hours.  At 24 hours, MMP-8 and 9 gene expression was increased to 3.1 fold (p<0.05) 
and 8.2 fold respectively (p<0.01) (Figure 9B).  In addition, there was a corresponding 
increase in protein secretion of MMP-8 and 9 at six and twenty-four hours respectively 
(p<0.01) (Figure 9C).  Annexin V and propidium iodide staining revealed that there 
was comparable neutrophil viability at 24 hours in both CoMCont and CoMTB-
stimulated cells (Figure 9D).  I further set out to ascertained if the total MMP-8 and -9 
(i.e sum of extracellular and intracellular) increased over time with CoMTB 
stimulation.  To do this, neutrophils were stimulated with CoMCont or CoMTB and at 
stated time points, neutrophil supernatants (extracellular MMPs) were harvested and 
cells lysed with RIPA buffer to determine intracellular MMPs.  In CoMTB stimulated 
neutrophils, the majority of MMP-8 remained intracellular, whilst the majority of 
MMP-9 was secreted (extracellular) (Figure 10A and B).  Total MMP-9 was increased 
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over time with CoMTB whilst the total MMP-8 seemed to be decreased with CoMTB 
stimulation although this was not statistically significant (Figure 10C). 
 
Figure 9: Kinetics of MMP-8 and -9 gene expression and secretion in CoMCont or 
CoMTB stimulated neutrophils.  2 x 106 neutrophils were stimulated with 1:5 dilution 
CoMCont or CoMTB for the specified duration. (A & B) Gene expression from 0-4 hours and 
0-24 hours.  Bars represent mean +/- SEM of 3 donors.  (C)  MMP-8 and -9 secretion from 0-24 
hours.  Bars represent mean +/- SEM of 3 donors which were used in (B). (D) Viable cells and 
proportion of apoptotic neutrophils over time.  5 x 105 neutrophils were stimulated with 1:5 
dilution of CoMCont or CoMTB and stained with Annexin V and Propidium iodide.  Bars 
represent mean +/- SEM of 3 donors.  p=NS.*p<0.5, **p<0.01, ***p<0.001, ****p<0.0001 
compared to CoMCont. 
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Figure 10: Kinetics of MMP-8/-9 from CoMTB stimulated neutrophils. (A) 
Extracellular MMP-8/-9 from 1.5 x 106 neutrophils (B) Intracellular MMP-8/-9.  
Neutrophils were lysed with 150µL of whole cell lysis buffer at the stated time points 
and lysate analysed with MMP-8/-9 using luminex array. (C) Total MMP-8/-9 / 106 
neutrophils.  The sum of extracellular MMPs and intracellular MMPs.  *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.  Bars represent mean +/- SD of an experiment 
done in triplicate and is representative of 3 separate experiments. 
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2.5 CoMTB-stimulated neutrophils show increased IL-8, IL-1RA, IL-12, 
TNF-α and MCP-1 protein secretion 
 The secretion of cytokines from CoMTB stimulated neutrophils was examined 
using a 30-plex cytokine luminex array.  The cytokines concentrations present in 
CoMTB alone were taken as a baseline.  What was most significant was that CoMTB 
stimulated neutrophils secreted significantly greater IL-8 concentrations (6.5 fold) 
compared to CoMTB (alone) (p<0.0001) (Figure 11).  There was slightly higher IL-
1RA (p<0.05), IL-12 (p<0.05), TNF-α (p<0.05), and MCP-1 concentrations (p<0.001) 
compared to CoMTB (alone).  All other cytokines concentrations were below that of the 
standard curve or undetectable. 
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Figure 11:  Cytokines secreted from CoMTB stimulated neutrophils.  7.5 x 105 
neutrophils were infected with M.tb MOI of 1 or stimulated with CoMTB at a 1:5 
dilution for 4 hours.  Bars represent mean +/- SD of an experiment done in triplicate.  
*p<0.05, ***p<0.001, ****p<0.0001.  
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 The cytokine luminex also determined the approximate amounts of chemokines 
and cytokines present in CoMTB at 1:5 dilution and this is listed in Table 7.  Only 
cytokines and chemokines relevant to this project have been listed. 
Cytokine/chemokine Concentration (pg/ml) 
TNF-α 6,300 
IL-1β 4,300 
IL-4 undetectable 
IL-6 15,000 
IL-8 2,200 
IL-10 undetectable 
IL-12 1,000 
IL-13 65 
MIP-1α 23,000 
MIP-1β 5,400 
MCP-1 194 
IFN-γ 600 
IL-1RA 2,700 
GM-CSF 42 
 
Table 7: Cytokines and chemokines present in CoMTB. 
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2.6 The effect of TB treatment immune modulators: Dexamethasone and 
anti-TNFα  inhibit MMP-8/-9 secretion in CoMTB stimulated 
neutrophils 
 Dexamethasone is used in patients with CNS-TB as an immunomodulatory 
therapy. Occasionally even with dexamethasone, patients fail to improve and remain in 
a comatosed state.  There are increasing reports that anti-TNFα therapy has improved 
patient outcomes in such scenarios [52].  I therefore set out to determine if 
dexamethasone and anti-TNFα would modulate neutrophil MMPs in this context.  The 
dose of dexamethasone used was similar to that used in clinical trials of patients with 
CNS-TB [216], whilst that of anti-TNFα neutralising antibody was determined to be the 
amount required to neutralise TNFα in CoMTB.  Dexamethasone inhibited MMP-8 and 
-9 secretion in M.tb-infected neutrophils and MMP-8 but not MMP-9 in CoMTB 
stimulated neutrophils (Figure 12A and B).  With TNFα neutralisation of CoMTB, 
neutrophil MMP-8 and -9 secretion was suppressed in a dose-dependent manner 
(p<0.001 with MMP-8 and p<0.01 with MMP-9) with MMP-9 completely suppressed 
at a dose of 5μg/ml of antibody (Figure 13A).  Gene expression of MMP-8 and -9 was 
similarly reduced with TNFα neutralisation (p<0.01 for MMP-8 and p<0.001 for MMP-
9 both at anti-TNFα of 5μg/ml) (Figure 13B).  TIMP-2 secretion is suppressed as well 
in a dose-dependent manner but TIMP-1 secretion was unaffected. 
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Figure 12:  Dexamethasone inhibits neutrophil MMP secretion.  7.5 x 105 
neutrophils were pre-incubated for 30 minutes with the specified concentrations of 
dexamethasone and subsequently stimulated.  (A)  M.tb infection.  Neutrophils were 
infected with M.tb at an MOI of 10 for 4 hours.  (B) CoMTB stimulation.  Neutrophils 
were stimulated with CoMTB at 1:5 dilution for 4 hours.  Bars represent mean +/- SD 
of an experiment done in triplicate and is representative of  2 independent experiments. 
*p<0.05, **p<0.01,  *** p<0.001. 
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Figure 13: Anti-TNFα inhibits MMP-8/-9 secretion and gene expression in CoMTB 
stimulated neutrophils.  CoMTB was pre-incubated for 2 hours with anti-TNFα and a 1:5 
dilution was subsequently used to stimulate neutrophils for 4 hours. (A) MMP-8 /9 and TIMP-
1/-2. (B) MMP-8/-9 gene expression.  Bars represent mean +/- SD of an experiment done in 
triplicate and is representative of 2 experiments. *p<0.05, **p<0.01, ***p<0.001, #p<0.05 
compared to control media only. 
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2.7 The effect of host TB immune modulators: IL-4 inhibits neutrophil 
MMP-9 secretion at low concentrations in CoMTB-stimulated cells 
 IL-4 is the principle Th2 cytokine increased in TB patients compared to normal 
subjects [226].  In addition, studies in murine models have indicated that IL-4 presence 
in lung lesions coincided with pneumonia and necrosis [227].  IL-4 also suppresses 
MMP expression in human fibroblasts [228].  I thus sought to determine if IL-4 would 
augment neutrophil MMP secretion.  Interestingly, at lower concentrations of IL-4, 
MMP-9 but not MMP-8 secretion is suppressed, while there seem to be an increase of 
MMP-9 with increasing concentrations of IL-4.  Conversely, TIMP-1 but not TIMP-2 
secretion was decreased with increasing IL-4 concentration (Figure 14). It has been 
previously reported that there is increased neutrophil phagocytosis with increasing IL-4 
(15 ng/ml) with concurrent enhanced neutrophil chemotactic migration [229] and 
further assessment would be required to determine if IL-4 truly affects neutrophil 
degranulation. 
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Figure 14:  Effect of IL-4 on CoMTB stimulated neutrophils.  7.5 x 105 neutrophils 
were pre-incubated for 30 minutes with IL-4 prior to stimulation with CoMTB at 1:5 
dilution for 4 hours.  Bars represent mean+/- SD of an experiment done in triplicate.  
*p<0.05, ***p<0.001. 
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2.8 M.tb and CoMTB stimulated neutrophils degrade collagen 
 Tissue destruction is a predominant feature of TB, and the question is if 
neutrophils play a role.  Type I DQ collagen which emits fluorescence when degraded 
was therefore used to investigate collagenase activity in an in vitro neutrophil model.  
When neutrophils plated onto collagen-coated coverslips were stimulated with  CoMTB 
(Figure 15) or M.tb (Figure 16), there was a resultant increase in fluorescence of DQ 
collagen as detected by confocal microscopy.  A similar increase in collagenase activity 
was demonstrated using a quantitative fluorescence assay in both M.tb and CoMTB 
stimulated neutrophils (Figure 17A).  Collagenase activity was abolished with 
doxycyline, an MMP inhibitor (Figure 17B). 
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Figure 15: CoMTB stimulated neutrophils degrade Type 1 collagen.  Coverslips 
were coated with 25 μg/ml DQ Collagen Type 1 for 1 hour prior to the addition of 5 x 
105 neutrophils stimulated with the respective agents in a 1:5 dilution for 4 hours.  
Images representative of 2 independent experiments.   
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Figure 16: M.tuberculosis infected neutrophils degrade Type 1 collagen.  Coverslips 
were coated with 25 μg/ml DQ Collagen Type 1 prior to the addition of 5 x 105 
neutrophils infected with M.tb MOI 10 for 4 hours.  Data representative of 2 
independent experiments.   
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Figure 17: M.tb infected neutrophils and CoMTB stimulated neutrophils degrade 
Type 1 collagen.  7.5 x 105 neutrophils were infected with M.tb (MOI 10) or stimulated 
with CoMTB at 1:5 dilution for 4 hours and the supernatant was incubated with 25 
μg/ml Type 1 DQ collagen for 24 hours.  (A) Collagenase activity of supernatants from 
M.tb and CoMTB stimulated neutrophils.  (B)  Doxycyline (Doxy) inhibits collagenase 
activity from M.tb-infected neutrophils.  Doxycyline and neutrophil supernatants were 
added concurrently into the assay without pre-incubation.  Bars represent mean +/- SD 
of an experiment in triplicate and is representative of 2 independent experiments.  
**p<0.01, *** p<0.001. 
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2.9 Neutrophil extracellular traps are produced following M.tb infection 
 It had previously been reported that neutrophils produce NETS after exporsure 
to M.tb and I wanted to confirm this with my experimental set-up, using 20 nM of PMA 
as a positive control.  NET production following treatment with M.tb was demonstrated 
by QuantiT Picogreen but minimal with CoMTB (Figure 18A).  Immunofluorescence 
(Figure 18B) clearly showed the mycobacterium trapped by the DAPI-stained DNA of 
the NETs. In addition, the NETS were associated with MMP-8 and -9 (Figure 18C and 
D).  Both PMA and M.tb induced sheet-like NETS which were digested by DNAse 
(Figure 19).  I also wanted to determine if the proteins present in M.tb cell walls 
induced NETs rather than M.tb secreted antigens. To do this, I utilised UV-killed M.tb 
and this induced NETS as well (Figure 20), confirming that it was proteins present in 
the mycobacterium cell wall responsible for this phenomenon.   
 NETS are associated with various neutrophil granular proteins such as 
neutrophil elastase and myeloperoxidase.  I wanted to assess if MMP-8/-9 are strongly 
associated with NETS, as early immunofluorescence studies had demonstrated the 
presence of these 2 MMPs To further confirm these observations, I attempted co-
immunoprecipitation of MMP-8/-9 for NET associated histones (H2B).  Initial co-
immunopreciptation experiments were done on NETS produced by M.tb-infected 
neutrophils.  However, I found that the process of sterile filterisation removed a 
considerable amount of NETs, notably genomic DNA (data not shown). I decided to 
optimise the protocol using PMA to stimulate the neutrophils to produce NETS and use 
these for co-immunoprecipitation studies prior to switching the stimulus to M.tb.  
However, co-immunoprecipitation with protein G Dynabeads using MMP-8/-9 antibody 
pull-down demonstrated non-specific binding of NET associated histone and H2B was 
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present even with IgG isotype control both on agarose gel (Figure 21A) and on 
Western blot (Figure 21B).  I attempted to optimise co-immunoprecipitation by 
blocking the beads with 5% BSA, preclearing the supernatant with Dynabeads or IgG 
bound-Dynabeads for 10 minutes to overnight but each experimental attempt still 
yielded histone proteins with IgG isotype control pulldown.  I also tried a different kit 
(Dynabeads Co-immunoprecipitation Kit, Invitrogen, Paisley, UK) but without any 
success.  Co-immunoprecipitation was attempted over a period of 3 months and 
eventually it was abandoned.  
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Figure 18:  M.tb induces NET formation.  (A)  Quantification of NETS using PMA as a 
positive control.  5 x 105 neutrophils were stimulated with 20nM of PMA, M.tb (MOI of 10), 
CC (CoMCont) or CoMTB (CT) for 4 hours, digested with 5U/ml micrococcal nuclease, 
supernatants sterile filtered and analysed using Picogreen DNA quantification kit.  Bars 
represent mean +/- SD of an experiment in triplicate and is representative of 3 independent 
experiments. *p<0.05, **** p<0.0001  (B-D)  Immunofluorescence demonstrate association of 
MMP-8/-9 with NETS. 5 x 105 neutrophils were incubated with M.tb (MOI of 10) for 4 hours 
and were stained for DNA with DAPI, histone 2B (H2B), M.tb, MMP-8 and -9. White arrows 
highlight NETS.  All immunoflurescence experiments were performed at least in 2 separate 
occasions.  
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Figure 19:  M.tb induces NET formation which is digested by DNAse.  5 x 105 
neutrophils were stimulated with 20 nM of PMA or M.tb (MOI of 10) for 4 hours, and 
10U/ml of DNAse or media subsequently were added for 20 minutes. 
Immunofluorescence experiments were done at least twice. 
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Figure 20:  UV-killed M.tb induces NET production.  H37Rv were subjected to UV 
exposure for 90 minutes.  5 x 105 neutrophils were stimulated with UV-killed M.tb 
(MOI 10) for 4 hours.  Slides were stained for Auramine-rhodamine and DAPI.  White 
arrows indicate NETs trapping M.tb. 
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Figure 21:  Co-immunoprecipitation of MMP-8/-9 for NETS.  (A) 4 x 106 neutrophils were 
infected with M.tb (MOI 10) for 4 hours and supernatant sterile filtered.  Co-
immunoprecipitation was performed using Protein G Dynabeads using MMP-8 and MMP-9 
antibodies.  The eluted supernatant was ran on a 2% agarose gel.  (B)  4 x 106 neutrophils were 
stimulated with 20 nM PMA for 4 hours.  Co-immunoprecipitation was performed using 
Protein G Dynabeads using MMP-8 and -9 antibodies and eluted proteins were immunoblotted. 
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3. Discussion 
 Neutrophils secrete a wide range of enzymes and proteins in response to 
pathogens, including myeloperoxidase, neutrophil elastase, α-defensins, as well as 
MMPs.  I have shown in my biological set-up that neutrophils secrete MMP-8 and -9 
and demonstrated that M.tb induces a highly significant up-regulation of secretion of 
MMP-8/-9 from neutrophils in a dose-dependent mechanism and over time.  This was 
not associated with an increase in TIMP-1, but there was a modest dose-dependent 
increase in TIMP-2.  The phenomenon of MMPs from neutrophils being secreted in 
response to a stimulus is not unique to M.tb.   It had been shown that LPS stimulated 
MMP-9 secretion from neutrophils in vitro and TNF-α, IL-8, and gram-negative and 
gram-positive infections similarly induced MMP-9 secretion from whole blood and this 
was likely to be derived from neutrophils [230].  Similarly, bacteria such as 
Actinobacillus species also induced neutrophil MMP-8 secretion [231]. I have found 
from my experiments that there is a high MMP to TIMP ratio from neutrophils and a 
shift in the balance towards degradation of the extracellular matrix, resulting in tissue 
destruction. This complements clinical findings, where MMP-9 concentrations are 
elevated and unrestricted by TIMP-1 in patients with TB meningitis [188] where 
disruption of the blood-brain-barrier occurs.  Elevated MMP-9 in the cerebrospinal fluid 
is correlated with focal neurological damage and death [188, 213] and correlates 
significantly with the absolute neutrophil count in the CSF of patients with TB 
meningitis [215].  
 Neutrophils and monocytes are among the first cells to arrive when M. 
tuberculosis invades the host so as to phagocytose and eliminate the pathogen [121, 
122].  It is likely that neutrophils and monocytes cross-prime each other during this 
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initial process.  A key finding in my research is that conditioned media from M.tb-
infected monocytes (CoMTB) upregulates MMP-8 and -9 protein secretion massively 
with an associated rise in gene expression in neutrophils.  Additionally, there is further 
up-regulation in secretion of the chemokines IL-1RA, IL-8, IL-12, TNF-α, and MCP-1, 
all of which are key cytokines produced as a result of the host immune response in TB 
[232-236].   The most marked increase is seen with IL-8 secretion, and this is possibly 
due to MMP-9 cleaving IL-8 into a more active truncated form, instigating a feed-
forward mechanism of IL-8 production.  
 One interesting observation was that with CoMTB stimulation, total MMP-8 
seemed to decrease, albeit not statistically significant.  This may be due to binding of 
MMP-8 to TIMP-2 and thus not detected by the luminex array, which only detects pro-
MMP-8, mature MMP-8 and MMP-8 complexed to TIMP-1.  Another possibility would 
be that the the active MMP-8 can also cleave itself when activated [237], and the 
smaller sized MMP-8 would also not be detected by the luminex array. 
 The cytokine multiplex studies performed on M.tb-infected neutrophils revealed 
that secretion of IL-6, IL-8 and MIP-1β are upregulated.  IL-6 has been found to have a 
critical role in driving T-cell responses in mycobacterial infections [238], and IL-6 
mRNA is significantly induced post-TB infection [122].  IL-8 is a well-known 
neutrophil attracting chemokine, and is present in the early host response to M. 
tuberculosis infection [141, 239].   It causes a feed-forward mechanism in neutrophils, 
with consequential release of more IL-8 and TNF-α [232].  MMP-9 processes IL-8, and 
results in a truncation variant of IL-8 with increased activity [162], while IL-8 
stimulation of neutrophils in turn results in MMP-9 release [208].  In addition, MMP-9 
can convert pro-TNFα to its active form [165].  However, it is surprising that minimal 
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amounts of TNF-α were found in M.tb infected neutrophils in my experiments, as it is 
well-documented that M.tb infection causes large amounts of TNF-α to be secreted 
from host neutrophils [240].  It is likely that there is a step-wise release of TNF-α from 
neutrophils after they are primed with IL-8 which has not been detected in the short 
time-frame of 4 hours in my experiments.  MIP-1β induces the activation and 
proliferation of T-cells [241] and of macrophages [242].  MIP-1β from neutrophils also 
induces the transmigration of dendritic cells from the intravascular space into 
inflammatory tissues [243].  The secretion of IL-6, IL-8 and MIP-1β from M.tb infected 
neutrophils suggests that neutrophils play an important role in the early human response 
after infection with tuberculosis and help orchestrate the host innate and adaptive 
immunity.   
 In the treatment of TB, adjunctive therapies in the form of dexamethasone and 
anti-TNFα have been used.  The former treatment has been used for CNS-TB and TB 
pericarditis and the latter for patients with CNS-TB refractory to dexamethasone [52, 
53].  The mechanism as to how these two agents aid in treatment and improve patient 
outcome is not fully known.  I have found that dexamethasone decreases neutrophil 
MMPs both in M.tb infection as well as in CoMTB stimulated neutrophils within 4 
hours, which may lead to less tissue destruction and host inflammation.  This 
supplements previous findings. In murine studies, glucocorticoids in the form of 
intraperitoneal dexamethasone decreased the amount of MMP-9 activity in the BAL 
fluid of mice given intranasal LPS and decreased neutrophilic inflammation [244].  In 
addition, glucocorticoids decreased the BAL MMP-9 concentration and gene expression 
in healthy controls but suppression was less pronounced in patients with severe asthma 
[245]. Steroids in the form of methylprednisolone and hydrocortisone also decreases 
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neutrophil degranulation [246].  It is likely that dexamethasone similarly suppresses 
neutrophil degranulation and therefore the release of neutrophil MMP-8 and -9.  The 
use of anti-TNFα therapy in cases of CNS-TB refractory to dexamethasone has received 
much interest, since it is widely known that anti-TNFα therapy by itself is a risk to TB 
reactivation. Additionally, withdrawal of anti-TNF therapy is a recognised precipitating 
cause of TB paradoxical reaction in a case series [247].  One possible mechanism of 
how anti-TNFα therapy may reduce host inflammation in such cases is that anti-TNFα 
decreases neutrophil MMP secretion by blocking the stimulatory effect of TNFα.  This 
effect may also occur in other cells and the consequential suppressed MMP secretion 
decreases tissue destruction which in turn improves host outcome in the context of 
CNS-TB. 
 The literature regarding IL-4 in TB is rather conflicting.  It is the main Th2 
cytokine increased in TB patients compared to normal subjects [226].  In addition, 
studies in murine models have indicated that IL-4 presence in lung lesions coincides 
with pneumonia and necrosis [227].  IL-4 also suppresses MMP expression in human 
fibroblasts [228].  I thus sought to determine if IL-4 would augment neutrophil MMP 
secretion.  Interestingly, at lower concentrations of IL-4, MMP-9 but not MMP-8 
secretion is suppressed, while there seem to be an increase of MMP-9 with increasing 
concentrations of IL-4.  Conversely, TIMP-1 but not TIMP-2 secretion was decreased 
with increasing IL-4 concentration. This could be associated with the increased 
neutrophil phagocytosis and chemotaxis with IL-4 at higher concentrations [229]. 
 Interstitial collagen fibrils are resistant to breakdown by most proteinases and 
only interstitial collagenases MMP-1, MMP-8 and MMP-13 can degrade the intact 
triple-helical collagen into one-quarter and three-quarter fragments.  MMP-1 and -13 
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preferentially cleave type III and II collagen respectively [200].  MMP-8 cleaves Type I 
collagen more potently than MMP-1 [200, 201] and this suggests that MMP-8 
(neutrophil collagenase) may be the main collagenase responsible for Type I collagen 
degradation.  Neutrophils are a major source of MMP-8, but other sources include 
macrophages, endothelial cells, smooth muscle cells [248] and fibrocytes [249]  among 
others.  I have focused on the extracellular matrix Type I collagen as it is the most 
abundant collagen in the human lung [250, 251].  Collagen is the most abundant protein 
in the lung, comprising 20% of dry weight of the adult human lung [252, 253].  Type I 
collagen is distributed through the lung including the tracheobronchial tree, blood 
vessels and alveolar interstitium. When tissue destruction occurs in TB, the structural 
support that is provided by the extracellular matrix will be eroded and together with cell 
death this will lead to cavity formation and areas of necrosis.  I have demonstrated that 
both M.tb-infected and CoMTB-stimulated neutrophils degrade Type I collagen and 
introduction of an MMP inhibitor, doxycyline abolished the collagenase activity from 
neutrophils.  I have chosen doxycycline as this is the only licensed MMP inhibitor by 
the Food and Drug Administration.  These observations support my hypothesis that 
neutrophil MMPs, particularly neutrophil MMP-8, are critical for tissue destruction.   
 NETs are produced when neutrophils encounter pathogens to assist in trapping 
and subsequent phagocytosis of pathogens.  This phenomenon was first described by 
Brinkman et al [97] who showed that NETs also help kill bacteria such as Shigella spp. 
and S.aureus and digestion with DNAse abrogated the killing effect of NETS.  NETS 
however do not have any M.tb killing effects [143].  NETS are comprised of many 
neutrophil granule proteins including myeloperoxidase, neutrophil elastase, cathepsin G 
as well as histone proteins (H1, H2A, H2B, H3, H4) as demonstrated by 
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immunofluorescence [97]. I have demonstrated that NETS are produced by neutrophils 
with M.tb infection in my system and this is compatible with previous finding [143].  I 
have shown that MMP-8 and -9 are associated with NETS by immunofluorescence.  
This association is likely to be non-specific because in immunoprecipitation-Western 
blot experiments, NET protein histone 2B is present even in the isotype control 
antibody pulldown.  The presence of DNA bands when running both the isotype control 
pulldown and MMP-8 and -9 pulldown on agarose gels confirms the non-specific 
association despite my extensive attempts to optimise the immunoprecipitation 
technique.  These ranged from preclearing the NET supernatant overnight, decreasing 
the amount of starting supernatant and using paraformaldehyde to cross-link MMPs to 
NETS. One possible explanation about this non-specific association is that NETS are 
inherently ‗sticky‘ so as to trap pathogens.  Additionally, Protein G a component of the 
immunoprecipitation kit is derived from streptococcal species and NETS are naturally 
associated with Protein G when the two come into contact.  Interestingly during my 
extensive literature search of immunoprecipitaion, I did not come across any reports 
describing immunoprecipitation of NET associated proteins.  Most techniques to 
determine NET components including the first by Brinkman et al [97] utilised 
immunofluorescence suggesting that immunoprecipitation of NET components is 
technically challenging.  One possible method to be used if this line of enquiry is to be 
further pursued will be mass spectrometry but the NET purification process needs to be 
stringent but not so overly harsh that it might destroy NETS itself. 
 In summary the MMP phenotype when neutrophils are infected with M.tb and 
stimulated with CoMTB have been described with MMP-8/-9 secretion vastly increased 
with minimal TIMP secretion, leading towards a proteolytic environment with 
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consequential tissue destruction as demonstrated by collagen degradation in DQ 
collagen assays.  Dexamethasone, anti-TNFα, doxycycline and low-dose IL-4 
conversely decreased MMP secretion.  NETs are induced with M.tb infection, both with 
live H37Rv and UV-killed organisms but not by CoMTB stimulation.  Interestingly, 
neutrophil MMP-8 and -9 seem to be associated with NETS in immunofluorescence 
studies but this has not been confirmed by immunoprecipitation.  
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CHAPTER 4 – EFFECT OF CROSSTALK OF M.TB INFECTED 
NEUTROPHILS ON OTHER CELLS AND ON M.TUBERCULOSIS 
GROWTH DYNAMICS 
1. Introduction 
 In the previous chapter, I had described the MMP phenotype when neutrophils 
encounter M.tb both in direct infection and in monocyte-dependent networks.  This 
chapter aims to address the effects of these encounters on other cells as well as on M.tb 
growth.   
Neutrophils are among the first immune cells to arrive at the site of infection.  
They are professional phagocytic cells and also orchestrate the body‘s defence system.  
In addition to the production of NETS that was described in the previous chapter, they 
concurrently secrete a wide arsenal of antimicrobial agents such as reactive oxygen 
species, human neutrophil peptides 1-3, cathelicidin LL-37 and lipocalin-2 in the 
attempt to kill or restrict the growth of pathogens.  Furthermore, they secrete 
chemokines and cytokines to set off a cascade of events following their recruitment to 
inflamed or infected tissues. Human neutrophils are a major source of cytokines such as 
BAFF [108] and APRIL [254] for the survival, maturation and differentiation of B 
cells.  They may also engage in cellular crosstalk between macrophages [255], dendritic 
cells [256], natural killer cells [112], lymphocytes [115] and mesenchymal stem cells 
[257].   
 Given the considerable amount of cellular crosstalk that can potentially happen 
with neutrophils, I was interested if the conditioned media from M.tb-infected 
neutrophils (CoNTB) would modulate the MMP secretion from other cells.  I looked 
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into the effects of CoNTB on monocytes, monocyte-derived macrophages and because 
of the neurological involvement of TB, several astrocytic cells lines, and the microglial 
cell line CHME3.  CoNTB was made by infecting neutrophils with M.tb MOI of 1 as 
this is thought to represent a physiological state of infection outside the pulmonary 
cavity (eg. CNS) where the bacillary burden would be lower. I also investigated if 
conditioned media from M.tb-infected astrocytic cell line (CoATB) would affect 
neutrophil MMP secretion. 
 Since neutrophils secrete an armamentarium of antimicrobial peptides, I was 
interested if CoNTB and neutrophil MMP-8/-9 would restrict or inhibit M.tb growth.  
As it had been demonstrated that neutrophil cathelicidin LL-37 and lipocalin-2 
restricted M.tb growth [126] and that these compounds are present in CoNTB, the 
hypothesis was that CoNTB would therefore modulate M.tb growth.  In addition to 
using the conventional optical density method of quantifying M.tb growth in 7H9 liquid 
broth and quantifying colony forming units on 7H11 agar, I utilised luminescent M.tb 
H37Rv luxG13 [217] [258] and measured luminescence as a readout of M.tb growth. 
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2. Results 
2.1 Effect of CoNTB on monocytes 
 As neutrophils and monocytes are among the first to arrive at the site of 
infection, the effect of neutrophil crosstalk with monocytes was investigated.  This was 
done by stimulating peripheral monocytes with CoNTB.  A Luminex array run at high 
sensitivity demonstrated that only MMP-7 was upregulated but this was not statistically 
significant (Figure 22). 
 
Figure 22:  Effect of CoNTB on monocytes. CoNTB and CoNCont was made by stimulating 
7.5 x 105 neutrophils with M.tb at MOI of 1 or the equivalent volume of PBS for 4 hours and 
sterile filtered.  5 x 105 monocytes were stimulated with CoNCont or CoNTB at a 1:5 dilution 
for 72 hours with 10 ng/ml of LPS as a positive control.  MMP-2, -3, -12, and -13 
concentrations were undetectable.  Bars represent mean +/- SD of an experiment done in 
triplicate.  p=NS for data. 
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2.2 Effect of CoNTB on monocyte-derived macrophages 
Macrophages are known to play key roles in TB pathogenesis.  I next investigated 
neutrophil interaction with monocyte derived macrophage (MDMs) by using CoNTB to 
stimulate them.  There was no significant upregulation of any MMPs from MDMs. 
(Figure 23). 
 
Figure 23:  Effect of CoNTB on MDMs.  CoNTB and CoNCont was made by stimulating 7.5 
x 105 neutrophils with M.tb at MOI of 1 or the equivalent volume of PBS for 4 hours and sterile 
filtered.  5 x 105 MDMs were stimulated with CoNCont or CoNTB at a 1:5 dilution for 72 hours 
with 10 ng/ml of LPS as a positive control.  MMP-12 and -13 concentrations were undetectable.  
Bars represent mean +/- SD of an experiment done in triplicate.  p=NS for data. 
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2.3 Effect of CoNTB on astrocytes 
 To further investigate neutrophil networking effects, astrocyte cell lines were 
examined.  These cells are part of the blood-brain-barrier and are affected in CNS-TB 
[189, 259].  Since neutrophils counts are raised in CNS-TB [215] I examined whether 
astrocytes would be affected by neutrophil-dependent networks.  I looked at stimulating 
the astrocyte cell lines U87MG, U373MG Uppsala and U251MG (from the Health 
Protection Agency Culture Collections) with CoNTB.  Experiments showed that most 
of the MMP-9 detected originated from the CoNTB only control (Figure 24A) with 
MMP-9 secretion unaffected when astrocytes were stimulated with CoNTB.  MMP-3 
secretion from astrocytes was also minimal.  The cells however appeared stressed (data 
not shown).  The experiment was repeated using CoNTB filtered through a 0.2 µM 
Anopore filter which decreased MMPs in the filtrate [219] (Figure 24B) in the hope of 
decreasing the MMP background but there was no significant increase seen in MMP-9 
secretion from astrocytes.  In addition, PMA and CoMTB, both proven to be positive 
controls of MMP-9 secretion from astrocytes, repeatedly produced minimal MMP-9 
secretion on gelatin zymograms and ELISAs (data not shown) from all the astrocyte 
cell lines. More than 5 experiments were repeated with similar results.  Hence, the 
investigation of CoNTB on astrocytes was halted. 
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Figure 24:  Effect of CoNTB on U251MG astrocytes.  CoNTB and CoNCont were made by 
stimulating 7.5 x 105 neutrophils with M.tb at MOI of 1 or the equivalent volume of PBS for 4 
hours and sterile filtered.  Astrocytes were stimulated with CoNCont or CoNTB at a 1:5 dilution 
for 72 hours with 100ng/ml of PMA as a positive control. (A) Luminex readout.  MMP-12 and -
13 concentrations were undetectable.  Bars represent mean +/- SD of an experiment done in 
triplicate.  p=NS for data.  (B) Gelatin zymography and corresponding densitometric analysis.  
Bars represent mean +/- SD of an experiment done in triplicate.  p=NS for data.  Similar results 
were obtained for U373MG Uppsala and U87MG astrocytic cell lines.  
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2.4 Effect of CoNTB on CHME3 microglial cell line 
 As microglial are resident macrophages in the CNS, I used the microglial cell 
line CHME3 to ascertain the effects of neutrophil networking. A Luminex run did not 
reveal any significant changes in MMP secretion from CHME3 (Figure 25). 
 
Figure 25:  Effect of CoNTB on CHME3 microglial cells.  CoNTB and CoNCont was made 
by stimulating 7.5 x 105neutrophils with M.tb at MOI of 1 or the equivalent volume of PBS for 
4 hours and sterile filtered. CHME3 cells were stimulated with CoNTB at 1:5 dilution for 72 
hours with 100 ng/ml of PMA as a positive control.   MMP-7 and -12 concentrations were 
undetectable.  Bars represent mean +/- SD of an experiment done in triplicate.  p=NS for data.   
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2.5 Effect of CoATB on neutrophils 
 The network effects of M.tb-infected astrocytes on neutrophils were 
investigated.  However, the experiment showed that there was no increase in MMP-8 
and -9 from neutrophils stimulated with Conditioned media from M.tb-infected 
astrocyte (CoATB) (Figure 26). 
 
Figure 26:  Effect of CoACont and CoATB on neutrophils.  U373MG Uppsala was 
infected with M.tb MOI of 10 or stimulated with the equivalent volume of PBS for 72 
hours.  Supernatants were filtered through a 0.2 µM Anopore membrane and termed 
Conditioned media from M.tb-infected astrocytes (CoATB).  Uninfected astrocytes 
were similarly treated and termed CoACont.  Neutrophils were stimulated with 
CoACont or CoATB at different dilutions for 4 hours. Bars represent mean +/- SD of an 
experiment done in triplicate.  p=NS for data. 
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2.6 Effect of neutrophil MMP-8/-9 on M.tb growth 
 Certain neutrophil antimicrobial peptides such as HNP 1-3 and lipocalin-2 are 
mycobactericidal [126].  I wanted to determine if neutrophil MMP-8 and -9 can also 
restrict or inhibit M.tb growth.  Purified MMP-8 and -9 from human neutrophil 
granulocytes were obtained from Enzo Life Sciences and the equivalent concentrations 
of MMP-8 at 250 ng/ml or MMP-9 at 1μg/ml which are in supernatants from 
neutrophils infected with M.tb at an MOI of 10 were used.  These were added to H37Rv 
in 7H9 broth and growth monitored using optical density and by plating H37Rv onto 
7H11 agar after 7 days. Neutrophil MMP-8/-9 however did not affect M.tb growth as 
there was no change in optical density or by CFU (Figure 27).  
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Figure 27: Neutrophil MMP-8 and -9 on M.tb growth.  A final concentration of 250 
ng/ml MMP-8 or 1 μg/ml MMP-9 and H37Rv at initial optical density of 0.1 were used 
in a total volume of 1.2mls.  Control was the buffer (50mM Tris, 200mM NaCl, 5mM 
CaCl2, 1μM ZnCl2, 0.05% NaN3, 0.05% Brij-35) in which MMPs were suspended in. 
Control and MMP-8/-9 were desalted to remove NaN3 using spin columns prior to 
addition to H37Rv in 7H9. (A) Optical density over time.  (B) CFU/ml.  H37Rv was 
plated out at Day 7 onto 7H11 agar and plates were read at 2 weeks.  p=NS for data.  
Bars represent mean +/- SD of conditions in triplicate and the experiment was 
representative of 3 independent experiments. 
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2.7 Effect of CoNTB and CoNCont on M.tb growth  
 Since purified neutrophil MMP-8 and -9 did not seem to have any effect of the 
growth of H37Rv, I wanted to determine if CoNTB which are reported to contain a 
range of neutrophil antimicrobial peptides in addition to MMP-8/-9 would modulate 
M.tb growth.  It appeared that the addition of CoNTB at 1:3 dilution to H37Rv 
conversely seemed to increase the growth of H37Rv (Figure 28). CoNTB at 1:2 
dilution did not have reproducible results on H37Rv growth in 2 separate occasions 
(data not shown).  
 
Figure 28:  Effect of CoNTB on H37Rv growth.  4 x 106 neutrophils were infected with M.tb 
at an MOI of 10 or the equivalent volume of PBS for 4 hours and sterile filtered to make 
CoNTB and CoNCont respectively.  These were added in a 1:3 dilution to H37Rv in 7H9 at a 
starting optical density of 0.1 to a total volume of 1.2mls. (A) Optical density over time.  (B) 
CFU/ml.  H37Rv were plated out at Day 16.  Plates were incubated for 2 weeks before colonies 
were counted.  Bars represent mean +/- SD of conditions in triplicate and is representative of 2 
independent experiments. ** p<0.01, *** p < 0.001, ****, p<0.0001. 
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 I was not convinced that the addition of CoNTB would increase the growth of 
M.tb, and was concerned that the results I obtained were artifactual. I thus decided that 
another way would be to measure the luminescence of H37Rv lux G13[217].  H37Rv 
lux G13 had been used to measure anti-tuberculous drugs in vitro [258] and would be 
another method to assess if CoNTB truly affected M.tb growth.  With the incubation of 
H37Rv luxG13 with CoNTB, CoNCont and media (RPMI), there was a trend towards 
an increased M.tb growth with CoNTB although this was not statistically significant 
between the different conditions (Figure 29). 
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Figure 29: Growth of H37Rv luxG13.  4 x 106 neutrophils were infected with M.tb at 
an MOI of 10 or the equivalent volume of PBS for 4 hours and sterile filtered to make 
CoNTB and CoNCont respectively.  These or RPMI(media) were added in a 1:3 
dilution to H37Rv luxG13 in 7H9 at a starting optical density of 0.1 to a total volume of 
1.2mls.   Bars represent mean +/- SD of conditions in triplicate and is representative of 
experiments done in 2 separate occasions. P = NS for data.  
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3. Discussion 
 In this chapter, I have investigated the networking effects of neutrophils on cells 
such as monocytes, macrophages, astrocytes and microglial cells.  There was a 
surprising lack of effect on the MMP secretion from the above cell types that were 
investigated, although the macrophages and astrocytes appeared stressed when 
stimulated with CoNTB.  One possible reason was that an MOI of 1 of M.tb used to 
make CoNTB may not be sufficient to elicit an increase in MMP secretion from other 
cells, and a higher MOI such as 10 may be required.  However, neutrophils also secrete 
a large amount of MMP-8 and -9 even when infected with M.tb MOI of 1, making it 
technically challenging to detect a relatively smaller increase in MMP-8 and -9 
concentrations from both monocytes and macrophages and MMP-9 from astrocytes, 
although other MMPs from these cells were not affected. Filtering CoNTB with 
Anopore filters to remove some neutrophil MMPs from CoNTB did not appear to help 
in this situation compared to CoMTB where it minimised the MMPs [219], as this is 
probably due to the larger amounts of MMP-8/-9 present in CoNTB.  In comparison, 
CoMTB had smaller quantities of MMPs and filtration further reduced the 
concentration of MMPs to a minimum.  Thus, it was easier to demonstrate the effect of 
CoMTB on other cell types and these have been shown in primary airway epithelial 
cells[180], astrocytes[190], fibroblasts[191] and microglial cells [260].  An alternative 
readout would be to evaluate the cytokines and chemokines secreted from these cells 
when stimulated with CoNTB.  
 I had looked at potential crosstalk between astrocytes and neutrophils, and there 
was a lack of MMP secretion from neutrophils when stimulated with CoATB from 
U373MG Uppsala.  One limitation was that I did not evaluate the effect of CoATB 
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made from other astrocyte cells lines.  It is quite likely however that there will also be 
lack of neutrophil MMP response with these other CoATB since these astrocytic cell 
lines are similarly derived from malignant glioblastoma astrocytomas. 
 MMPs are well-known for their role in extracellular matrix turnover but there is 
limited literature if they possess any pathogen killing effect.  Houghton et al [261] 
described MMP-12 -/- mice exhibiting impaired bacterial clearance and had increased 
mortality when challenged with both Gram-negative and Gram-positive bacteria at 
macrophage-rich portals of entry, namely the peritoneum and lung.  Additionally, they 
have shown in in vitro studies that full-length recombinant human MMP-12 exhibited 
dose-dependent inhibition of S.aureus.  I thus wanted to determine if neutrophil MMP-8 
and -9 would also have any bactericidal, specifically mycobactericidal effects.  
However, incubation of H37Rv with purified MMP-8 and -9 did not show any effects 
on M.tb growth.  This however does not mean that MMP-8 and -9 do not have any 
pathogen killing effects as other pathogens have not been tested. 
 It was interesting to note that CoNTB seemed to increase M.tb growth using the 
readouts of optical density and growth on agar.  The results of CoNTB on luminescent 
M.tb although not statistically significant showed a trend towards increase as well.  
When neutrophils are infected with M.tb, they secrete antimicrobial peptides such as 
human neutrophil peptide 1-3 and lipocalin-2 which have both been shown to inhibit 
M.tb growth [126], so I was surprised that M.tb growth was conversely increased when 
CoNTB was added to H37Rv in 7H9.  It had also been shown that human neutrophils 
exhibited potent intracellular killing activity on M.tb in vitro [262] which is 
independent of oxidative mechanisms.  One possibility is that neutrophils secrete some 
growth factors for M.tb and this would need further investigation, perhaps using mass 
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spectrometry to identify various components of CoNTB, and testing each individual 
component on M.tb growth. 
 In summary, I had shown a lack of networking effects from neutrophils on 
monocytes, macrophages, astrocytes and microglial cells in terms of increasing MMP 
secretion from these cells.  There was no astrocyte cross-talk to neutrophils when 
astrocytes were infected with M.tb.  Human MMP-8 and -9 do not have 
mycobactericidal effects and there seemed to be an increase in growth of M.tb when 
cultured with conditioned media of M.tb infected neutrophils (CoNTB).   With the 
neutrophil MMP phenotype defined with M.tb exposure and the effects of neutrophil 
cross-talk on other cells explored, the mechanisms regulating neutrophil MMP secretion  
will be discussed in the next chapter. 
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CHAPTER 5 – INTRACELLULAR SIGNALLING PATHWAYS AND 
TRANSCRIPTION FACTORS REGULATING NEUTROPHIL MMP 
SECRETION 
1. Introduction 
 The secretion of MMPs from cells is regulated by a few key pathways.  The 
MAP kinase and the PI3 kinase have been well-described to regulate MMP secretion 
from macrophages[181], microglial [192] and astrocytes [189] among other cells.  
However, it is crucial to note that these cells unlike neutrophils synthesise most of their 
MMPs when gene expression is induced.  Neutrophils conversely store majority of 
MMP-8 and -9 in their secondary and tertiary granules respectively in their pro-form 
although a small amount of gene expression is involved as described in Chapter 3.  The 
question is which pathways are regulating the release of neutrophil MMPs in TB.  
Identifying these pathways are essential as they are potential points in which therapeutic 
interventions can be made to modulate MMP secretion, altering the effects that result 
from excessive MMP secretion and matrix destruction. 
 In this chapter, I shall delineate the various pathways and transcription factors 
that regulate neutrophil MMP secretion both in the context of direct M.tb infection as 
well as in monocyte-dependent networks when neutrophils are stimulated by CoMTB.  
This is done by western blotting, phosphoarrays and pharmacological inhibitors.  In 
addition, I spent 6 months attempting siRNA on neutrophils which proved to be 
technically difficult to transfect.  Lastly, I have also analysed the neutrophil MMP 
secretion from a rare cohort of patients with AMPKγ2 mutation with resultant functional 
AMPK deficiency and compared this with healthy controls in the same experimental 
setting. 
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2. Results 
2.1 Role of MAP-kinase and PI3-kinase pathways in M.tb infected 
neutrophils 
 The Mitogen-activated protein kinase pathway and Phosphoinositide 3-kinase 
pathway have been implicated in regulating MMP secretion from neutrophils.  [194, 
208, 263]  To examine the effect M.tb has on these pathways, I investigated the 
phosphorylation of p38, ERK and the Akt substrate of the PI3-kinase pathway of 
control versus M.tb-infected neutrophils over time.   The kinetics experiment 
demonstrated that p38 was phosphorylated at time = 0 for both control and M.tb-
infected neutrophils probably due to activation from the neutrophil extraction process.  
Phosphorylation was subsequently absent in control cells but present through 120 
minutes in M.tb-infected neutrophils.   Phospho-ERK is present from 15 minutes, peaks 
at 30 minutes and declines by 120 minutes, while Phospho-Akt starts and peaks at 15 
minute and declines by 120 minutes in M.tb-infected neutrophils.  ERK and Akt 
phosphorylation was not detected in control cultures (Figure 30).   
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Figure 30:  Phosphorylation kinetics of p38, ERK and Akt with control (PBS) and 
M.tb infection in neutrophils.   2 x 10 6 neutrophils were incubated with either PBS or 
TB MOI of 10 and at specified time points, cells were pelleted and lysed with SDS 
sample buffer.   Data is representative of 2 separate experiments.  
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 As the MAP-kinase and PI3-kinase pathways are activated in neutrophils in 
response to M.tb infection, the question is if they are of any functional significance.  To 
investigate this, I utilised 3 chemical inhibitors: the p38 inhibitor SB 203580, the ERK 
inhibitor PD98059, and the PI3-kinase inhibitor LY294002 and investigated their 
effects on MMP-8 and -9 secretion on M.tb-infected neutrophils.    A TB MOI of 10 
was used in the experiments to accentuate the secretion of MMP-8 and -9 so as to 
demonstrate a dose-dependent suppression if any.  No inhibitory effect was 
demonstrated with the three chemical inhibitors (Figure 31) even when the neutrophils 
were pre-incubated with the inhibitors for 60 rather than 30 minutes (data not shown).  
Neutrophils were also incubated with DMSO, a commonly used solvent to dissolve 
chemical inhibitors on a separate occasion and this did not have any effect on neutrophil 
MMP secretion in the context of M.tb infection and CoMTB stimulation (data not 
shown). 
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Figure 31:  Effects of ERK inhibitor, p38 inhibitor and PI3 kinase inhibitor on 
M.tb-infected neutrophils.  7.5 x 105 neutrophils were re-suspended with media, 1 µM 
or 10 µM of the respective inhibitor and pre-incubated for 30 minutes before infected 
with M. tuberculosis at an MOI of 10 for 4 hours. Supernatants were analysed using 
luminex array as described in methods.  Bars represent mean +/- SD of three samples 
and is representative of 2 separate experiments done in triplicate.  p = NS for data 
shown.  
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2.2 Role of NF-kB in M.tb-infected neutrophils 
 Next, the role of NF-kB on MMP-8 and -9 secretion from neutrophils was 
investigated with the use of 2 inhibitors: Helenalin, an NF-kB inhibitor which targets 
the p65 subunit, and SC-514, an inhibitor of IKK2, up-stream of NF-kB.  Helenalin 
demonstrated a significant dose-dependent suppression of both MMP-8 and -9 to 
baseline from M.tb-infected neutrophils with maximal suppression at a concentration of 
100 µM (p<0.001 for both MMP-8 and 9) (Figure 32).  Interestingly, inhibition of 
M.tb-infected neutrophils with SC-514 did not show any effect on MMP-8 and MMP-9 
secretion.  The viability of neutrophils in both experiments were >90% by trypan blue. 
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Figure 32:  NF-kB inhibitors on M.tb-infected neutrophils.  7.5 x 105 neutrophils 
were resuspended with media, 1 µM, 10 µM, or 100 µM of the inhibitors, pre-incubated 
for 30 minutes and subsequently infected with a TB MOI of 10 for 4 hours.  
Supernatant were analysed using luminex array.  (A) Effect of Helenalin on M.tb-
infected neutrophils.  Bars represent mean +/- SD of an experiment done in triplicate 
and is representative of 2 separate experiments.  ***p<0.001.  (B) Effect of IKK2 
inhibitor SC-514 on M.tb-infected neutrophils.  Bars represent mean +/- SD of an 
experiment done in triplicate and is representative of 2 independent experiments.  
*p<0.05, **p<0.01.  
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2.3  Role of MAP-kinase and PI3-kinase in CoMTB stimulated neutrophils 
 Since the MAP-kinase and PI3-kinase pathways in neutrophils are activated 
with M.tb infection, I hypothesized that these pathways would similarly be activated 
with CoMTB stimulation. I examined the phosphorylation of the p38, ERK, JNK, and 
Akt pathways by western blotting (Figure 33).  With CoMTB stimulation, phospho-
p38, which was present at time =0, peaked at 15 minutes and remained phosphorylated 
through 120 minutes.  Phospho-ERK, phospho-JNK and phospho-Akt appeared at 15 
minutes and subsided by 120 minutes.  However, I faced difficulty in demonstrating the 
presence of total-JNK due to the high background signal after the membrane was 
stripped.  This attempt was made on three occasions, and using bovine serum albumin 
instead of skimmed milk during blocking of the membrane in the possible event that it 
was a component of milk that may have caused non-specific binding of the primary 
antibody.  However, the use of BSA did not improve the quality of the blot.  Attempts 
at using beta-actin as a substitute for protein loading was also not successful (data not 
shown). 
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Figure 33:  Phosphorylation kinetics of CoMTB-stimulated neutrophils.  2 x 106 
neutrophils were stimulated with CoMCont or CoMTB at 1:5 dilution and at the 
specified time points cells were pelleted and lysed with SDS lysis buffer.  Data is 
representative of 4 independent experiments.  
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 Similarly, since the MAP-kinase and the PI3 kinase pathways were activated, 
the question is whether these pathways actually regulate neutrophil MMP secretion with 
CoMTB.  I went on to investigate the effect of inhibition of these pathways using p38 
inhibitor SB 203580, ERK inhibitor PD 98059, PI3 kinase inhibitors LY 294002 and 
Wortmannin.  There was a dose-dependent suppression of MMP-8 and 9 secretion 
which was statistically significant at 10 µM of PD 98059 (p<0.01 and p<0.05 
respectively) and 10 µM of SB 203580 (p< 0.01 and p< 0.001 respectively) (Figure 
34A).  There was also a dose-dependent suppression of MMP-9 secretion with LY 
294002 at 10 µM (p<0.01), but this effect was not observed for MMP-8 (Figure 34B). 
Wortmannin did not suppress MMP-8 and 9 secretion from CoMTB stimulated 
neutrophils (Figure 34C) possibly as it has other non-specific, off-target actions. [264, 
265]  
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Figure 34:   Effect of MAP-kinase and PI3-kinase inhibitors.  7.5 x 105 neutrophils were 
pre-incubated with inhibitor for 30 minutes and subsequently stimulated with CoMTB at 1:5 
dilution for 4 hours.  Supernatants were analysed using luminex array.  (A) Effect of ERK 
inhibitor PD 98049  and p38 inhibitor SB 203580 on CoMTB stimulated neutrophils.  Bars 
represent mean +/- SD of an experiment done in triplicate and is representative of 2 separate 
experiments.  *p<0.05, **p<0.01, ***p<0.001.  (B)  Effect of PI3 kinase inhibitor LY 294002 
on CoMTB stimulated neutrophils.  Bars represent mean +/- SD of an experiment done in 
triplicate and is representative of 2 separate experiments.  *p<0.05, **p<0.01.  (C)  Effect of 
Wortmannin on CoMTB stimulated neutrophils.  Bars represent mean +/- SD of an experiment 
done in triplicate and is representative of 2 separate experiments. p=NS for data. 
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2.4 Role of NF-kB in CoMTB stimulated neutrophils 
 Next, I investigated the role of NF-kB in CoMTB stimulated neutrophils using 
the p65 subunit inhibitor Helenalin and IKK2 inhibitor SC-514.  There was a significant 
dose-dependent suppression of MMP-8 and -9 back to baseline at the maximum 
concentration of 100µM of Helenalin (p <0.001 for both) (Figure 35). SC-514 also 
demonstrated a significant dose-dependent suppression of MMP-8 and 9 in CoMTB 
stimulated neutrophils (p <0.001).  
 
Figure 35:  Effect of NF-kB inhibitors on CoMTB stimulated neutrophils.  7.5 x 105 
neutrophils were pre-incubated with the respective inhibitor for 30 minutes and subsequently 
stimulated with CoMTB at 1:5 dilution for 4 hours.  Supernatants were analysed using luminex 
array.  (A) Helenalin on CoMTB stimulated neutrophils.  (B) SC-514 on CoMTB stimulated 
neutrophils.  Bars represent mean +/- SD of an experiment done in triplicate and is 
representative of 2 independent experiments each.  **p<0.01,***p<0.001. 
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2.5 MAP-kinase, PI3kinase, AMPK and STAT pathways are activated in 
CoMTB stimulated neutrophils 
 To dissect other pathways that may be activated in CoMTB-stimulated 
neutrophils, I used the Human Proteome Profiler Phospho-kinase Array kits.  5 donors 
on 5 separate occasions were used for this.  The blots confirmed that the MAP kinase 
and PI3 kinase pathways are activated with CoMTB stimulation (Figure 36).  ERK1/2 
which is a component of the MAPK pathway and p53 which is upregulated in apoptosis 
was found to be phosphorylated from all donors. In addition, members of the AMPK 
pathway (Akt, AMPKα2, p70 S6 kinase), the master regulator of energy homeostasis,  
and STAT pathways (STAT1, STAT 5b and STAT 6) which play critical roles in 
cytokine and chemokine secretion were also found to be consistently phosphorylated.   
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Figure 36:  Phosphokinase array.  2.5 x 106 neutrophils were stimulated with CoMTB 
or CoMCont at 1:5 dilution and cells were lysed after 30 minutes.  The amount of 
protein was quantified using a Bradford assay, and equal amounts of cell lysates were 
added onto the membranes overnight. Blots were developed using ECL. (A) 
Representative array from one donor. The red circles denotes AMPKα2. (B) 
Densitometric analysis.  Bars represent mean +/- SEM of values from arrays of 5 
donors. 
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2.6 AMPK regulates MMP secretion in CoMTB-stimulated neutrophils  
 The Human Proteome Profiler Phospho-kinase Array kits had shown that 
AMPKα2 was phosphorylated consistently.  5‘ Adenosine monophosphate-activated 
protein kinase is activated when there is increased AMP:ATP ratio, hence regulating 
cellular energy homeostasis,  and is involved in various metabolic pathways including 
regulating cellular uptake of glucose, steroid synthesis and biogenesis of GLUT-4 [266, 
267].  Activation of AMPK has also been shown to decrease neutrophil pro-
inflammatory activity and decrease TNF- α [268]. I first investigated phosphorylation 
of AMPKα2 in CoMTB stimulated neutrophils.  The primary antibody from Cell 
Signalling UK was available only for phospho-AMPKα1/2 (T172) and not for phospho-
AMPKα2 alone and other manufacturers do not have a phospho-AMPKα2 (T172) 
antibody.  Nevertheless, Western blotting showed that AMPKα1/2 is phosphorylated 
from 0 minutes through 120 minutes and confirmed that AMPKα was activated (Figure 
37A). I next investigated the possible role that AMPK may have in regulating MMP-8 
and -9 in CoMTB stimulated neutrophils.  I used AMPK inhibitor Compound C and 
AMPK activator AICAR on CoMTB-stimulated neutrophils using doses that have been 
previously described[268, 269].  There was a significant dose-dependent suppression of 
both MMP-8 and -9 with Compound C maximally at a concentration of 100 (p<0.001 
and p<0.01 respectively) (Figure 37B).  TIMP-2 was similarly suppressed at a dose-
dependent manner maximally at 100 µM of Compound C (p<0.01) (Figure 37C).   
Ideally, AMPK inhibition should be done with another chemical inhibitor to determine 
that the suppression of neutrophil MMP was not a non-specific effect of Compound C 
but there is no other inhibitor available at the time of writing this thesis.  There was no 
effect of AMPK activation with AICAR on neutrophil MMP secretion (Figure 38). 
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Figure 37:  AMPK regulates neutrophil MMP secretion in CoMTB-stimulated 
neutrophils.  (A) Phosphorylation kinetics AMPKα1/2 with CoMCont and CoMTB. 2 
x 106 neutrophils were stimulated with CoMCont or CoMTB at 1:5 dilution and at 
specific time points cells were lysed.  Data representative of 2 separate experiments.  
(B) MMP-8/9 secretion in CoMTB-stimulated neutrophils pretreated with Compound 
C.  7.5 x 105 neutrophils were pre-incubated for 30 minutes with Compound C (Cpd C) 
before stimulating for 4 hours with CoMTB at 1:5 dilution.  Supernantants were 
analysed by luminex array.  (C)  TIMP-1/2 secretion.  Bars represent mean +/- SD of an 
experiment done in triplicate and is representative of 2 independent experiments.  
**p<0.01, ***p<0.001.  
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Figure 38:  AMPK activation on neutrophil MMPs.  7.5 x 105 neutrophils were pre-
incubated for 30 minutes with AICAR before stimulating for 4 hours with CoMTB at 
1:5 dilution.  Supernantants were analysed by luminex array.  (A) MMP-8 and -9 (B) 
TIMP-1/-2.  Bars represent mean +/- SD of an experiment done in triplicate and is 
representative of 2 independent experiments.  P=NS for data. 
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2.7 Neutrophil MMP secretion is independent of the mTOR/p70 S6 kinase 
pathway in CoMTB stimulated neutrophils 
As the mTOR and p70S6 kinase (identified as S6K1 below) pathway is downstream of 
the AMPK pathway (see adaption), I next evaluated if this pathway might be regulating 
neutrophil MMP secretion. 
 
Adapted from Sheckleford et al Nature Reviews Cancer 2009  
I first evaluated if p70S6 kinase was activated with CoMTB.  Western blotting 
confirmed that p70S6 kinase (T229) was phosphorylated with CoMTB commencing 
from 15 minutes to 240 minutes (Figure 39A).  Next, I used rapamycin in an attempt to 
inhibit mTOR and to determine if the mTOR pathway would regulate neutrophil MMP 
secretion.  Rapamycin did not affect neutrophil MMP secretion with CoMTB 
stimulation (Figure 39B).  
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Figure 39:  Neutrophil MMP secretion is independent of the mTOR/p70S6 kinase 
pathway.  (A) Kinetics of p70S6 kinase phosphorylation with CoMCont and CoMTB.  
2 x 106 neutrophils were stimulated with 1:5 CoMCont or CoMTB and lysed with SDS 
lysis buffer at specified time points.  Data representative of 2 separate experiments.  (B)  
Rapamycin does not affect neutrophil MMP-8/-9 secretion.  7.5 x 105 neutrophils were 
incubated with rapamycin for 30 minutes and subsequently stimulated with 1:5 CoMTB 
for 4 hours.  Bars represent mean +/- SD of triplicates and is representative of 2 
independent experiments.  P=NS for data. 
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2.8 MMP-8/9 secretion is independent of the AMPK pathway in M.tb-
infected neutrophils 
 Given that the AMPK pathway is regulating neutrophil MMP secretion in the 
context of CoMTB stimulation, I wanted to determine if this would be a similar 
situation when neutrophils are infected with M.tb.  I ascertained that phospho-
AMPKα1/2 was present in M.tb infection and commenced from 15 minutes through to 
120 minutes (Figure 40A).  The AMPK inhibitor Compound C did not affect neutrophil 
MMP secretion but did inhibit TIMP-2 (p<0.01) (Figure 40B and C).  Turning my 
attention to AMPK activation in M.tb infected neutrophils, activation with AICAR did 
not affect neutrophil MMP or TIMP secretion (Figure 41) which was similar to the 
context of CoMTB stimulation. 
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Figure 40:  AMPK pathway is activated but do not regulate MMP-8/9 secretion in 
M.tb infection.  (A) Kinetics of AMPKα phosphorylation with PBS and M.tb.  2 x 106 
neutrophils were infected with M.tb MOI of 10 and at specified points cells were lysed 
and sterile filtered.  Data representative of 2 independent experiments.  (B and C)  
MMP-8/-9 and TIMP-1/-2 secretion in neutrophils treated with Compound C (Cpd C) in 
M.tb infection.  7.5 x 105 neutrophils were preincubated with Cpd C for 30 minutes 
prior to infection with M.tb MOI of 10 for 4 hours.  Bars represent mean +/- SD of 
samples in triplicate and is representative of 2 separate experiments.  P=NS. 
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Figure 41:  AMPK activation does not affect neutrophil MMP secretion in M.tb 
infection.  7.5 x 105 neutrophils were preincubated with AICAR for 30 minutes prior to 
infection with M.tb MOI of 10 for 4 hours.  Supernatants were analysed using luminex 
array.  (A) MMP-8 and -9.  (B)  TIMP-1 and -2.  Bars represent mean +/- SD of 
conditions in triplicate and is representative of 2 independent experiments.  P=NS for 
data. 
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2.9 siRNA attempt on neutrophils 
 One criticism on the use of pharmacological inhibitors is that they may have 
non-specific properties and the suppression of MMP secretion, if any, may be due to 
these non-specific properties that they possess.  To circumvent this, I attempted siRNA 
on human neutrophils.  The main bulk of literature on the use of this technology has 
been mainly reported on neutrophil differentiated HL-60 (human promyelocytic 
leukemia cells), but the use of the technology has been increasingly reported in primary 
human neutrophils [270, 271], and hence I thought this would be a feasible approach.  I 
used the Deliver X siRNA kit (Panomics, France) which utilised a novel ―MPG‖ 
delivery technology which uses virus-derived amphipathic peptides that directly interact 
with nucleic acid cargos to form nanoparticles (150-200nm) capable of diffusing 
through plasma membranes and releasing their contents inside the cell [272].  The 
mechanism of entry is receptor-independent, involves MPG/lipid membrane 
interactions and avoids the endocytic pathway thus preventing degradation of nucleic 
acid cargos.  This method was chosen in preference to other technology as there was a 
publication substantiating its use in primary human neutrophils [273].  Lipid-based 
technology such as lipofectamine has low transfection efficiency in neutrophils and 
require cell-sorting to select for transfected cells (personal communication with Dr R 
Mittal, Division of Infectious Diseases, Children‘s Hospital Los Angeles).  
Furthermore, techniques that involve electro or nucleoporation inherently causes 
degranulation in primary human neutrophils [274] since the process permeabilises the 
plasma membrane which would undesirable in my experiments since MMP secretion 
would be affected.  Initial experiments to silence GAPDH to assess transfection 
efficiency appeared successful with gene knockdown of more than 70% (Figure 42), 
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and neutrophil viability using propidium iodide staining was reasonable.  However 
AMPKα1 and α2 gene silencing were inconsistent with CoMTB stimulation despite 
varying the time of stimulation after transfection from immediate to letting the 
transfected cells rest overnight and stimulating them the following morning.  
Eventually, I reverted to confirm if GAPDH protein was decreased with gene silencing 
using western blotting as I was doubtful whether neutrophils were successfully 
transfected but GAPDH protein suppression was not detected (data not shown).  siRNA 
was thus abandoned after 6 months. 
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Figure 42: GAPDH silencing in human neutrophils.  Primary human neutrophils were 
transfected with non-targeting siRNA (NT-siRNA) or GAPDH siRNA for 4 hours before cells 
were lysed and RNA extracted.  (A) Real-time PCR GAPDH normalised to beta-actin.  Bars 
represent mean +/- SD of samples in duplicate.  (B) Neutrophil viability by FACS.  Neutrophils 
were stained with 20 μg/ml propidium iodide and 10 000 events were gated. 
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2.10 Neutrophil MMPs are decreased with CoMTB stimulation in 
patients with AMPK mutation 
 I next looked at the neutrophil MMP secretion from a rare group of patients with 
AMPK mutations. This was done in collaboration with the Department of Cardiology at 
The Heart Hospital which has 3 of such patients. These patients present with 
cardiomyopathy as well as cardiac arrhythmias and have been genotyped to have 
AMPKγ2 mutations [275].  They have dysfunctional AMPK phosphorylation [276] and 
defects in activation of the α1β1γ2 complexes by AMP [277, 278].  Neutrophils from 
healthy volunteers were also stimulated at the same experimental setting.  There were 
thus 3 sets of AMPK and healthy controls (S1-S3) and their details are in Table 8. 
 With CoMTB stimulation, neutrophil MMP-8 and -9 was decreased in 2 out of 3 
of the AMPK patients compared to healthy volunteers (Figure 43A, B and C).  The 
pooled data showed that MMP-8 was decreased with CoMTB stimulation (p<0.01) and 
MMP-9 showed a trend towards suppression (p = 0.093) (Figure 43D).  In the context 
of M.tb infection, both neutrophil MMP-8 and -9 secretion was unaffected in the pooled 
data.  I next evaluated the AMPKα activation and was surprised to note that the AMPK 
patients had increased basal activity of AMPKα1/2 (T172) phosphorylation (Figure 
43E).  The p70S6 kinase phosphorylation was similar in both healthy and AMPK 
patients.  Attempts to probe for phospho-TSC which is also downstream of AMPK as 
well as AMPKγ2 were unsuccessful (data not shown) as there were no signal for the 2 
proteins. 
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Set Healthy AMPK gene mutation patients 
Age Gender Age Gender Disease manifestation 
S1 25 M 47 M Hypertrophic cardiomyopathy with permanent 
pacemaker 
S2 32 M 55 M Hypertrophic cardiomyopathy with implantable 
cardio-defibrillator, myopathy 
S3 32 F 40 F Hypertrophic cardiomyopathy with implantable 
cardio-defibrillator 
P= NS for age in the groups by Mann-Whitney. 
 
Table 8: Demographics of healthy controls and patients with AMPK gene 
mutation.   
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Figure 43:  Neutrophil MMP secretion is decreased with CoMTB stimulation in AMPK 
patients.  (A-C) Individual sets S1-3 of healthy volunteers and AMPK patients. 7.5 x 105 
neutrophils with infected with M.tb MOI 10 or CoMCont/CoMTB 1:5 dilution for 4 hours and 
supernatants were analysed using luminex array.  Open bars denote healthy control and red bars 
denote AMPK deficient patient.  Bars represent mean +/- SD of triplicates.   (D) Pooled data 
from 3 healthy-patient sets.  Each point represents an individual sample. 
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Figure 43 (continued):  (E) Phospho-AMPKα1/2 and phospho-p70S6k in healthy and AMPK 
patient.  2 x 106 neutrophils were infected with M.tb MOI 10 or CoMCont/CoMTB 1:5 for 30 
minutes and cells were lysed.  Data representative of the 3 healthy-patient sets. 
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3. Discussion 
 In summary, I have shown that neutrophil MMP secretion is stimulus specific, 
with M.tb infection and CoMTB stimulation driving different intracellular signalling 
pathways (see diagram below) resulting in MMP-8 and -9 secretion. 
 I have established that the p38/ERK MAP kinases, PI3-kinase and the AMPK 
pathways are activated when neutrophils are infected with M.tb.  However, MMP-8 and 
-9 secretion are not suppressed with chemical inhibitors (PD 98059, SB 203580, LY 
294002 and Compound C) in M.tb-infected neutrophils.  One possible explanation is the 
dose of M.tb used at MOI of 10 simply overwhelmed the system and caused massive 
unregulated secretion of the MMPs.  Another explanation is that the secretion of MMPs 
in M.tb-infected neutrophils is regulated by a different pathway, independent of the 
MAP-kinase, PI3-kinase and AMPK pathway.  Thirdly, the pathways could still be 
regulating neutrophil MMP secretion but this was not demonstrated in my set-up.  This 
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can be due to the requirement of using a much higher dose of inhibitors or a different 
inhibitor that act on the same path. Regardless, intracellular signalling paths involve 
activation of NF-kB which can be suppressed by the p65 subunit inhibitor Helenalin.  
Interestingly IKK2 inhibitor SC-514 did not affect the neutrophil MMP secretion in this 
context.    The NF-kB pathway comprises of the canonical and non-canonical pathways.  
It is the latter that is independent of IKK2 [279] and it might be that the NF-kB non-
canonical pathway regulates neutrophil MMP secretion in M.tb infection.  
 Intracellular signalling pathways that regulate MMP secretion from CoMTB-
stimulated neutrophils include the ERK/p38 MAP kinase and the PI3-kinase pathways 
and differs from the M.tb-infected neutrophils.  It is interesting that MMP-9 secretion 
but not MMP-8 is regulated by the PI3-kinase pathway.  This suggests that the secretion 
of MMP-8 and -9 is regulated by different mechanisms.  MMP-8 is stored in the 
secondary (specific) granules and MMP-9 is stored in tertiary (gelatinase) granules in 
neutrophils in their pro-forms.  Recent studies suggest profound differences in the 
regulation of tertiary granules versus that of primary and secondary granules in 
neutrophils, [280, 281] and this may be the case for MMP-8 and -9 secretion.  The 
finding that MMP-9 secretion is also regulated by PI3-kinase in neutrophils is 
consistent with literature [282].  With regards to transcription factors, herein also lies a 
difference from M.tb infected neutrophils.  IKK2 inhibitor SC-514 was able to suppress 
the neutrophil MMP secretion with CoMTB stimulation and this suggests that 
neutrophil MMP secretion in this context was dependent both on the p65 subunit and 
IKK2 pathway, namely the canonical pathway. 
 The phosphokinase array further confirmed that the MAP kinase is activated 
with CoMTB stimulation.  In addition AMPK, STAT, p53 and Yes were shown to be 
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activated.  AMPK plays a vast role in cellular signalling including cellular energy 
homeostasis, carbohydrate and lipid metabolism, cell growth and apoptosis, and protein 
synthesis.  It is activated by metabolic stresses such as hypoxia, ischemia, and low 
glucose when there is an increased AMP:ATP ratio.  It is a heterotrimeric complex that 
comprises the alpha catalytic subunits and the β and γ regulatory subunits.  
Phosphorylation of Thr 172 in the activation loop of AMPK is required for AMPK 
activation and this was detected in the phosphoarray.  STAT 5b and 6 were also 
activated.  In neutrophils, STAT 5b is known to be activated by GM-CSF [283] which 
is present in CoMTB.  STAT 6 is activated by IL-4 [284] and IL-13 [285], the former 
which is undetectable in CoMTB and the latter in small amounts (Table 7).  It would 
have been ideal to determine if the STAT pathways do regulate neutrophil MMP 
secretion but this was hampered by the inavailability of a specific STAT inhibitor, and 
that siRNA is technically challenging in neutrophils.  The p53 pathway is a well-known 
regulator of cell apoptosis but neutrophils are terminally differentiated cells and so it is 
interesting that this is activated with CoMTB stimulation.  One possible explanation is 
that p53 regulates NF-kB activity in neutrophils as LPS treated p53-/- neutrophils 
demonstrated increased NF-kB DNA binding compared to p53 +/+ neutrophils [286].  
Lastly, Yes is a member of the src family of kinases and is activated when neutrophils 
degranulate [287] and is involved in neutrophil signal transduction[288].   
 I have demonstrated in my in vitro experiments that AMPK regulates MMP-8 
and -9 secretion in CoMTB stimulated neutrophils. Inhibition of AMPK with 
Compound C caused a dose-dependent suppression of the MMPs.  Ideally, a second 
specific AMPK inhibitor should be used to confim this but there was none available 
currently.  Furthermore, siRNA attempts were not successful. Although I observed gene 
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silencing with GAPDH that was used as a positive gene knockdown, this did not 
translate into protein silencing in neutrophils.  Otherwise, siRNA would have been a 
useful technology to confirm that neutrophil MMP secretion was regulated by AMPK. 
 An often used method in immunology to investigate a particular pathway or 
protein is by utilising a genetic approach with transgenic animals.  I studied the role of 
AMPK using humans with AMPK γ2 mutation.  AMPKα mutations have yet to be 
described in man.  Even though the subunit of interest is different, it had been shown 
that these patients have defects in activation of the α1β1γ2 complexes by AMP [277, 
278].  All three patients have decreased neutrophil MMP secretion compared to healthy 
volunteers whose neutrophils were taken in the same experimental setting.  This is 
likely due to their inherent genotype and phenotype but a possible confounding factor is 
that these patients are also on medication which may have affected neutrophil MMP 
secretion. This confounding factor however cannot be removed.  There is nevertheless 
consensus between the in vitro findings and that from the AMPK patients.  Neutrophil 
MMP secretion was not affected in M.tb-infection with AMPK inhibition with 
Compound C nor in the AMPK patients (pooled data).  Furthermore in CoMTB 
stimulation, AMPK inhibitor Compound C and in AMPK patients MMP-8 secretion 
was suppressed more than MMP-9.   Ideally there should have been more healthy-
patient sets to further confirm but we only have access to these AMPK patients in 
London.   I have chosen to extract neutrophils from healthy volunteers at the same time 
to minimise factors such as environmental temperature or extraction processes in a 
different setting which may introduce variability to neutrophil MMP secretion.  It is 
known that variations in temperature modify the effects of proinflammatory cytokines 
on cells [289].  Furthermore, neutrophil apoptosis varies with temperature with 
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apoptosis suppressed at temperatures lower than 15oC [290]and thus if there is 
difference in environmental temperatures for 2 experiments, neutrophil degranulation 
which inherently depends on viability of cells will be different.  
 It is interesting to note that the basal AMPKα phosphorylation is increased in 
these patients although this has been previously reported [276].  The current consensus 
appears that in such patients basal activity of AMPK is increased which reduced the 
sensitivity of the protein to AMP [291].  Investigation of mTOR/p70S6 kinase pathway 
which is downstream of the AMPK pathway showed that neutrophil MMP secretion 
was independent of it.  Inhibition with rapamycin did not affect neutrophil MMP 
secretion.  Furthermore, the phosphorylation of p70S6 kinase in the AMPK patients was 
similar to healthy controls.  
 The AMPK pathway is a novel pathway in the context of infection.  Upon 
activation, AMPK increases cellular energy levels by inhibiting anabolic energy 
consuming pathways such as fatty acid synthesis and protein synthesis and stimulate 
energy producing catabolic pathways (fatty acid oxidation, glucose transport, etc).  
Hypothalamic AMPK activation reverses cancer anorexia by blocking the expression of 
interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α) in rats [292], while AMPK 
inhibition induces feeding-independent weight loss in thyrotoxic rats [293]. It is 
possible that AMPK may play a role in the anorexia and weight loss seen in TB patients 
who are in a state of catabolism.  AMPK also functions in inflammatory conditions and 
infectious diseases. Activation of AMPK has been shown to decrease neutrophil pro-
inflammatory activity and decrease TNF-α in a murine model of acute lung injury 
[268].   Thus one would have expected that AMPK activation and not inhibition would 
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have decreased neutrophil MMP secretion but the reverse was found in my 
experiments. 
 AMPK has a role in mycobacterial infections. Mycobacterial antigens activates 
autophagy in monocytes by activating AMPK [294].  Trials on the use of cilostazol, a 
phosphodiesterase (PDE3) inhibitor that also activates/phosphorylate AMPK[295] have 
been done in tuberculosis and have been shown to shorten TB therapy in murine models 
by improving sterilisation of mouse lungs one month earlier than the standard 6 month 
TB drug regimen [296].  Furthermore, cilostazol decreases TNF-α in mouse lungs 
compared to untreated mice and acts as an immunomodulatory agent.  The AMPK 
pathway may be a potential therapeutic point for interventions to modulate the host 
response and improve outcome. 
 Together, neutrophil MMP secretion in M.tb infection is dependent on 
transcription factor NF-kB but I have been unable to demonstrate inhibition of 
neutrophil MMPs with MAPK, PI3kinase and AMPK inhibitors. These pathways 
however may still be regulating neutrophil MMP secretion in direct M.tb infection. 
Conversely with CoMTB stimulation, I have demonstrated inhibition of neutrophil 
MMPs with the respective pathway inhibitors and confirmed that MMP secretion is 
dependent on the MAPK, PI3kinase, AMPK pathways and on the canonical pathway of 
NF-kB but independent of the mTOR/p70S6 kinase pathway.  In vitro and human data 
support that the AMPK pathway regulates neutrophil MMP secretion in monocyte-
dependent networks in TB.  The AMPK pathway is a novel and potential point in which 
therapeutic interventions may be made to improve outcome in TB infections.  
 
CHAPTER 6 – PATIENT DATA ANALYSIS 
 170 
CHAPTER 6 – THE POTENTIAL ROLE OF NEUTROPHIL MMPS IN 
TB PATIENTS: ANALYSIS OF INDUCED SPUTUM SAMPLES FROM 
A COHORT OF PERUVIAN TB PATIENTS 
1. Introduction 
 In the previous chapters, I described the upregulation of neutrophil MMPs in 
both M.tb infection as well as monocyte-dependent networks, and explored the 
mechanisms regulating neutrophil MMP secretion. To ascertain what I found in vitro of 
the neutrophil matrix degrading phenotype would translate to patients, I investigated the 
induced sputum samples from a group of healthy controls and TB patients from Peru.  
This was done in collaboration with Dr Cesar Ugarte-Gil from the Universidad Peruana 
Cayetano Heredia in Lima who shipped over the samples and was part of a longitudinal 
study assessing MMP secretion with anti-tuberculous treatment [297].  
 In TB patients, neutrophils are the predominant phagocytic cells in their 
respiratory secretions [121] and in murine models their accumulation has been shown to 
be detrimental to the host [298].  I wanted to determine if neutrophils played a role in 
TB associated tissue destruction in man.  I first assessed markers of neutrophil 
activation in the respiratory secretions of TB patients and determined if these correlate 
with induced sputum MMP-8 and -9.  I further investigated if the neutrophil MMPs 
would correspond to the severity of presentation and disease. Our group previously 
published data showing that in a smaller group of patients comprising of 32 patients 
with respiratory symptoms as controls and 33 TB patients that MMP-1 and -3 are 
upregulated in TB patients compared to controls [185] but MMP-8 and -9  were not 
found to be elevated.  An important difference from my current study is that the 
controls  in that study had diseases such as pneumonia and underlying cancer which 
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may inevitably raise neutrophil MMPs.  Hence it is crucial to evaluate how the induced 
sputum MMPs in TB patients would compare to healthy controls.  
 Lastly, I looked at immunohistochemistry staining of both human TB lung 
specimens as well as CNS-TB from patients in London to investigate neutrophil MMP-
8 and -9 in vivo.  This was done in collaboration with Dr Jo Porter at UCL and Dr 
Federico Roncaroli at the Neuropathology Unit at Charing Cross Hospital. 
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2. Methods 
Study recruitment 
 This study received the Institutional Review Board approval from Universidad 
Peruana Cayetano Heredia (Lima, Peru) and the Regional Health Department in East 
Lima.  A subset of 108 TB and control patients were randomly selected from the 
original cohort of 137.  TB patients were recruited at the time of diagnosis prior to 
starting TB therapy and were smear and/or culture positive, had no prior history of TB 
or TB treatment and were HIV negative. Healthy controls were recruited from the same 
healthcare facilities and were recruited among the relatives who were accompanying 
pregnant women, children for routine medical visit or patients with non-related TB 
disease. They were age ≥ 18 years, did not have symptoms associated with TB, no 
known TB contact and had a normal chest radiograph and a negative sputum TB 
culture.  All subjects underwent HIV testing and chest radiography.  
 
TB score 
 To evaluate the severity of the disease, we used the TB Score [299] which is a 
clinical score that evaluated the following: cough, haemoptysis, dyspnoea, chest pain, 
night sweats, conjunctival pallor, tachycardia, axillary temperature above 37oC, body 
mass index and middle upper arm circumference (MUAC).  
 
CXR score 
 Chest radiographs were scored for degree of pulmonary infiltration with Image J 
1.43U (NIH, USA) using the formula: (Area of TB consolidation/Total lung area) x 
(Mean Absorbance of TB consolidation/Mean lung absorbance) x 100% 
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Induced sputum analysis 
 Induced sputum of at least 3 mls was obtained from TB patients and healthy 
controls and the samples were sterile filtered using a 0.2μm Durapore membrane 
(Millipore). Total protein concentrations were measured using Bradford assay (Sigma-
Aldrich, St Louis, MO, USA).  Concentrations of MMP-1, -2, -3, -7, -8, -9 were 
analysed by Luminex multiplex array (R&D Systems, Minneapolis, MN, USA). TIMP-
1 and TIMP-2 were analyzed by ELISA kit (R&D Systems, Minneapolis, MN, USA).  
The former two analyses were performed by Dr Cesar Ugarte-Gil.  Human 
myeloperoxidase ELISA (R&D Systems) and human NGAL ELISA(Bioporto 
Diagnostics, Denmark) and DQ collagenase assay were analysed as described in 
Chapter 2 – Materials and Methods.  
Analysis of NETS 
 Induced sputum samples were diluted 1:2 with TE buffer and extracellular DNA 
was quantified using QuantiT Picogreen (Invitrogen, Paisley,UK) as previously 
described in Chapter 2.  This was normalised to total protein concentration.  For 
detection of H3 citrulline, an induced sputum sample with a protein content of 10μg 
was acetone precipitated overnight using a ratio of 1:4 protein to acetone volume ratio.  
The precipitate was spun 10, 000g for 10 minutes at 4oC, supernatant decanted and the 
residual acetone was left to evaporate for 5 minutes at room temperature.  The protein 
pellet was subsequently washed with 1 ml of 20 mM Tris HCl 80% acetone, spun at 10, 
000g for 5 minutes and solubilised with 10 μL of SDS loading buffer.  This was 
evaluated using western blotting as previously described. 
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Confocal microscopy  
 Permanox chamber slides (Nunc Labtech, Thermo Fisher Scientific) were 
coated with 0.1 mg/ml fibrinogen with 25 µg/ml of Type I DQ collagen for 30 minutes 
and then aspirated.  Induced sputum were diluted 1:10 with 1x reaction buffer and 
activated with activated with 4-amino-phenyl mercuric acetate (APMA) (Sigma-
Aldrich) for 1 hour at 37oC and this was added to the collagen coated slide.  The slide 
was incubated for 24 hours and fluorescent images were captured using Leica confocal 
microscope (Leica TCS SP5). 
 
Statistical analysis 
 Continuous variables were compared with Mann-Whitney while categorical 
variables were analysed using Fisher‘s exact tests.  Multiple intervention experiments 
were compared with one-way ANOVA followed by Tukey‘s post-test correction, using 
GraphPad Prism Version 5.04 for Windows (GraphPad Software).  A  p – value of less 
than 0.05 was taken as statistically significant using a two-tailed test. 
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3. Results 
3.1 Neutrophil MMP-8 and -9 are significantly raised in patients with TB 
and correlate with markers of neutrophil activation 
 I initially evaluated neutrophil myeloperoxidase (MPO) and neutrophil 
gelatinase associated lipocalin (NGAL) in vitro to assess their suitability as markers of 
neutrophil activation. An experiment was done assessing of the effect of M.tb added 
together with CoMTB on neutrophil MMP secretion. This demonstrated that the effects 
of stimulating M.tb with CoMTB were additive on neutrophil MMP-8 and -9 secretion 
(Figure 44).  Both MPO and NGAL concentrations correlated strongly with MMP-8 
and -9 (r > 0.8, p<0.0001 for all), confirming their suitability as surrogate neutrophil 
markers for the clinical specimens (Figure 45).  In the induced sputum samples, MMP-
1,-2, -3, -8 and -9 are significantly elevated in TB patients[297]. Of note, MMP-8 had 
the highest concentrations and MMP-9 the second highest of all the MMPs (MMP-8 
p<0.0001 and MMP-9 = 0.0007) (Table 9 and Figure 46A).  In addition, MPO and 
NGAL were also significantly elevated (p<0.0001 and p<0.01 respectively) (Figure 
46B and C).  When analysed, MMP-8 and MMP-9 concentrations strongly correlated 
with those of MPO and NGAL with a Spearman‘s correlation coefficient of above 0.5 
(p<0.0001 for all) (Figure 46D to G).  Correlation analysis revealed that MPO and 
NGAL concentrations correlated the strongest with MMP-8 (MPO with MMP-8, 
r=0.8259, p<0.0001; NGAL with MMP-8, r=0.6833, p<0.0001) (Table 10), which is 
highly suggestive that MMP-8 in the induced sputum in TB patients is derived from 
neutrophils.  
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Figure 44: Effect of M.tb with CoMTB on neutrophils in vitro.  7.5 x 105 neutrophils 
were incubated with the respective stimuli for 4 hours and MMP-8, -9, NGAL and 
MPO were measured.  Bars represent mean +/- SD of experiment done in triplicate and 
is representative of 2 independent experiments.   
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Figure 45: Effect of M.tb with CoMTB on neutrophils in vitro – correlation 
analysis.  Correlation of NGAL and MPO with MMP-8, and NGAL and MPO with 
MMP-9 from Fig.  43.   Correlation was done using Spearman‘s coefficient.  *p<0.05, 
***p<0.001.  
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Variablea Control TB P valueb 
Number 
 
 
 
 
57 51  
Sex (M:F) n 11 : 46 32 : 19 <0.0001 
 Age (years) 28 (18-62) 25 (18-72) 0.1571 
BMI 25.1 (18.5-37.5) 20.9 (11.8-27.9) <0.0001 
Pulse    (per min) 76 (61-104) 96 (64-139) <0.0001 
MMP-1 (pg/ml)c 285.9 (132.4-776.6) 1394 (406-4759) <0.0001 
MMP-2 (pg/ml) 1065 (384.3-2737) 4329 (1858-9012) <0.0001 
MMP-3 (pg/ml) 952.6(311.4-2366) 11237 (3861-31330) <0.0001 
MMP-7 (pg/ml) 39425 (23548-54187) 36930 (29441-46905) 0.5629 
MMP-8 (pg/ml) 89114 (21956-268483) 772962 (338088-1590000) <0.0001 
MMP-9 (pg/ml) 8840 (250.6-53291) 74733 (8334-651907) 0.0007 
TIMP-1 (pg/ml) 16582 (7997-39908) 91890 (32587-179832) <0.0001 
TIMP-2 (pg/ml) 2975 (1421-6171) 10878 (5429-18839) <0.0001 
a. Values are median (Interquartile range) 
b. Comparison of continuous variables using Mann-Whitney U and categorical 
variables using Fisher‘s exact. 
c. All MMP and TIMP values are normalised to total protein content. 
Table 9: Demographic data, MMPs and TIMPs of control and TB patients.  This 
was from a subset of 137 control and patients from the original study [297]. 
  
CHAPTER 6 – PATIENT DATA ANALYSIS 
 179 
 
Figure 46: MMP-8 and -9 are raised in TB patients and correlate with markers of 
neutrophil activation MPO and NGAL.  (A) Induced sputum from controls (open bars) and 
TB patients (hashed bars) were analysed for MMP-1, -2, -3, -7, -8, -9 and TIMP-1 and -2. (B 
and C)  MPO and NGAL from control and TB patients.  (D-G) Correlation between MMP-8 
and -9 with MPO and NGAL using Spearman‘s correlation coefficient in TB patients (n=51). 
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Neutrophil marker Variable Correlationa p-value 
MPO MMP-1 0.1051 0.4629 
MMP-2 0.6218 <0.0001 
MMP-3 0.3567 0.0102 
MMP-7 0.2167 0.1267 
MMP-8 0.8259 <0.0001 
MMP-9 0.6285 <0.0001 
NGAL 0.7486 <0.0001 
NGAL MMP-1 0.3382 0.0152 
MMP-2 0.5765 <0.0001 
MMP-3 0.4335 0.0015 
MMP-7 0.2827 0.0444 
MMP-8 0.6833 <0.0001 
MMP-9 0.5426 <0.0001 
a. Correlation using Spearman‘s coefficient. 
b. n=51 TB patients 
 
 
Table 10: Comparison of neutrophil markers myeloperoxidase (MPO) and 
neutrophil gelatinase associated lipocalin (NGAL) with MMPs and TIMPs in TB 
patients.  
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3.2 MMP-3 and -8 sputum concentrations strongly correlates with patient 
TB score and CXR score 
 I next evaluated if MMP-8 would correlate with clinical severity using the TB 
score as well as the chest radiograph score.  One limitation was that not all the chest 
radiographs were available.  Despite this, MMP-3 and MMP-8 strongly correlated with 
both TB score (MMP-3, r = 0.6, p<0.0001; MMP-8, r =0.55, p<0.0001) and CXR score 
(MMP-3, r =  0.59, p<0.0001; MMP-8, r = 0.52, p<0.001) (Table 11).  
Clinical Variable Measured Variable Correlation coefficient a P value 
TB score MMP-3 0.6077 <0.0001 
MMP-8 0.5566 <0.0001 
MPO 0.4619 <0.0001 
MMP-2 0.4515 <0.0001 
MMP-1 0.4313 <0.0001 
MMP-9 0.3453 0.003 
NGAL 0.2251 0.0192 
MMP-7 -0.04742 NS 
CXR score MMP-3b 0.5930 <0.0001 
MMP-8b 0.5166 <0.0001 
MMP-2b 0.4966 <0.0001 
MPOc 0.3873 0.0035 
MMP-1b 0.3619 <0.0001 
MMP-9b 0.3073 0.0077 
NGALc 0.1452 0.2901 
MMP-7b 0.01310 NS 
a. Correlation done using Spearman‘s correlation coefficient.  MMP-8/-9, MPO 
and NGAL are normalised to total protein content. 
b. Data available for n=74 
c. Data available for n=55 
 
Table 11:  Analysis of TB and CXR scores with MMPs, myeloperoxidase (MPO) 
and neutrophil gelatinase associated lipocalin (NGAL).   
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3.3 Induced sputum of TB patients have increased collagenase activity 
which is abrogated with neutralisation by anti-MMP-8 antibodies 
 I next assessed the collagenolytic activity in the induced sputum of TB patients 
and control samples. As the main collagen in the lung is Type I [223], the effect of 
induced sputum on Type I DQ collagen destruction was evaluated.  The induced sputum 
from TB patients had an increased collagen destroying activity compared to healthy 
controls (p = 0.02) (Figure 47A).  In addition, confocal microscopy revealed patches of 
fluorescence indicating areas of collagen destruction (Figure 47B).  When analysed, 
only the presence of MMP-8 significantly correlated with Type I collagenase activity (r 
= 0.6894, p=0.0004) (Table 12, Figure 47C) indicating that induced sputum MMP-8 
was most likely responsible for Type I collagen destruction.  When MMP-8 activity was 
neutralised using an antibody (without pre-incubation), collagenase activity decreased 
from a mean of 723.8 mU/ml (SEM 254.4 mU/ml) to 528.1 mU/ml (SEM 270 mU/ml) 
(p = 0.01) (Figure 47D). In retrospect, a period of pre-incubation of the neutralising 
MMP-8 antibody with the induced sputum samples may further reduce the collagenase 
activity.  
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Figure 47:  Induced sputum of TB patients have increased capability for collagen 
destruction.  (A) Induced sputum were activated with 2 mM APMA for 1 hour and 
collagenase activity assessed using Type I DQ collagenase assay. N=11 for both 
controls and TB patients. (B) Confocal microscopy of induced sputum samples on Type 
I DQ collagen. Samples were activated with APMA for 1 hour and incubated for 24 
hours on DQ collagen. N = 3.  (C) Correlation of MMP-8 and collagenase activity. (D)  
Collagenase activity is neutralised with MMP-8 neutralising antibody. MMP-8 
neutralising antibody was added to the DQ collagenase assay without pre-incubation. N 
= 11.  MMP-8 concentrations from the 11 samples were not statistically different from 
the 51 TB patients by Mann-Whitney. 
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Measured Variable Measured Variable Correlation coefficient a P value 
Type 1 collagenase 
activity 
MMP-1 -0.1654 ns 
MMP-2 0.1406 ns 
MMP-3 0.3721 ns 
MMP-7 -0.2072 ns 
MMP-8 0.6894 0.0004 
MMP-9 -0.09656 ns 
Correlation using Spearman‘s correlation coefficient.  MMPs have been normalised 
total protein content. N = 11 controls and 11 TB patients. 
Table 12: Comparison of Type 1 collagenase activity versus MMP concentration in 
induced sputum.  
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3.4 Induced sputum MMP-1 has minimal collagenase activity in TB 
patients 
 The other interstitial collagenases are MMP-1 and MMP-13.  I focused on the 
possibility that MMP-1 activity could also contribute to Type I collagen destruction 
since MMP-13 concentrations were not detected.  First, I performed an in vitro analysis 
of MMP-1 on Type I collagen degradation using purified MMP-1 from fibroblasts.  
This showed that MMP-1 had minimal collagenase activity compared to neutrophil 
supernatants which contained the same protein concentration of MMP-8 (Figure 48A).  
I had refrained from using molarity as MMP-8 exists in different molecular weights.  
The molecular weight of latent neutrophil MMP-8 is 85 kDa while activated MMP-8 is 
64 kDa.  MMP-1 is 54 kDa.  Hence even if MMP-8 concentrations are compared at a 
molarity level, this was less than MMP-1.  In this context, the Type I collagenase 
activity of MMP-8 was still higher than that of MMP-1.  I analysed the collagenase 
activity of 5 samples and the effects after neutralising MMP-1.  There was no 
significant change from a mean of 106.8 mU/ml (SEM 10 mU/ml) to 102.1 mU/ml 
(SEM 9.25) (p = NS) (Figure 48B).  The MMP-1 concentrations of the 5 samples were 
not significantly differerent from the original group of TB patients. 
  
CHAPTER 6 – PATIENT DATA ANALYSIS 
 186 
 
Figure 48:  (A) M.tb infected neutrophils secreting MMP-8 preferentially degrade 
Type 1 collagen compared to fibroblast derived MMP-1.  Fibroblast MMP-1 and 
M.tb-infected neutrophil supernatants were activated with 2mM APMA for 1 hour and 
incubated with Type I DQ collagen for 24 hours.  (B) Neutralising MMP-1 antibody 
in induced sputum of TB patients does not decrease collagenase activity (n=5).  
Induced sputum diluted 1 in 10 were activated with 2mM APMA for 1 hour and 
subsequently incubated with Type I DQ collagen with or without neutralising MMP-1 
antibody for 24 hours. MMP-1 concentrations from these 5 samples were not 
statistically different from the 51 TB patients. 
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3.5 Components of NETS are present in the induced sputum of TB patients 
 I next investigated if NETS or their components could be detected in the 
induced sputum samples.  A previous study looking at NETS in the respiratory 
secretions in mice given pulmonary instillation of LPS and P.aeruginosa used confocal 
microscopy staining for NETS, Picogreen QuantIT kit to detect extracellular DNA and 
detecting citrulline H3 using western blotting [300], a well-known marker for NETS 
[301, 302].   Unfortunately the TB induced sputum samples were sterile filtered which 
would have removed neutrophils and hence made it impossible to perform confocal 
microscopy to detect NETS.  However it was possible to use the latter 2 techniques on 
the induced sputum samples.  I used samples from 10 controls and 10 TB patients. 
Extracellular DNA was raised at a mean concentration of 2830 ng/mg (SEM 479.7 
ng/mg) compared to controls at a mean concentration of 855.8 ng/mg (SEM 241 ng/mg) 
(p=0.0021) (Figure 49A).  As this could be due to lysed cells, I subsequently looked for 
and detected citrulline H3 in the induced sputum samples of TB patients but not in 
controls (Figure 49B).  I went on to confirm that this was not due to dead cells by 
comparing PMA stimulated neutrophils which produces NETS to Triton-X lysed 
neutrophils.  The latter did not produce citrulline H3 (Figure 49C). 
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Figure 49:  Induced sputum from TB patients contain components of NETS.  (A) 
Induced sputum samples were diluted 1:2 and extracellular DNA was quantified using 
Picogreen QuantIT (n=10 for both groups).  Values were normalised to total protein 
content by Bradford assay.  (B) Citrulline H3 is present in induced sputum of TB 
patients.  10μg of protein was acetone precipitated and immunoblotted. Blots represent 
2 independent experiments.  (C) Dead cells do not contain citrulline H3.  Supernatants 
from neutrophils stimulated with 20nM PMA was used as a positive control while 
supernatants of 0.1% Triton-X lysed neutrophils was used to represent dead cells.  10μg 
of protein was acetone precipitated and immunoblotted. 
  
CHAPTER 6 – PATIENT DATA ANALYSIS 
 189 
3.6 Neutrophils expressing MMP-8 and -9 are present in human lungs and 
CNS infected with TB 
 Next, human lung TB sections from the UK were analysed by 
immunohistochemistry in collaboration with University College London.  These 
patients were confirmed to have pulmonary TB.  Neutrophils were present in the inner 
wall of the pulmonary cavity (Figure 50A and B) and they stained positive for MMP-8 
and MMP-9 (Figure 50C) with these stains located within the neutrophil cytoplasm.  
Phospho-AMPKα1/2 (T172) stained the nucleus of neutrophils indicating that it is 
predominantly intra-nuclear (Figure 50C).  Concurrently in collaboration with the 
neuropathologist unit in Charing Cross Hospital, immunohistochemistry was performed 
on human TB brain biopsy specimens.  This also demonstrated that neutrophils 
containing MMP-8 and -9 were present in human TB infected brains (Figure 51). 
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Figure 50:  Neutrophils are present in human TB lung.  (A) H&E (B) Neutrophil 
elastase stain (NE) present in the inner wall of the cavity (C) Inset of (A) magnified 
demonstrating neutrophils stain positive for MMP-8, MMP-9 and phospho-
AMPKα1/2(T172) (red arrows) and isotype control antibody. 
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Figure 51:  Neutrophils are present in CNS-TB.  (A) Low power magnification (4x).  
(B) High power magnification (10x). Inset (40x).  (C)  Appropriate positive and 
negative controls for the antibodies. 
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4. Discussion 
 This chapter seeks to fulfil the final aim of my project which is to investigate 
MMP and TIMP activity and their regulation in neutrophils in vivo.  I have approached 
this by evaluating the induced sputum samples of TB patients as well as human TB lung 
and brain specimens.  I have found that MMP-8 and -9 concentrations are raised in the 
induced sputum of TB patients compared to healthy controls and these correlated with 
the markers of neutrophil activation i.e neutrophil myeloperoxidase and neutrophil 
gelatinase associated lipocalin.  This is the first time that both MMP-8 and -9 
concentrations in respiratory secretions have been found to be raised in TB patients.  
Our group has published on MMPs in respiratory secretions in 2 other TB patient 
groups [185, 186].  The first compared TB patients with patients with respiratory 
diseases and found that MMP-1 and -3 but not MMP-8 or -9 were not elevated [185].  
Walker et al [186] in a cohort which has both HIV-positive and HIV-negative TB 
patients demonstrated that MMP-1, -2, -3 and MMP-8 but not -9 were elevated.  The 2 
groups studied had inherent differences when compared to the group that I used for my 
project which analysed TB patients and healthy controls in HIV negative subjects and 
this could account for why both MMP-8 and -9 are raised in this study and not others.    
 There is no one ideal marker of neutrophil activation and I have chosen to use 
both neutrophil myeloperoxidase and neutrophil gelatinase associated lipocalin (NGAL) 
which are secreted in large amounts in activated neutrophils and are commonly used 
neutrophil markers [303-305].  One limitation is that myeloperoxidase and NGAL are 
also secreted from other cells (albeit in smaller quantities) such as monocytes [306] and 
macrophages [307] and hence the decision to use not just one marker but two to 
increase the specificity to neutrophil origin when correlating induced sputum MMP-8 
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and -9 to them. Furthermore, I have confirmed in my in vitro work prior to testing on 
clinical samples that both MPO and NGAL concentrations closely correlated with 
MMP-8 and -9 concentrations.  The induced sputum MMP-8 and -9 from TB patients 
also correlated strongly with MPO and NGAL all with an r value of above 0.5 
indicating that the majority of the MMP-8 and -9 present was most likely neutrophil 
derived.  The correlation was stronger with MMP-8 than MMP-9 suggesting that MMP-
8 was more neutrophil specific.  In addition MMP-8 and -9 have the highest 
concentrations among all the MMPs in the induced sputum which supports them being 
predominantly neutrophil derived given that neutrophil influx is a hallmark of active 
pulmonary TB[121]. Interestingly when correlating MPO and NGAL with the other 
MMPs, MMP-2 had the second highest r value after MMP-8 (r=0.6218 with MPO and r 
= 0.5765 with NGAL).  MMP-2 is a gelatinase that is secreted by macrophages and Th1 
cells [308]  and the former is also known to secrete NGAL.  It is possible that activated 
macrophages in the induced sputum of TB patients are responsible for the MMP-2 and 
MPO/NGAL correlation.  
 When evaluating tissue destruction using the TB clinical severity score and 
CXR score, MMP-3 and MMP-8 were found to have the strongest correlations (r values 
> 0.5).  MMP-3 is a stromelysin secreted by activated/infected respiratory epithelial 
cells and it is likely that the effect of M. tuberculosis infection of these cells with or 
without resultant cell death caused a decline in respiratory function clinically which is 
also reflected radiographically.  It is interesting to note that MMP-8 is also associated 
with clinical and radiographic severity and this is possibly due to its matrix destructive 
properties.  MMP-8 substrates include Type I, II, III, VIII and X collagen as well as 
cartilage aggrecan, laminin, fibronectin and proteoglycans[309].  The human lung is 
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made up of many of such substrates to provide the structural support.  The high MMP-8 
found in the induced sputum of TB patients thus would result in consequent pulmonary 
tissue destruction as reflected by the strong clinical and radiographic correlation. 
 Collagen is resistant to proteolytic degradation and only MMPs are able to 
initiate collagen degradation [153]. Type I collagen is the main structural protein of the 
human lung[223] and the question was which collagenase is responsible for its 
degradation.  I have demonstrated that the induced sputum of TB patients have 
increased collagenase activity and that only MMP-8 concentration correlated with Type 
I collagen degradation.  Furthermore, MMP-8 neutralisation decreased collagen 
destruction which further supports it being the main collagenase responsible for 
destroying structural protein in the human lung.  The other interstitial collagenases that 
can degrade Type I collagen are MMP-1 and MMP-13, the former which is in lower 
concentrations than MMP-8 in the induced sputum and the latter was not detected.  It is 
crucial to note that previous literature had made observations that MMP-8 is more 
potent in degrading Type I collagen than MMP-1 [200, 201].  My in vitro work using 
fibroblast-derived MMP-1 on DQ collagen degradation showed that there was minimal 
Type I collagenolytic activity with MMP-1 compared to neutrophil supernatants 
containing the same concentration of MMP-8 further substantiates this.  Furthermore, 
neutralising MMP-1 in the induced sputum of TB patients did not decrease the 
collagenolytic activity. 
 I have demonstrated that components of neutrophil extracellular traps are found 
in the induced sputum of TB patients by showing an increase in extracellular DNA 
compared to controls as well as the presence of citrulline H3 a well known marker of 
NETS [301, 302].  During neutrophil extracellular trap formation, histones undergo 
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post-translational modification with the enzyme peptidylarginine deiminase 4 (PAD4) 
converting arginine to citrulline [301].  There is currently no evidence supporting 
citrullination of H3 occuring during cell death.  One other possible cause of increased 
extracellular DNA is increased cell death in the respiratory secretions in TB patients.  
However citrulline H3 is not present in the supernatants of lysed neutrophils.  Ideally to 
prove that NETS are truly present in the induced sputum of TB patients, 
immunofluorescence staining for DNA and neutrophil granule proteins should be done.  
However this could not be done as the samples have been sterile filtered prior to 
shipping to our lab. 
 Neutrophils were present along the circumference of the inner wall of the lung 
cavity in the human TB lung biopsy specimens as indicated by H&E stain by 
morphology and a positive neutrophil elastase stain.  In addition, these neutrophils stain 
positive for MMP-8 and -9.  This suggests that neutrophils are eroding the wall of the 
cavity.  The presence of MMP-8 and -9 staining in the cytoplasm are in keeping with 
intra-cellular storage of neutrophil MMPs.  In addition, phospho-AMPKα is present in 
the nuclei of the neutrophils in keeping with nuclear translocation of phospho-AMPK 
consistent with literature [310].  When cells were exposed to stress such as heat, energy 
depletion and oxidants, the level of phospho-AMPKα accumulates in the nuclei [310] 
and relocates back into the cytoplasm with removal of the stress and this shuttling is 
dependent on carrier Crm1.  It is likely a similar stress situation occurs in the context of 
M.tb infection resulting in the positive nuclear staining of phospho-AMPK as seen in 
the lung biopsy specimens.  The immunohistochemistry studies of the CNS-TB biopsy 
specimens also demonstrated staining of neutrophils positive for MMP-8 and -9, 
underscoring the significance of neutrophils in TB. 
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 In summary, I have shown that neutrophil MMP-8 and -9 are raised significantly 
in the induced sputum samples of TB patients compared to controls and that the 
majority of MMP-8 and -9 are most likely neutrophil derived.  Induced sputum MMP-8 
correlated with TB clinical severity score and CXR score.  The induced sputum from 
TB patients have an increase in MMP-8 dependent Type I collagen destruction and 
contain components of NETS.  MMP-8 and -9 positive neutrophils are present in the 
inner wall of the cavity in human TB lung biopsy and CNS-TB specimens which 
support their significant role in tissue destruction 
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CHAPTER 7 - CONCLUSION 
 In this chapter, I shall first discuss how my research contributes to the 
knowledge of the role of neutrophils in TB pathogenesis.  I shall then explore the 
potential interventions that can be made to modulate tissue destruction in TB at an 
extracellular level as well as at sites of intracellular signalling pathways and 
transcription factors. 
 Much of TB pathogenesis has been thought to be attributed to cell-mediated 
immunity with important roles played by alveolar macrophages and T-cells.  My data 
has elucidated an additional key role that neutrophils play in TB pathogenesis, 
particularly tissue destruction.  The question is however what function they play.  It has 
been previously suggested that neutrophil proteolytic enzymes contribute to cell death 
as well as dissolution of lung tissues [311, 312].  My results support and expand this 
theory by demonstrating for the first time that this is in part due to the secretion of 
neutrophil MMP-8 and -9, which destroy Type I and IV collagen respectively upon 
M.tb infection.  Although MMPs particularly MMP-9 are crucial for neutrophil 
transmigration to the site of infection [313], exposure to M.tb results in excessive 
secretion of neutrophil MMPs with consequent collateral damage.    Neutrophils are 
nevertheless professional phagocytes and with their additional ability to form 
extracellular traps, they help to contain the dissemination of M.tb within the host.  It is 
probably in such a scenario that pulmonary cavitation occurs in TB – the continuous 
influx of neutrophils causes a vicious cycle of tissue destruction with further influx of 
neutrophils consequent to the MMPs that they secrete. 
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Neutrophils causing a vicious cycle of tissue destruction and dissemination of M.tb 
 
 Pulmonary cavitation arising from tissue destruction is a hallmark of TB 
infection.  Cavitation contributes to the spread of the disease to new hosts and the 
resultant global success of TB.  This is because cavitatory pulmonary TB contain a 
higher mycobacterial burden [314] which frequently necessitates longer anti-
tuberculous treatment.  In my first chapter, I have demonstrated a dose-dependent 
increase in neutrophil MMPs with increasing M.tb MOI, and this supports the clinical 
finding that a higher bacterial burden is associated with increased cavitation.  The 
finding in TB lung biopsy specimens of neutrophils lining the inner wall of the TB 
cavity possibly aiding in the erosion of the pulmonary interstitium in Chapter 6 further 
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supports this theory.  Both direct M.tb infection and monocyte-dependent intercellular 
networks result in neutrophil MMP secretion.  It is important however to keep in mind 
that tissue destruction is not solely dependent on neutrophils.  Other cells such as 
macrophages, monocytes and respiratory epithelial cells also secrete MMPs explaining 
the general increase of MMPs found in the induced sputum of TB patients compared to 
controls in Chapter 6 and these together contribute to the breakdown of various 
components of the pulmonary extracellular matrix and cavity formation.  
 Further to their role in limiting dissemination of pathogens, neutrophils also kill 
via oxidative and non-oxidative mechanisms.  In the latter case, neutrophils secrete a 
wide armamentarium of antimicrobial peptides including human neutrophil peptides 1-
3, cathelicidin LL-37 and NGAL [126].  On the other hand, I have found that neither 
CoNTB which would contain all the above antimicrobial peptides, nor MMP-8 /-9 
inhibit or kill M.tb in Chapter 4.  This is possibly due to lower concentrations of such 
peptides secreted extracellularly and thus the lack of extracellular killing/inhibition 
against M.tb.  It is likely that the antimicrobial peptides exert their activity within the 
intracellular compartment of the phagosome.  However it is controversial if neutrophils 
kill M.tb.  Corleis et al showed recently that neutrophils phagocytose but cannot kill 
M.tb when incubating both for up to 6 hours by assessing colony counts [315].  
Conversely Brown et al demonstrated a reduction of 14CO2 as a representation of 
growth by H37Rv M.tb when culturing neutrophils with H37Rv for 60 minutes [316]. 
Lowe et al similarly showed a reduction of relative light units when luminescent M.tb is 
incubated with neutrophils [317].  Nevertheless, it is probably the difference in the 
assays used to assess M.tb growth that may explain the different observations, and these 
need further investigation.  It has been ascertained by Ramos-Kichik et al [143] that 
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neutrophil extracellular traps which are bactericidal to Listeria monocytogenes, do not 
kill M.tb.  NETS prevent the dissemination of mycobacteria and this may set the scene 
for granuloma formation. 
 Neutrophils are thought to be essential for early granuloma formation [124].  
Depleting neutrophils from mice impaired granuloma formation and neutrophil-
mediated regulation of granuloma formation depended on chemokines signalling 
through CXCR3, especially MIG.  Additionally, Volkman et al demonstrated that 
MMP-9 contributed to nascent granuloma maturation and bacterial growth in M. 
marinum infected zebrafish model, offering a possibility that targeting MMP-9 can hold 
promise as a host-targeting tuberculosis therapy [184].  There is also emerging data 
about the role of MMP-8 in TB.  Lyadova et al observed that IL-11, MMP-8 and MMP-
10 were over-expressed in I/St mice after infection with M.tb up to 5 weeks [318] and 
MMP-8 induction correlated with TB progression and weight loss.  Furthermore, they 
identified lung phagocytes as the major immune cells producing cytokines and 
chemokines associated with TB progression in mice.  In Chapter 6, I found that MMP-8 
is increased in the induced sputum samples of TB patients and controls and this is 
predominantly neutrophil derived.  Similar to the murine study aforementioned, MMP-8 
correlated with clinical TB severity score and CXR score.  Furthermore, the raised 
collagenolytic activity seen in the induced sputum of TB patients is likely due to MMP-
8 as collagenolytic activity is suppressed with MMP-8 neutralisation.    Neutrophils thus 
seem to be a double-edged sword in TB pathogenesis.  They both limit the 
dissemination of M.tb and assist in granuloma formation but in so doing cause collateral 
damage by the secretion of their proteolytic enzymes and consequent tissue destruction. 
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 To limit tissue damage in TB, it is accordingly crucial to modulate MMP 
secretion.  Steroids are frequent adjunctive therapies used especially in the context of 
TB pericarditis and CNS-TB, where excessive inflammation in restricted spaces of 
these organs can be potentially lethal. Rarely, anti-TNFα agents have been used in 
CNS-TB in patients refractory to steroids [52, 53].  I have shown in Chapter 3 that both 
dexamethasone and anti-TNFα suppress neutrophil MMP-8 and -9 secretion, the latter 
at the level of gene expression.  The inhibition of MMP secretion may explain how 
dexamethasone and anti-TNF agents act to decrease inflammation and improve the 
outcome in TB patients.  In addition, I have also shown that doxycycline the only FDA 
licensed MMP inhibitor for use in treating periodontal disease [319], also decreases 
collagen destruction at an extracellular level in Chapter 3.  This can potentially be a 
new adjunctive therapy to decrease tissue damage.  Doxycyline has mycobactericidal 
effects,  has been shown recently to decrease MMPs [186], and also suppresses TNF-α, 
a key cytokine in the immune response to TB [320].       Randomised control trials will 
need to be conducted to assess its efficacy as an anti-mycobacterial and 
immunomudulatory agent.   
 I have demonstrated in Chapter 5 that the MAP-kinase, PI3-kinase and the 
AMPK pathway regulate neutrophil MMP-8 and -9 secretion in CoMTB stimulated 
neutrophils but not in M.tb-infected neutrophils.  This indicates that neutrophil MMP 
secretion is stimulus specific.  M.tb infection induces NET formation as well as 
neutrophil cell death while CoMTB stimulation results in degranulation of neutrophils 
and this may explain the divergence. Ideally to target tissue destruction in TB, an agent 
needs to suppress MMP secretion when neutrophils are exposed to both stimuli.  I have 
shown that the NF-kB inhibitor Helenalin suppresses neutrophil MMP secretion both in 
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direct M.tb infection as well as CoMTB stimulation.  Thus NF-kB may potentially be a 
target for therapeutic intervention in TB.  Already, oncology clinical trials on NF-kB 
inhibitors are being carried out and some agents which have NF-kB inhibitory activities 
such as thalidomide and bortezomib (Velcade ®) are being routinely used in 
haematological malignancies like multiple myeloma.  Animal and human trials need to 
be conducted to ascertain their efficacy in the context of TB, but considerations also 
need to be given to their side effect profile as well as drug costs.   
 In summary, I have shown that neutrophils contribute to TB pathology both in 
pulmonary and CNS-TB.  They limit the dissemination of M.tb infection by 
phagocytosis and by production of neutrophil extracellular traps.  Concurrently, 
infection with M.tb and stimulation by monocyte-dependent networks result in 
neutrophil MMP-8 and -9 secretion with consequent matrix destruction.  Adjunctive TB 
therapies that decrease host inflammation such as dexamethasone and anti-TNFα 
suppress neutrophil MMP secretion and provides an insight into how these agent may 
act. Targeting neutrophil MMP-8 and -9 may decrease tissue destruction and potentially 
improve patient outcome.   
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CHAPTER 8 - FUTURE DIRECTIONS 
 In this chapter, I shall first discuss directions of research looking at evaluating 
further the pathogenesis of TB.  I shall then discuss potential therapies that can improve 
patient outcome. 
 Hitherto, most TB research on treatment have concentrated on understanding 
and attacking the organism itself with much less attention being paid to the host 
response and the way that TB has exploited and evaded host immune control.  In this 
thesis I have set out to partially redress this imbalance of knowledge.  The role of 
neutrophils in immune responses to combat infectious diseases is well known and 
studied.  Conversely very little is known about the role that these cells can play in 
advancing the disease by causing cavitation and lung destruction.  What, for instance, 
delineates the ability of the host to form granulomas and effectively ‗contain‘ the 
disease (albeit in a latent state) and full-blown cavitation with bacterial dissemination?  
The presence of neutrophils in both these scenarios, particularly the latter is indicative 
of an active role of neutrophils in both of these processes.  Although my data has shown 
a role that neutrophils and MMPs play in tissue destruction, one must bear in mind that 
there are also other proteases from other cells that contribute to tissue destruction in TB.  
There are a total of 553 human proteases encompassing threonine, aspartic, cysteine, 
metallo and serine proteases[321]. An in depth analysis of how these proteases and the 
role that they have in human TB cavitation is warranted.  Ideally, human infected 
samples need to be analysed and compared with controls to determine the significance 
of these proteases, the role that they have in tissue destruction, mycobactericidal 
activities if any, cellular source of the proteases and if they would be amenable to 
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interventions that can reduce tissue damage. Additional work, be it in vitro and/or 
animal models need to be performed to substantiate the findings.   
 As host inflammation is a critical component in TB, investigations into how 
immune cells contribute to phenomenons such as paradoxical reactions, thrombosis and 
immune reactivation inflammatory syndrome (IRIS) in the context of co-infection with 
HIV is essential.  Some of these immune reactions may be fatal even when the 
appropriate anti-tuberculous therapy is initiated.  It is consequently important to 
determine the cause of such immune phenomena and how components such as 
neutrophil activity and functions can be regulated or controlled so as not to act to the 
detriment of the host.  Conradie et al reported that in addition to NK cells, the 
proportion of neutrophils and IL-8 were significantly raised in patients undergoing TB 
treatment and then initiated anti-retroviral therapy as well as patients with TB-IRIS 
compared to HIV patients [322].  Furthermore, it has been described that neutrophil 
extracellular traps cause thrombosis [323] and even thrombotic microangiopathies 
[103].  Accordingly NETS may play a role in CNS-TB associated cerebrovascular 
events.  Animal and human studies need to be further conducted to explore the 
pathogenesis of such inflammatory reactions. 
 The prolonged anti-tuberculous treatment of a minimum of 6 months combined 
with the need to take multiple drugs to treat TB contributes to non-adherence, treatment 
failure and emergence of drug resistance.   Should a shortened treatment regimen be 
devised, this would improve adherence to drugs, decrease the incidence of treatment 
failure and consequently tackle the global problem of rising incidence of drug-resistant 
TB.  We thus need an anti-tuberculous agent that has good tissue penetration and 
possess immunomodulatory activities to circumvent TB paradoxical reaction that is 
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frequently seen.   There are several new drugs in the drug-discovery pipeline among 
them bedaquiline (TMC207), PA824, and OPC67683 which has the potential to shorten 
TB therapy.  Bedaquiline has already been approved by the US FDA for treatment of 
drug-resistant TB [46] and has the potential in combination with other agents to deliver 
a shortened drug regime for drug-susceptible TB.  Steroids are often administered in TB 
paradoxical reactions but some cases may prove refractory.  It is thus necessary to 
evaluate other potential immunomudulatory agents as an adjunctive therapy and these 
include MMP inhibitors such as doxycycline, anti-TNFα agents, or NF-kB inhibitors.  
The ideal immunomodulatory agent should be cheap, easily administered by a 
convenient route with minimal side effects.  Anti-TNFα agents are notoriously known 
for their potential to reactivate TB [324, 325] and are expensive.    NF-kB inhibitors 
such as thalidomide and bortezumib have severe side effects.  One might consider the 
use of MMP inhibitors such as doxycyline but considerations for tissue penetration need 
to be bourne in mind when evaluating the potential as an immunomodulatory agent.  In 
the context of the lung, inhibitors could for example be delivered by nebulisation or by 
an inhaler akin to the approach used to deliver liposomal amphotericin B for 
aspergillosis.  In a situation where long-term therapy is necessary as is the case for TB 
treatment, slow more localised (i.e non-systemic) release may help to address some of 
the drug compliance issues.  This can potentially lead to a scenario whereby it is not 
possible to fully eradicate the organism in the host but by manipulating the immune 
system such therapies would severely restrict the ability of the pathogen to infect new 
hosts.  However as there is no ideal animal model to study TB infection [326] let alone 
TB paradoxical reactions, studies evaluating the drug efficiency in such circumstances 
would need to be conducted in humans in a multi-center setting.  
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 Finally, in the days before anti-TB drugs were available, TB patients were sent 
to TB sanatoriums for treatment where fresh air, plenty of rest and sunshine were 
prescribed for at least 6 months.  In more severe pulmonary TB cases, surgical therapy 
in the form of lobectomy, thoracoplasty, phrenicotomy, plombage or even 
pneumonectomy would be performed to in the hope that this would kill M.tb and cure 
the patient.  This has been attributed to the role that oxygen plays in innate immunity.  
The role of hypoxia in the human immune system has been the subject of increasing 
interest. Neutrophils delay apoptosis in hypoxic or anoxic conditions [327, 328] 
prolonging inflammation.  Intermittent hypoxia in healthy adults has been shown to 
activate neutrophils, increase circulating complement and immunoglobulins [329].  It 
has been demonstrated as well that hypoxia exposure in humans increased the 
chemotaxis of neutrophils to fMLP, the phagocytosis of neutrophils to E.coli and the 
release of neutrophil oxidant products [330].  Prelimnary in vitro investigations had 
shown that hypoxia increased MMP secretion from both neutrophils and macrophages 
(unpublished data), and so it would be interesting to assess if hyperoxia does the 
converse in inhibiting MMP secretion both in vitro and in animal models.  If proven 
true, a possibility would be to subject TB patients to oxygen as an adjunctive therapy in 
a randomised control trial and assess if this would modify their time to culture 
conversion, effects on paradoxical reactions, and monitor inflammatory markers, 
chemokines and cytokines.   
 In summary, future research efforts need to be directed towards understanding 
the human-M.tb interaction.   Efforts need to be placed into dissecting the key pathways 
regulating inflammation as well as identifying agents and modalities that can improve 
patient outcome.  This is crucial especially in this age of increasing drug-resistance 
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where even totally-drug resistant TB has emerged, returning us back to the era when 
standard chemotherapy was unavailable.  We have to reverse the looming possibility of 
TB becoming once again ‗the captain of the men of death‘. 
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AMPK   5‘ Adenosine monophosphate -activated protein kinase 
APMA   4-amino-phenyl mercuric acetate 
ART    Anti-retroviral therapy 
BBB    Blood brain barrier 
BSA    Bovine serum albumin 
CoATB  Conditioned media from M.tb infected astrocytes 
CoACont  Conditioned media from uninfected astrocytes 
CoMTB  Conditioned media from M.tb infected monocytes 
CoMCont  Conditioned media from uninfected monocytes 
CoNTB  Conditioned media from M.tb infected neutrophils 
CoNCont  Conditioned media from uninfected neutrophils 
CT    Cycle threshold 
DMEM  Dulbecco‘s minimal essential medium 
DNA   Deoxyribonucleic acid 
ECACC  European Collection of Cell Cultures 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
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ESAT-6  Early secreted antigenic target 6 kDa protein 
FACS   Fluorescent activated cell scanning 
FCS    Foetal calf serum 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
HBSS   Hanks‘ balanced salt solution 
HIV    Human immunodeficiency virus 
HRP    Horse radish peroxidase 
MACS   Magnetic activated cell sorting 
MAPK   Mitogen-activated protein kinase 
M-CSF  Macrophage colony stimulating factor 
MDM   Monocyte derived macrophage 
MDR   Multi-drug resistant 
MEM   Minimal essential media 
MMPs   Matrix metalloproteinases 
MOI    Multiplicity of infection 
MPO   myeloperoxidase 
M.tb    Mycobacterium tuberculosis 
NADPH  Nicotinasmie adenine dinucleotide phosphate-oxidase 
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NEI    Neutrophil elastase inhibitor 
NETS   Neutrophil extracellular traps 
NGAL   Neutrophil gelatinase-associated lipocalin 
OD    Optical density 
PAMP   Pathogen-associated molecular patterns 
PBS    Phosphate buffered saline 
PE    Phycoerythrin 
PEG    Polyethylene glycol 
PI3-kinase  Phosphatidylinositol 3-kinases 
PMA   Phorbol-12-myristate-13-acetate 
PVC    Polyvinyl chloride 
PVDF   Polyvinylidene fluoride 
RNA    Ribonucleic acid 
RT-PCR  Reverse transcriptase polymerase chain reaction 
SDS    Sodium dodecyl sulphate 
siRNA   small interfering ribonucleic acid 
TAE    Tris-Acetate-EDTA 
TB    Tuberculosis 
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TB supp  TB supernatant 
TBS    Tris-buffered saline 
TE    Tris-EDTA 
TIMPs   Tissue inhibitors of matrix metalloproteases 
TLR    Toll-lie receptors 
XDR   Extensively drug resistant 
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